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     The reversible phosphorylation of proteins catalyzed by the opposing actions of 
protein kinases (PKs) and protein phosphatases (PPs) has been identified as one of the 
major post-translational modes (PTMs) of cellular signal transduction. These two 
classes of enzymes and their extremely intricate protein interaction networks and 
associated signal cascades play the most crucial roles in maintaining the normal 
cellular physiology. Being the key mediators of several cellular communications, the 
activities of members in these two classes of enzymes are tightly controlled by a 
variety of mechanisms and in many cases imbalances in such a control and the 
resultant aberrant activities of some of these proteins have been identified as the root 
causes of several pathological conditions in humans. Hence detailed investigations of 
individual members in these two classes of enzymes, both in their purified and 
isolated form (i e. in vitro) and in their native cellular environment (i e. in vivo), is of 
paramount importance both in terms of our better understanding of their roles in the 
cellular functioning and in developing more selective and effective therapeutic agents. 
Although conventional proteomic methods provide valuable information regarding the 
expression levels of the proteins, relatively newer approaches such as Activity-Based 
Protein Profiling (ABPP) provide more insights into the functional states of these 
proteins, which are of more relevance in the cellular physiology and pathology. This 
dissertation reports certain chemical approaches developed towards better-
understanding and manipulations of some important members in these two classes of 
proteins.  
     In Chapter 2, the design and development of a panel of peptide-based Activity-
Based Probes (ABPs) for protein tyrosine phosphatases (PTPs) with a key PTP-
 xii 
 
reactive unnatural amino acid has been described. Labeling reactions with the panel of 
probes using purified and isolated proteins showed activity-based labeling specificity 
consistent with the known substrate preferences of different PTPs. The strategy has 
also been found to be useful for efficient labeling reactions of PTPs from highly 
complex biological samples. A caged version of the unnatural amino acid with a 
photolabile o-nitrobenzyl group on the phosphate moiety (caged-2-FMPT) was 
subsequently synthesized and incorporated into peptides to generate peptide-based, 
caged, ABPs (Chapter 3). Using these probes, with PTP1B as a model system, the 
concept of photo-uncaging followed by activity-based labeling was validated. Chapter 
4 describe the development of a synthetic strategy using the modular and efficient 
nature of the Cu (I) catalyzed click-reaction to rapidly assemble inhibitor libraries of 
Abelson (Abl) tyrosine kinase. Biochemical assays using the click-inhibitor library 
revealed a set of moderately potent and selective inhibitors of the Abl kinase.  In 
Chapter 5, the synthesis and biochemical evaluation of an improved mechanism-based 
cross-linker, naphthalene 2,3-dicarboxaldehyde-adenosine (NDA-AD), for the 
identification of kinase-substrate interactions from crude proteomes is described. The 
cross-linker NDA-AD, in addition to its improved labeling performances from crude 
proteomes was found to be suitable for the detection of kinase-pseudosubstrate 
interactions of both tyrosine-specific and serine/threonine-specific protein kinases. In 
Chapter 6, the development of selective small molecule-based ABPs for the Abl 
kinase using two different strategies namely a dialdehyde-based cross-linking and 
photo-affinity labeling is described. Chapter 7 provides a brief outlook to some of the 
future developments possible in line with the ABPP- and inhibitor-developments of 
PKs and PTPs discussed in the previous chapters.   
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     It is hoped that the kinase- and phosphatase-directed ABPP and inhibitor-
development approaches presented as part of this thesis, would provide a guideline for 
the future developments of more powerful tools for the investigation of these 
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Chapter 1: Introduction 
With the advancements in the genome sequencing projects, functional annotations of 
an innumerable number of proteins, already known and newly predicted, gained 
accelerated research interests. In particular, understanding the catalytic roles and 
interaction networks of enzymes, the most important bio-catalysts, has become a very 
active area of research. Being the key regulators of virtually every aspect of cellular 
physiology, even minor imbalances in certain enzyme activities are known to have 
profound implications in many pathological conditions.1 Most enzyme families 
consist of, several sub-families and classes and with the structure and functions of 
majority of members remaining largely unexplored, in-depth understanding of 
molecular configurations that are recognized and accepted by individual enzymes or 
enzyme classes, which has direct relevance to drug developments, functional 
annotations and even identification of their signalling cascades, remains a daunting 
task. To meet these goals one of the major requirements is amenable synthetic 
chemistry in combination with high-throughput enzyme screening and 
characterization technologies. These combinations of different powerful chemical and 
technological advances directed towards elucidating and modulating the catalytic 
functions of enzymes are described in a unified platform termed Catalomics (Figure 
1.1).2  
     Context-dependant post-translational protein modifications (PTMs) have long been 
known to play key roles in regulating the activities and functions of many proteins.3 
Of the different PTMs, the reversible protein phosphorylation catalyzed by the 
opposing actions of protein kinases (PKs) and protein phosphatases (PPs) has been 
identified as one of the most important modes of cellular signal transduction.4 Hence, 
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detailed investigations on various aspects; such as the expression levels, sub-cellular 
localizations, catalytic activities and functional roles of these reversible 
phosphorylation-mediating enzymes are of paramount importance in our 
understanding of their roles in maintaining the normal cellular physiology. Together 
with several conventional proteomic techniques, relatively newer approaches such as 
activity-based protein profiling (ABPP) are providing unprecedented advancements in 
this field in recent years. Furthermore, as the aberrant activities and expression levels 
of many of these enzymes are characterized, and in many more cases implicated, as 
root causes for several pathological conditions, selective and powerful ways of 
modulating their activities, e.g. with inhibitors or activators, remains another 
important area in protein kinase/phosphatase research. This chapter gives a brief 
introduction into the fundamental conceptual and technical framework, upon which 

































1. 1 Proteomic approaches for the global analysis of protein expression 
and functions. 
1. 1. 1 Methods based on liquid chromatography-tandem mass 
spectrometry (LC-MS/MS)  
     The field of proteomics is primarily involved in the large scale analysis of proteins 
in complex biological samples such as normal and cancer cells, tissues and fluids. 
Such a global analysis of proteins is of fundamental importance in identifying the 
functional roles of proteins and protein complexes, their interaction networks, 
expression levels and co-operative effects in the cellular physiology. The simplest 
method to resolving proteins from mixtures is the use of one-dimensional 
polyacrylamide gel electrophoresis (1D-PAGE) where denatured and sodium dodecyl 
sulfate (SDS) capped proteins are separated according to their sizes in a cross-linked 
and porous polymeric gel matrix under an electrical potential difference across the gel 
bed. However given the high heterogeneity and finite quantity of biological samples, 
the resolution of 1D-PAGE is typically not sufficient for global protein analysis.  
Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) coupled to mass 
spectrometry (MS) is perhaps the most widely used method for the large scale protein 
separation and identification. In 2D-PAGE, proteins are first separated in one 
dimension based on their differences in the isoelecric points (pI) and then in the 
second dimension based on their differences in the molecular weight, thus giving rise 
to a higher resolution. Although widely used, the 2D-PAGE is low-throughput and in 
many cases the sample preparations, extraction of spots, digestion and analysis of 
each spot are all tedious and time consuming. Moreover proteins of extreme pI, very 
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high or very low molecular weight proteins, low abundance proteins and membrane-
bound proteins are typically not tractable with this technique.  
     The shortcomings of the gel-based 2D separation are eliminated in an alternative 
2D separation method developed by Link et al (Figure 1.2).5 The researchers 
developed a two-dimensional liquid chromatography (2D-LC) system equipped with a 
microcapillary column packed with two independent chromatographic stationary 
phases (a strong cation exchange resin phase and a reverse phase) for the 2D 
separation of peptides generated from the tryptic digestion of denatured protein 
complexes and an online coupling of the LC unit to tandem mass spectrometry 
(MS/MS) and comparison of the obtained MS data with existing protein MS database 
provides a quick identification of the corresponding proteins from which the peptide 
fragments are generated. The strategy has been successfully employed for the large 
scale analysis of proteome samples from various biological sources.6 Such 2D-LC 
coupled to MS/MS is also known as multidimensional protein identification 
technology (MudPIT) and the technique, by virtue of its enhanced resolution and 
sensitivity, has been identified as a powerful tool for detailed proteomic analysis of 




Figure 1. 2 Schematic representation of 2D-LC coupled to tandem MS for protein analysis of 
complex samples 
1. 1. 2 Methods based on isotope coded affinity tagging – tandem mass 
spectrometry (ICAT- MS/MS) 
     Isotope coded affinity tagging (ICAT) is a mass spectrometry-based technique 
developed towards quantitative proteomics.7 The technique employs reagents 
equipped with a thiol reactive group, a biotin tag and an isotopically coded linker. The 
reagent exists in light and heavy isotopic forms (Figure 1.3). Protein samples in two 
different cell states are separately treated with the two isotopic forms of the reagent, 
upon which the thiol reactive group covalently labels the sulfhydryl residues in every 
protein. The protein mixtures are then combined, digested with trypsin and the tryptic 
peptides are isolated using affinity purification with avidin beads.  The labeled 
peptides are separated by microcapillary liquid chromatography (µ-LC) followed by 





Figure 1. 3 Chemical structures of the light and heavy isotopic forms of the ICAT reagents 
     A pair of ICAT labeled identical peptides from the two different cell state samples 
remain chemically identical and coelute but are distinguished in the mass 
spectrometry due to the mass difference between the isotopically labeled probes they 











































the mass spectrum provides a quantitative measure of the corresponding relative 
protein levels in the two samples. Several improvements in the basic ICAT-MS/MS 
technique such as solid phase labeling methods with isotopically labeled amino acids 
and photocleavable linkers have been reported.8 Similar mass spectrometry based 
techniques such as Stable isotope labeling by amino acids in cell culture (SILAC)9 
which employs isotopically labeled amino acids in cell growth medium and Isobaric 
tagging for relative and absolute quantification (iTRAQ)10 which employs amine 
reactive N-hydroxysuccinimide esters are also increasingly used in the large scale 
proteomic research. 
 





1. 1. 3 Yeast two-hybrid assays 
     The metabolism and homeostasis of cells depends on protein-protein interactions. 
Thus a molecular level understanding of the life process requires detailed knowledge 
about such intricate protein interaction networks. Several standard techniques such as 
the use of glutathione-s-transferase fusion proteins, coimmunoprecipitation, use of 
chemical cross-linkers, phage-display methods and yeast two-hybrid assays have been 
developed to characterize protein-protein interactions. The yeast two-hybrid (Y2H) 
system (Figure 1.5) is one of the most widely used techniques for mapping out protein 
interaction networks.11 This technique is based on the modular domain structure of the 
transcription factor, GAL4, of yeast which is made up of a DNA binding domain and 
a transcription activation domain and the two domains become functional in close 
proximity to each other even in the absence of a direct binding between the two. In 
the Y2H assay, a protein whose interaction partner has to be identified (termed bait) is 
expressed as a hybrid with the DNA binding domain of the yeast GAL4 while the 
potential interaction partner (termed prey) is expressed with the activation domain. If 
the two proteins (the bait and the prey) interact, it functionally reconstitutes the GAL4 
which in tern induces the expression of reporter genes. On the other hand if the 
proteins do not interact, the transcription of the reporter gene does not take place. The 
Y2H system also allows the screening of the protein of interest expressed with the 
DNA binding domain with a library of proteins fused to the activation domains from 




Figure 1. 5 Overview of Yeast two-hybrid assay 
1. 1. 4 Activity-based protein profiling (ABPP) 
     The comparative proteomic methods discussed above primarily depend on the 
expression levels of proteins; therefore the study of low abundant proteins remains 
extremely cumbersome with these techniques. Moreover these methods, although 
provide valuable information about the global protein expression, protein interaction 
networks and protein abundance, are inherently limited in their ability to directly 
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report the functional states and activities of proteins in their native cellular 
environment. Since most of the proteins/enzymes activities are regulated by 
autoinhibitory domains or endogenous inhibitors/activators and a myriad of post-
translational events with a direct correlation to the normal cellular physiology and 
pathology, complementary protein-profiling strategies capable of reporting the 
functional states of the proteins rather than their mere abundance are of extreme 
importance. Towards this, a novel chemical proteomic strategy called Activity-Based 
Protein Profiling (ABPP) has been emerged.12 This technique employs active site 
directed chemical probes which report the functional integrity and activity of the 
target protein. These Activity-Based Probes (ABPs), not only are able to identify their 
target proteins from a crude proteome but more importantly distinguishes the 
functionally active form of the target protein from its zymogen or inhibitor-bound 
forms. As such, competitive profiling of enzymes with ABPs in the presence of 
enzyme inhibitors allows a convenient means to identify potent and selective 
inhibitors which could provide impetus in drug discovery efforts toward several 
diseases. Furthermore, large-scale comparative proteomic profiling of cellular lysates 
with ABPs may helps in the functional annotations of uncharacterized proteins as well 
as in the identification of functional roles of known proteins in normal cellular 
physiology versus pathological cellular conditions.  
1. 1. 4. 1 General design considerations of activity-based probes 
     The general designs of the ABPs contain three parts (Figure 1.6a). (1) active-
site targeting reactive group, sometimes called warhead (W), that directs the probe 
to the active site and causes covalent reaction with the protein. (2) a reporter unit, 
which is typically a fluorophore or biotin for the  direct read out of the protein’s 
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activity and (3) a linker, which minimize the possible disruption from the reporter 
tag in the protein recognition of the reactive unit. The early stage developments of 
ABPs solely relied on known electrophilic irreversible inhibitor scaffolds capable 
of forming stable covalent bonds with nucleophilic residues near the active-site of 
the target proteins. This approach, although highly desirable, encounter significant 
challenge from proteins that lack such active-site targeting covalent binding 
scaffolds. Photo-affinity reagents13 offered a powerful alternative strategy to probe 
such proteins and several research groups have developed photo-affinity based 
probes (AfBP) for different proteins via appending a photoreactive molecule such 
as benzophenone, alkyl or aryl diazirine or aryl azides, to tight-binding reversible 
inhibitor scaffolds targeting those proteins.14 The AfBP first recognizes the active 
site of the target protein using the reversible inhibitor scaffold and subsequently, 
upon irradiation with UV light, a reactive intermediate is generated from the 
photo-reactive group which causes covalent cross-linking of the probe with a 
suitable proximal residue near the active-site of the protein (Figure 1.6b). These 
photo-affinity-based probes typically label the target enzyme in an activity-





Figure 1. 6 Schematic of ABPP showing two different approaches using either ABPs 
(activitiy-based probes) or AfBPs (affinity-based probes). (a) In this approach, a crude 
proteome is treated with the activity-based probe which bears a reactive group or warhead 
(W, shown in yellow) and the reporter unit (R, shown in red). The probe covalently reacts 
with the active site of the target protein and the labeling is visualized by in-gel 
fluorescence scanning following separation of proteins on SDS-PAGE. (b) In this 
approach, the crude proteome is treated with an AfBP whose warhead (W, shown in green) 
first recognizes the target protein’s active site via non-covalent interactions. Subsequently 
upon UV irradiation, a reactive intermediate generated from the photo-reactive unit 
(depicted as blue oval) covalently reacts with suitable residues near the active site. The 
labeled protein is separated by SDS-PAGE and visualized by in-gel fluorescent scanning. 
 
     Although the primary role of the linker portion is to minimize the possible 
steric hindrance from the reporter tag in the protein active-site recognition of the 
reactive group, variations in linker designs, in many cases, lead to altered labeling 
performances of the probes. For instance, long chain alkyl linkers causes 
hydrophobic interactions which are favourable in certain cases of protein 
recognition while it limits aqueous solublility of the probes. On the other hand, 
polyethylene glycol (PEG) linkers facilitates hydrophilic interactions and increases 
the aqueous solubility of the probes. Peptide-based linkers have been designed to 
perform isoform-selective labeling of certain proteins where the amino acid 
sequences in the linkers exploit the substrate specificity of different proteins 
within the same family.15 A recent improvement in the linker designs is due to the 
introduction of cleavable units which could be conveniently removed using a 
suitable trigger after the proteome labeling. The cleavage trigger could be an acid 
(e. g. TFA for acid-cleavable linkers),16 a protease (for protease-cleavable 
linkers),17 UV light (for photo-cleavable linkers)18 or a mild reducing agent (e. g. 
sodium hydrosulfite for diazobenzene-based reductively cleavable linkers).19 The 
use of cleavable linkers eliminate the need of harsh elution conditions required in 
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the case of biotinylated probe-labeled proteins as well as non-specific bindings 
from endogenously biotinylated proteins in the post-labeling protein enrichment 
using avidine beads.       
     Many ABPs use biotin as the reporter tag as it facilitates, in addition to 
visualization of the labeled protein by streptavidine blot, purification and 
enrichment of the labeled protein by means of proteomic pull-down with 
streptavidine/neutravidine coated magnetic/agarose beads. But the incorporation of 
biotin into probes could cause adverse effects, in particular several non-specific 
bindings and membrane impermeability. Since the biotin-avidine interation is one 
of the strongest interactions known in biology (Kd ≈ 10-15 M), harsh elution 
conditions are required to separate the labeled proteine from the avidine beads, 
which sometimes lead to protein loss and labeling artifacts. Furthermore, the 
biotin probe labeled protein is visualized indirectly with antibiotin antibodies or 
neutravidine-HRP complexes and such assyas are limited in sensitivity and have a 
very narrow dynamic range, making quantitative labeling assesments and 
comparisons of different protein samples extremely cumbersome. The use of 
fluorescent tags elliminates most of these difficulties. Fluorescently labeled 
proteins can be directly visualized by in-gel fluorescent scanning following protein 
separation by SDS-PAGE. Moreover, fluorescence is much more sensitive and the 
availability of fluorophores with a large range of spectral properties provides a 
large dynamic range of protein detection and facilitates proteomic labeling of 
complex biological samples using probes with spectrally distinct tags. The most 
commonly used fluorophores include rhodamine derivatives, fluorescein, BODIPY 




1. 1. 4. 2 “Label-free” versions of ABPs 
     Many ABPs, due to the presence of their reporter tags, suffer obvious 
limitations both from synthetic point of view and in their labeling performance. 
Fluorophores are expensive, and typically the synthetic steps of the probes with 
reporter tags are difficult to purify due to the peculiar solubility and polarity 
properties of most of the fluorophores/biotin. Even more serious drawbacks appear 
in the biological labeling performance of these probes mainly due to their poor 
membrane permeability. Moreover, the bulky reporter units, in many cases, disrupt 
the proper binding interaction between the reactive unit and the protein’s active 
site. To override these problems, the labs of Cravatt and Overkleeft independently 
reported the first “label-free” versions of ABPs, where a two-step protein profiling 
strategy making use of a bioorthogonal labeling of the probe treated proteome was 
employed.20 Overkleeft and co-workers used an azide functionalized vinyl sulfone 
probe to target proteasomes in cell lysates as well as in live cells. After the probe 
treatment, the lysates were subjected to Staudinger ligation with a biotinylated 
triarylphosphine reagent and the labeling was visualized by immunoblotting. The 
Cravatt’s lab, on the other hand, utilized click chemistry for the labeling. In their 
original work, Cravatt and co-workers treated cell lysates from COS7 cells 
overexpressing glutathione S-transferases (GSTO 1-1) with an azide derivatized 
phenyl sulfonate (PS) probe. The probe treated sample upon click-conjugation 
with a rhodamine alkyne followed by SDS-PAGE and in-gel fluorescence 




Figure 1. 7 Schematic of ABPP using clickable activity-based probes. The proteome is 
treated with the clickable probe whose warhead W (yellow) covalently reacts with the 
active site of the target protein. The reporter R (shown in red) is then incorporated into 
the probe-protein complex using CC, which enables subsequent visualization of the 
labeled protein with in-gel fluorescent scanning. 
 
     With the initial success, the label-free clickable ABPP strategy has been 
quickly adopted for other classes of proteins. Alexander and Cravatt utilized an N-
alkynyl derivative of a known tight binding inhibitor against fatty acid amide 
hydrolases (FAAHs), named JP104, for the comprehensive evaluation of the in 
vivo proteome reactivity of these enzymes.21 Similarly in an effort to determine 
protein targets of bioactive natural products, Cravatt and co-workers performed 
cell-based screening with a small-molecule clickable probe library bearing 
different natural product scaffolds.22 The researchers identified one probe, MJE3, 
which possesses an 1-oxa-spiro[2,5]octane scaffold, showing signifcant inhibition 
of breast cancer cell proliferation. The probe was found to covalently label a 
glycolytic enzyme called phosphoglycerate mutase 1 (PGAM1) in cancer cells. 
Cravatt and co-workers recently reported a set of clickable probes for the enzymes 
Cytochrome P450s.23 The researchers observed that their probes were able to 
detect both inhibition and activation of cytochrome P450s by different small 
molecules. Similarly, Taunton and co-workers developed a clickable probe, called 
fmk-pa, to study the autoactivation mechanisms of the p90 ribosomal protein S6 
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(RSK) kinase.24  
1. 1. 4. 3 “Label-free” clickable versions of AfBPs 
     Similar to ABPs, clickable versions of photo affinity-based probes (AfBPs) 
have also been developed. The first design of a clickable AfBPs was from the 
Pieters group. Based on the known binding interaction of β-galactoside containing 
motifs to galectins, the group designed a clickable photo-affinity probe which was 
shown to bind purified galectins.25 The same group subsequently reported a 
divalent version of the original probe, which possesses improved detection limits 
and enabled specific labeling of endogenous galectin 3 in human colon carcinoma 
lysate.26 Sieber et al adopted the same strategy for targeting metalloproteases using 
hydroxamate-containing peptide-based probes.27 In another recent development, 
Cravatt’s laboratory reported a very sensitive clickable photoreactive probe, 
named, SAHA-BPyne, for detection of histone deacetylases (HDACs).14b The 
SAHA-BPyne was found to detect endogenous class-1 and class-2 HDACs as well 
as some of the HDAC-interacting proteins in the close proximity of the probe in 
highly complex whole cell proteomes and live cells.  
 
Figure 1. 8 Schematic of AfBPP using clickable photo-reactive probes. The warhead, W 
(shown in green), which first occupies the target protein’s active site. Subsequent UV 
irradiation leads to covalent cross-linking of the probe with the target protein. The 
reporter is then incorporated into the probe-protein complex using CC and the labeled 




1. 1. 4. 4 Non-directed approaches in ABP designs 
     Besides the rationally designed probes with known/predicted protein targets, 
the ABPP strategy has been applied in a conceptually different manner using the 
so called “non-directed probe libraries”. In this approach, a probe library equipped 
with several structurally different electrophilic warheads are applied to a complex 
proteome were each protein/protein class may exhibit its own characteristic 
labeling profiles with the different warheads and the comparitive labeling profiles 
thus generated would be useful for the functional characterization of unidentified 
proteins and also in the identification of preferred reactive units of each protein. 
Cravatt and co-workers employed a non-directed library of sulfonate ester (SE) 
probes bearing different aryl/alkyl binding groups against various proteome 
samples.28 The researchers identified six mechanistically different enzyme classes 
as the probes targets with each target exhibiting unique labeling profile with the 
probes. Recently dipeptidic α-chloroacetamide (α-CA)29 and spiroepoxide22 
reactive-groups based non-directed probe libraries have also been reported.  
 
1. 2 Protein phosphorylation - An important post-translational 
modification (PTM) 
     The most fundamental knowledge-bearing molecular entities in the cells are the 
genes; however the genome carries nothing but the information to generate primary 
structures of proteins. It is the proteins and their highly intricate and tightly controlled 
interaction networks that regulate and mediate virtually every aspect of cellular 
functions. Post-translational modifications (PTMs) of proteins, which involve both 
reversible and irreversible incorporation of a wide range of chemical moieties such as 
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phosphates, lipids, sugars, alkyl, acyl and sulphates is one of the most important 
cellular mechanisms that control the structure, localization and functions of proteins. 
It is one of the three fundamental modes of cellular signal transduction; the other two 
being direct contact-based interactions such as the interaction between G-proteins and 
receptors and communications mediated through diffusible signalling molecules such 
as hormones, neurotransmitters, cytokines etc. Among the different PTMs, the 
reversible protein phosphorylation has been identified as the most dynamic and 
ubiquitous mechanism for intracellular communications. Also, several exogenous 
signals transmitted through receptor proteins trigger intracellular protein 
phosphorylation/dephosphorylation cascades by which the cell decipher and process 
external stimuli/signals. Thus not only the intracellular signal transductions but the 
cellular response to several exogenous signals and hence the associated intercellular 
signal transduction events also depend on the protein phosphorylation.  
     Phosphorylation of proteins is catalyzed by enzymes called protein kinases which 
facilitate the transfer of a single phosphate (γ-phosphate) from ATP molecules to the 
side chain hydroxyls of serine, threonine and tyrosine residues in proteins. The 
reverse reaction, i.e. removal of phosphate from the side chain hydroxyls of 
phosphorylated serine, threonine and tyrosine residues in proteins, is catalyzed by a 
group of enzymes called protein phosphatases. The co-operative actions of these two 
classes of enzymes mediate a large array of vital cellular processes but the specific 
outcome of a protein’s phosphorylation/dephosphorylation event is typically context-
dependant. Thus although the reversible phosphorylation acts as a binary code for the 
cell to decipher and process many signals, the exact meaning of the signal depends on 
the context, and in many cases the same phosphorylation/dephosphorylation event 
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conveys different meanings and triggers different cellular processes, making the study 





Figure 1. 9 Reversible protein phosphorylation mediated by protein kinases and protein 
phosphatases. Protein kinases catalyze the transfer of a phosphate from ATP molecules to 
hydroxyls of Serine, Threonine and Tyrosine residues in proteins while protein phosphatases 
catalyze the dephosphorylation of such phosphorylated residues.  
 
1. 2. 1 Protein kinases 
     Protein kinases are classified into two main groups4 1) the Ser/Thr – kinases, 
which constitute around 80% of the protein kinases and 2) the Tyr – kinases. The two 
classes of kinases, although phosphorylate different residues, have similar catalytic 
domain structure which consists of a bi-lobed structure with a small N-terminal lobe 
predominantly made up of β-sheets and a larger C-terminal lobe predominantly made 
up of α-helices with the ATP-binding site located in between the two lobes. The 
tyrosine-specific kinases have a deeper catalytic cleft to accommodate the tyrosine 
residue which is presumably the major reason for the Tyr vs. Ser/Thr substrate 
selectivity between the two classes of kinases. However this selectivity is not 
exclusive; several Ser/Thr kinases are known to phosphorylate tyrosine residues as 











     Approximately 2% of the entire eukaryotic genome encodes protein kinases and it 
is estimated that at any given time approximately 30% of cellular proteins are 
phosphorylated on at least one residue. Around 17% of amino acid contribution for 
proteins being Ser, Thr and Tyr residues, for every given protein kinase there are 
hundreds of thousands of potential phosphorylation sites, yet a typical kinase is 
known to phosphorylate from one to a few hundred protein substrates only. Such a 
degree of specificity in substrate recognition from a large potential substrate 
background is the result of a variety of mechanisms including polar, hydrophobic and 
hydrogen bonding interactions with the substrate in and around the catalytic pocket 
and also due to distal docking interactions between motifs on the substrate and 
interaction domains on the kinase.  
     The kinase catalyzed phosphoryl transfer from ATP to substrates requires an 
essential divalent mental ion, typically Mg2+ or Mn2+, and the phosphoryl transfer 
occurs via a transient interaction with the substrate without the formation of any 
stable intermediate. Protein kinase activities are regulated via several mechanisms 
including phosphorylation/dephosphorylation events of activation loop and/or tale 
ends, allosteric interactions, interactions with regulatory units and domains, fatty acid 
acylation, interactions with secondary messengers and subcellular localization. The 
aberrant regulation of kinase activities have been implicated in many human diseases 
including several cancers.1c,30 Thus the kinome remains an important target for many 
pharmaceutical drugs, besides the interests in knowing the important roles of these 





1. 2. 2 Protein phosphatases 
     The protein phosphatases are classified into two main classes based on their 
substrate specificity and protein structure; they are 1) the Ser/Thr protein 
phosphatases (PPs) and 2) the protein tyrosine phosphatases (PTPs). The PP class is 
further divided into two distinct gene families namely PPP and PPM. The two classes 
of phosphatases (i.e. PPs and PTPs) use fundamentally different catalytic mechanisms. 
Most PTPs utilize a nucleophilic cysteine residue to initiate the formation of an 
enzyme-phosphate intermediate whereas PPs utilize a dinuclear metal ion centre 
which is proposed to activate a water molecule for direct hydrolysis of 
serine/threonine phosphoester bonds in protein substrates.  
     Protein tyrosine phosphatases (PTPs) are important signalling enzymes that 
catalyze the dephosphorylation of phosphotyrosine residues in protein substrates. A 
set of 107 genes in the human genome have been identified to encode the PTPs. The 
PTP family is classified into four sub-families based on the amino acid sequence of 
their catalytic domains.31 They are 1) Class 1 cysteine-based phosphatases which 
include both the classical PTPs, which dephosphorylate only phosphotyrosine (pTyr) 
residues in substrates and dual specific protein phosphatases (DSPs), which can 
dephosphorylate both pTyr and posphoserine/phosphothreonine (pSer/pThr) residues, 
2) Class 2 cysteine-based PTPs, which include the pTyr specific low molecular 
weight phosphatases which appear to have evolved from a different ancestor 
compared to the class 1 cysteine-based phosphatases, 3) Class 3 cysteine-based 
phosphatases which are both pTyr and pThr specific phosphatases and 4) Class 4 
aspartic acid-based phosphatases, which unlike the other three classes of PTPs use an 
aspartic acid residue and a cation to carry out the catalysis. 
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1. 2. 3 Catalytic mechanism of PTPs 
     All the three major PTP classes share the same catalytic mechanism.31,32 The PTP 
signature motif has been identified to be CX5R(S/T) where the catalytic cysteine 
residue is of unusually low pKa value (~ 4.5) which enables it an efficient nucleophile 
to initiate a nucleophilic attack on the phosphorous atom of the phosphorylated 
substrate. When the substrate binds to the catalytic pocket the enzyme undergoes a 
conformational change which brings the pTyr residue of the substrate in close 
proximity to the catalytic cysteine and a nucleophilic attack on the phosphorous atom 
leads to the formation of a pentacoordinate intermediate whose geometry is stabilized 
by ionic interaction with the positively charged arginine residue at the active site. An 
aspartic acid residue near the catalytic site may further stabilize the negative charge in 
the intermediate via protonating the phosphate. The aspartic acid residue plays 
multiple roles in the catalysis. It first acts as a general acid to protonate the phenolic 
hydroxyl in the tyrosine, making it a good leaving group and then once the 
thiophosphoryl intermediate is formed, the aspartate acts as a general base to activate 
a water molecule to attack the intermediate to release the cysteine and regenerate the 
enzyme after the product separation. The role of the conserved serine/threonine 
residue is presumably the stabilization of the negative charge of the catalytic cysteine 
thiolate through hydrogen bonding interactions with the side chain hydroxyls and the 










Figure 1. 10 Catalytic mechanism of PTPs with PTP1B as a representative32b,c 
 
1. 3 Enzyme inhibitor developments - Fragment-based approaches and 
high-throughput chemistry 
     Enzymes, which encompass some of the most valuable drug targets for the 
potential treatment of several human diseases, receives substantial research interest in 
the context of potent and selective inhibitor developments. Since every major enzyme 
family consists of many sub-families and classes, with the structure and functions of 
the majority of members remaining largely unexplored, developing highly selective 
and potent inhibitor for a particular member, which is typically the key step in 
developing many drugs, is often a very challenging task. To meet this requirement, 
the most inevitable component is synthetic chemistry that can keep up with pace of 
protein target identification through rapid and efficient synthesis of a large number of 
diverse chemical compounds. Conventional drug development efforts typically rely 
on medicinal chemistry both at the very first stage of lead finding and at the next stage 
of lead optimization. High-throughput synthetic methods such as combinatorial 
approaches and synthesis using solid supports together with amenable chemical 
reactions such as the “click” reactions and multicomponent reactions could potentially 
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     Many enzymes are known to possess multiple binding pockets yet conventional 
inhibitor developments generally focus more on only the active site. However, in 
many cases the secondary/allosteric binding sites confer selectivity as well as potency. 
To tackle this issue, new strategies such as fragment-based assembly have been 
emerged and gained significant attention in recent years.33 Fragment-based assembly 
is a novel approach which enables high-throughput identification of molecules 
through the exploration of N2 possibilities from N+N combination of fragments. Thus 
in the case of inhibitor developments, N+M combination of inhibitor fragments lead 
to the generation of N×M potential bidentate inhibitors. It typically involves a two 
step process namely the fragment identification and the fragment linkage. NMR/X-
ray-based strategies33,34 and MS-based tethering strategies35 are well-known existing 
approaches which are now routinely used to facilitate the fragment-based assembly in 
drug discovery.  
1. 3. 1 “Click chemistry” in enzyme inhibitor developments 
     Fragment-based assembly using click chemistry has drawn significant attention for 
enzyme inhibitor developments and accelerating the proteomic research in general.36 
Click chemistry is a term coined by Sharpless to represent a set of reactions with 
features such as excellent chemoselectivity, good solvent compatibilities, modularity, 
minimum synthetic demands and high yields.37 The best known click reaction is 
perhaps the Cu (I) catalyzed version of the Huisgen 1,3-dipolar cycloaddition 
reaction38 between azides and terminal alkynes to afford 1,2,3-triazoles, discovered 
independently by Meldal and co-workers39 and Sharpless and co-workers.40 This 
reaction is highly chemoselective, bioorthogonal (as typically there is no terminal 
alkynes or azides in living systems) and suitable for rapid and modular assembly of a 
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large number of compounds. It exploits the inherent kinetic stability of terminal 
alkynes and azides under a variety of reaction conditions and regioselective formation 
of 1,4-regio isomer of the triazole is formed in the presence of catalytic amount of Cu 
(I). Because of the high efficiency and water-compatible nature of this reaction, in 
most cases, the assembled products could be directly screened for inhibition without 
the need of any purification.  
     Various research groups including ours have successfully used click chemistry to 
assemble inhibitors against important proteins such as protein tyrosine phosphatases,41 






Figure 1. 11 CC facilitates a highly modular and rapid assembly of potential bidentate 
inhibitors (N×M compounds) from N number of alkynes and M number of azides. This high-
throughput inhibitor assembly can be performed in a 96- or 384-well plate (one compound per 
well) and the inhibitors in each well can be directly screened with the enzyme (in situ 
screening) without the need to purify the compounds.      
 
1. 3. 2 “In-situ click chemistry” facilitated enzyme inhibitor 
developments 
    The azide-alkyne cycloaddition reaction has been utilized in a conceptually and 















technique called “in-situ click chemistry” the target protein is used as a template for 
the proximity enhanced cycloaddition of the two fragments. Previously, ingenious 
approaches such as molecular imprinting techniques47 and dynamic combinatorial 
chemistry (DCC),48 both based on proteins acting as a template for the assembly of 
molecules, have been developed to identify tight-binding partners of proteins. In the 
former case irreversible linkages are formed between reactive partners that typically 
recognize protein surface sites whereas the later strategy is active-site directed, where 
reversible reactions between mixtures of interconverting species are employed. The 
key to the active-site directed approaches is the ability of the protein to choose and 
stabilize molecular combinations with highest binding affinity under thermodynamic 
conditions. Based on Mock’s finding that the very high kinetic barrier in the 1,3-
dipolar cycloaddition reaction between azides and alkynes could be tremendously 
reduced when the two components are brought together into close proximity in a 
Cucurbituril (a nonadecacyclic cage compound) host structure,49 Sharpless and co-
workers designed in-situ click chemistry as a powerful strategy towards kinetically 
controlled (unlike the thermodynamic control in the conventional DCC) target-guided 
synthesis of enzyme inhibitors. In this approach the non-protein host structure in 
Mock’s original designs were replaced with the active sites of enzymes where the 
otherwise slow cycloaddition reaction gets heavily accelerated. Sharpless and co-
workers have successfully developed this strategy to identify extremely potent 












Figure 1. 12 Schematic of in situ CC. In the in situ CC, the enzyme is incubated with a 
mixture of alkyne- and azide-equipped ligand scaffolds from which the enzyme chooses 
the most preferred binders under the kinetic control. In the enzyme active site, the two 
components react to form the triazole linkage and hence a stable bidentate inhibitor due to 




























Chapter 2: Development of Peptide-Based Activity-Based 
Probes (ABPs) for Protein Tyrosine Phosphatases (PTPs) 
Summary: 
This chapter summarizes the development of a panel of peptide-based activity-based 
probes that allow target-specific profiling of the important signalling enzymes protein 
tyrosine phosphatases. At the heart of the probe development, we designed and 
synthesized a new tyrosine phosphatase-reactive unnatural amino acid, termed 2-
fluoromethylphosphotyrosine (2-FMPT), and incorporated it into the consensus 
substrate peptide sequences of different tyrosine phosphatases. The probes, by virtue 
of the presence of the unnatural amino acid unit covalently react with the enzymes 
while the presence of the peptide sequence provide an additional degree of specificity 
for each probe towards its most preferred enzyme. The probes were equipped with 
fluorescent tags which facilitate the visualization of the labeled protein band by in-gel 
fluorescence scanning. Labeling reactions with the panel of probes using purified and 
isolated proteins showed activity-based labeling specificity consistent with the known 
substrate preferences of the PTPs and the probes were found to be useful for efficient 
labeling reactions from highly complex biological samples.  
2. 1 Introduction 
     The functional state of PTPs in a cell is highly dynamic and tightly regulated. In 
human, there are well over 100 known PTPs, which, together with several hundred 
protein kinases, control the phosphorylation of as many as 1-2% of all human proteins. 
In order to maintain an intricate balance of this highly complex phosphoproteome 
network, PTPs carry out dephosphorylation with a high degree of specificity inside 
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the cell; although in vitro they have shown only moderate specificity towards 
synthetic peptide substrates.53 Consequently, chemical and biological methods that 
report not only the global PTP activities, but more importantly the precise enzymatic 
activity of individual PTPs, may offer unprecedented views on how these enzymes 
carry out their biological functions under native physiological settings.  
     Activity-based protein profiling (ABPP) is a chemical proteomics strategy that 
employs active-site directed chemical probes to detect active enzymes present in a 
crude proteome. Over the past few years, this technique has been successfully applied 
to different classes of enzymes including phosphatases. In order to develop activity-
based probes (ABPs) that detect global PTP activities, Lo et al first explored small 
molecules containing a 4-fluoromethylphenyl phosphate (FMPP) moiety which serves 
as a phosphotyrosine mimic, and upon dephosphorylation by a PTP, generates a 
highly reactive quinone methide intermediate that subsequently alkylates nucleophiles 
present in the PTP active site.54 Yao et al made similar PTP probes using 2-
difluoromethyl phenyl phosphate (DFPP) which presumably works via a similar 
mechanism as FMPP.55 Unfortunately, due to the diffusible nature of the quinone 
methide generated, both classes of probes possess poor PTP specificity and cross-
react with other nearby proteins in the crude proteome. Zhang et al recently developed 
a PTP probe that uses α-bromobenzylphosphonate (BBP) as a nonhydrolyzable 
phosphotyrosine (pTyr) mimic.56 The probe was shown to be specific towards PTPs in 
proteomic experiments, but the highly reactive/unstable nature of the probe renders it 
impractical for wide-spread use. The same group developed a newer version of PTP 
probes by using phenyl vinyl sulfone/sulfonate as the enzyme-targeting warhead.57 
These probes operate via an electrophilic capture of the active site Cys residue via a 
1,4-conjugate addition and these probes, compared to the BBP based probes, have 
 29 
 
better hydrolytic stability at pH greater than 7 and were shown to have better 
membrane permeability as well. Vinyl sulfones/sulfonates are, however, well-
established irreversible inhibitors of other cysteine-utilizing enzymes (i.e. cysteine 
proteases), and are likely to cross-label them as well. Notwithstanding, all four 
existing classes of PTP probes have so far failed to address one of the most important 
issues in PTP biology -  how can one monitor/profile the active state of individual 
PTPs in a crude proteome, where these enzymes’ native cellular environment is 
closely emulated? 
     To address these issues, a novel unnatural amino acid, 2-FMPT was designed, 
whose incorporation into peptide-based probes could provide a potential means for 
the target-specific activity-based profiling of PTPs (Figure 2.1a). Apart from an 
additional 2-fluoromethyl group located in the aromatic ring, 2-FMPT is structurally 
identical to pTyr and should cause minimal disruption in PTP recognition. The most 
significant advantage of 2-FMPT over other existing PTP probes is that, with its N- 
and C-terminus (as in the case of naturally occurring amino acids), essential peptide 
recognition elements which occupy the proximal positions of pTyr in a naturally 
occurring PTP substrate could be introduced. With this, the corresponding peptide-
based probes could achieve target-specific binding to/profiling of different PTPs. As 
shown in Figure 2.1b, the peptide-based probe works  by first binding to the active 
site of the target PTP in a sequence-specific manner, and is subsequently 
dephosphorylated (I; as in the case of a synthetic PTP substrate). The ensuing charge 
delocalization followed by spontaneous elimination of –F generates the reactive 
quinone methide intermediate which, upon attack by a nearby nucleophilic residue in 
the enzyme, would give rise to the covalent enzyme-probe complex (II). We 
anticipated that, in our newly developed probes, introduction of the additional peptide 
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fragments specific towards individual PTPs should improve probe binding affinity as 
well as specificity, thus overcoming the diffusion problem observed in the previous 











Figure  2. 1 (a) Structures of known ABPs (top) of PTPs and the unnatural amino acid, 2-
FMPT, and its corresponding peptide-based ABPs (boxed). (b) Proposed mechanism of the 
sequence-specific, activity-based labeling of the peptide-based probes. 
 
2. 2. Synthesis of the unnatural amino acid, 2-FMPT 
     The synthesis of the Fmoc-protected 2-FMPT (2-10 in Scheme 2.1) was carried out 
from L-tyrosine. Briefly, the free amino group of L-tyrosine was protected with Boc 
to get 2-2 (90%). Formylation of 2-2 at the ortho position of the phenolic group by 










































protected to give the corresponding benzyl ester 2-4 (80%), followed by 
phosphorylation with chlorodiethylphosphate to give 2-5 (70%). Subsequent 
reduction of the CHO group in 2-5 with NaBH4 gave 2-6 (69%) followed by 
fluorination with DAST, giving 2-7 (74%). Finally, deprotection of the benzyl ester in 










Scheme 2. 1 Synthesis of the unnatural amino acid (2-FMPT) 
 
2. 3 Solid-phase synthesis of substrate peptides and peptide-based 
activity-based probes 
     The unnatural amino acid was incorporated into peptides using standard solid-
phase peptide synthesis (SPPS) protocols. Eleven peptide probes, designed against 
five different PTPs (PTP1B, TCPTP, SHP1, SHP2 and LMWPTP), were synthesized 
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phosphopeptides were also synthesized, in which the naturally occurring pTyr was 
used in place of 2-FMPT. The SPPS was performed on an automated peptide 
synthesizer (Chemspeed Technologies ASW2000) utilizing standard Fmoc chemistry 
on rink amide resin (ChemPep Inc.). All the natural Fmoc amino acids (4 eq.) 
(Advanced ChemTech) were activated by DIC/HOBt (4 eq. each) (Advanced 
ChemTech) and each coupling reaction was performed for 2 h in the presence of 8 eq. 
of DIEA. For coupling of the unnatural amino acid, pre-activation of the unnatural 
amino acid with HOBt/HBTU (4 eq. each) in the presence of 8 eq. of DIEA for 10 
min was performed before being added to the growing peptide chain on the resin. 
After washing with DMF (6X), the Fmoc-protecting group was removed using 20% 
piperidine in DMF, followed by another washing with DMF (6X). The N-terminus of 
each peptide was coupled to a Rhodamine dye containing an acid linker (or biotin) 
employing the same pre-activation method as earlier described for the unnatural 
amino acid. Finally deprotection of the phosphate ethyl ester groups was performed 
by treating the resin-bound peptide with 10 eq. of TMSI in dry DCM, followed by 
washings with DMF (6X) and DCM (6X). Prior to cleavage of the peptide, the resin 
was washed with MeOH (6X), DCM (6X), and MeOH (6X), and dried in vacuo. 
Peptide cleavage was carried out with an 1-mL cleavage cocktail (95:2.5:2.5 of 
TFA:H2O:TIS) at RT for 2 h. The synthesis and cleavage of the phosphopeptides were 
done as previously described.59 After filtration and precipitation with cold ether, the 
precipitated peptides were washed twice with cold ether, followed by drying in vacuo 
(Genevac). Each peptide was purified by HPLC and characterized by LC-MS (IT-
TOF) (Shimadzu). Appropriate standard solutions were made in DMSO and stored at 



















































































































































Table 2. 1 The 11 probes and their AA sequences and substrate preferences 
 
2. 4 Expression and purification of PTPs 
     The catalytic domain (1-321) of PTP1B was amplified by polymerase chain 
reaction (PCR) and sub-cloned using Nde1 and BamH1 restriction sites into a pET-
28b vector to give PTP1B with a C-terminal hexahistidine tag. The two PTP1B 
mutants (D/A and C/S mutants) were obtained by site-directed mutagenesis using the 
QuikChange Mutagenesis Kit (Stratagene) following manufacturer’s instructions. The 
final constructs were verified by DNA sequencing and transformed into Escherichia 
coli BL21 DE3 cells for protein expression. A single colony was grown overnight at 
37 oC in Luria Bertani media that contain the antibiotic Kanamycin at a final 
concentration of 50 g/ml. Subsequently, the overnight culture was diluted 1:100 and 
grown at 37 oC to an optical density of 0.6-0.8 at 600 nm. Isopropyl-1-thio-β-D-









































P11 PTP1B Stat5b Rh-K(Biotin)-KAVDGXVKPQI‐NH2 
3 X = 2-FMPT. 
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further 4 hours at 30 oC. The culture was harvested and lysed by sonication on ice, in 
the presence of complete proteases inhibitor (Roche). The histidine-tagged PTP1B 
proteins were purified from the clarified lysates on Nickel-nitrilotriacetic acid (Ni-
NTA) metal-affinity chromatography matrices (Qiagen) according to manufacturer’s 
instructions. The plasmid encoding TC-PTP was a kind gift of Prof Harry 
Charbonneau and was modified to insert a C-terminal hexahistidine tag in-frame with 
the TCPTP gene. The mutagenesis was carried out using the QuikChange 
Mutagenesis Kit (Stratagene) following manufacturer’s instructions. The final 
construct was verified by DNA sequencing and were transformed into BL21 DE3 
cells for protein expression. TC-PTP-(His)6-protein was expressed and purified 
following the same protocol as for the PTP1B proteins, with the only difference being 
that IPTG was added to a final concentration of 50 M and grown for a further 12-16 
h at 18 oC. The plasmids encoding Shp1 and Shp2 were obtained from Addgene.org 
(Plasmid 8578, Plasmid 8322), while the plasmid encoding LMW-PTP was a kind gift 
of Prof. Tomas Mustelin. All purification steps were performed at 4 oC following the 
same protocol described above. Briefly, the pelleted cells were resuspended in lysis 
buffer containing 50 mM Tris (pH 8.0), 300 mM NaCl, 0.2 mM DTT and 1X 
complete proteases inhibitors. Sonication was done on ice and lysate was clarified by 
centrifuging at 12000 g for 30 min. The supernatant was then incubated with 
Glutathione Sepharose 4B beads (Amersham Pharmacia Biotech) for 30 min, with 
rotation. Subsequently, beads were washed 4X 5 min with 1X PBS (140 mM NaCl, 
2.7 mM KCl, 10 mM Na2HPO4, and 1.8 mM KH2PO4, pH 7.4) wash buffer, 
complemented with 0.2 mM DTT and 0.2% Tween 20. Elution was carried out using 


















Scheme 2. 3  Schematic representation of different PTP constructs used in the work. 
 
2. 5 Results and Discussions 
2. 5. 1 Labeling experiments with purified proteins 
     Labeling reactions with PTPs (e.g. PTP1B, TCPTP, YOPH, LMWPTP) and non-
PTP proteins (e.g. 14-3-3 protein, Sortase, BSA & CnA), were initiated by adding 1 
μL of the probe 7 (a representative probe) to a pre-equilibrated enzyme/protein 
solution in an appropriate buffer at 25 oC. The final probe concentrations in all the 
reactions were 10 μM and the protein amounts were 1 μg. Tris buffer (50 mM, pH = 
7.5) with ionic strength adjusted to 150 mM with NaCl was employed for PTP1B and 
TCPTP and YOPH. Sodium acetate buffer (50 mM, pH = 5.2) was used for LMWPTP. 

























Labeling reactions with non-PTP proteins were performed in Tris buffer (50 mM, pH 
= 7.5, 150 mM NaCl). All labeling reactions were run for 1 h and subsequently 
quenched by the addition of 6X SDS loading dye followed by heating at 95 oC for 10 
min. The proteins were resolved on a 10% SDS-PAGE gel and the labeled bands were 
visualized by in-gel fluorescence scanning with Typhoon 9200 fluorescence gel 
scanner using green (533 nm) laser with optimum emission filters and the scanned 
images were quantified with the ImageQuant 3.3 (Molecular Dynamics) software. As 
shown in Figure 2.2, under standard labeling conditions, the probes were found to 



















Figure 2. 2 Activity-based labeling of proteins using probe 7. lane 1- TCPTP; lane 2-Boiled 
& cooled TCPTP; lane 3- CnA; lane 4- Sortase; lane 5- YOPH; lane 6- PTP1B; lane 7-  
Boiled & Cooled PTP1B; lane 8- empty; lane 9- BSA; lane 10- LMWPTP; lane 11- 14-3-3 
protein. 
 
     Activity-based labeling of the ten rhodamine-containing probes, P1 to P10, with 
five different PTPs was tested to generate the so-called activity-based fingerprints.60 
As shown in Figure 2.3, clearly distinctive labeling profiles of individual PTPs were 
observed, and to a large extent corroborated well with their known substrate 
(a) Fluorescence                                                 (b) Coomassie 
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preferences (Table 2.1). For example, the top-5 probes (P2, P3, P7, P9 & P10) which 
generated the strongest labeling against PTP1B, were derived expectedly from known 
PTP1B substrates. TCPTP, known to have similar substrate preferences as PTP1B, 
gave a correspondingly similar activity-based fingerprint. For SHP1, two of the most 
active probes are P1 and P6. Of the two SHP2-specific probes (P8 & P10), one was 
derived from its known substrate. Similarly, LMWPTP also gave a distinctive 
labeling profile, which is in good agreement with its substrate preference.61 
 
Figure 2. 3 (a) Fluorescent labeling profiles of five different PTPs (top to bottom) with 
the ten peptide probes (left to right). The fluorescent gels clearly showed a sequence-
dependent labeling of different PTPs. The labeling profiles of P3 were highlighted (boxed 
in Red). (b) The fluorescent intensity of each band is quantified using ImageQuant 
software and the relative fluorescence intensity (Y-axis) of labeling of the 5 different 








2. 5. 2 Detection limits of the probes 
     In order to determine the fluorescence detection limit of the probes, 200 ng of 
PTP1B was incubated with probe P3 (one of the highly selective probes for PTP1B) 
at a final probe concentration of 2 mM in the reaction buffer (50 mM Tris buffer, pH 
7.5, 150 mM NaCl) for 1 h. After quenching the reaction, the labeled PTP1B was 
serially diluted with the same buffer and separated from excess of the probe on SDS-
PAGE and the labeled bands were visualized by in-gel fluorescence scanning 
                       20     10     5      2      1     0.5     0.1    0.03    0.01   PTP1B (ng)                     
                     
               Figure 2. 4 Detection limit of PTP1B with Probe P3. 
 
2. 5. 3 Labeling experiments with mutant PTPs 
     PTPs possess a highly conserved Cys residue in the active site that plays a key role 
in the catalytic mechanism via initiating a nucleophilic attack on the phosphotyrosine 
of the substrate, leading to the formation of a thiophosphoryl enzyme intermediate 
which eventually collapses to give the dephosphorylated product. PTPs with 
mutations at this position (e.g. 215Cys→Ser mutant of PTP1B) are catalytically 
inactive. The substrate binding into the active site of PTPs is followed by a well 
characterized conformational change in the highly conserved “WPD” loop in which it 
flips over the phosphotyrosine residue such that the aspartic acid in this loop gets 
close enough to the phosphoryl-cysteine intermediate for effective general acid 
mechanism (protonating the leaving phenolic oxygen). For PTP1B, mutation of this 
Asp in the WPD motif to Ala (e.g. 181Asp→Ala mutant shown in Scheme 2.3) was 
shown to significantly reduce the kcat of the enzyme. In order to get more insight into 
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the activity-based labeling of PTP1B using our probes, we performed labeling 
experiments with both C/S and D/A mutants of PTP1B (Figure 2.5a). As anticipated, 
the labeling result showed a complete lack of labeling with the mutants as well as the 
heat-denatured PTP1B, showing that the probes are indeed activity-based. Microplate-
based enzymatic assay of the mutants using DiFMUP as substrate, revealed no 
catalytic activity for the C/S mutant while the D/A mutant retained a very low activity 
(Figure 2.5b). 
 

















Figure 2. 5  (a) Labeling experiment with mutant PTPs. lane 1. PTP1B C/S mutant; lane 2. 
PTP1B; lane 3. Boiled and Cooled PTP1B; lane 4. PTP1B D/A mutant. (b) Microplate-based 
enzymatic assay of PTP1B and mutants used with DiFMUP as the fluorogenic enzyme 
substrate. 
 
2. 5. 4 Effect of H2O2 on PTP activity assessed with the probes 
     The catalytic Cys residue in the active site of PTPs exhibit an unusually low pKa 
value which makes it an efficient nucleophile and at the same time makes the enzyme 
susceptible to oxidative inactivation. H2O2 generated during cellular insulin 
stimulation is shown to cause inactivation of PTPs via oxidizing the catalytic Cys to 
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cysteine sulfenic acid (Cys-SOH) or a cyclic sulfenamide species.62 Since cysteine 
sulfenic acid and the cyclic sulfenamide species can be reduced back to free cysteine 
by various cellular reductants, this mode of oxidative inactivation of PTPs may have a 
significant role in controlling the tyrosine phosphorylation-dependant signal 
transduction events. If the PTP is exposed to higher levels of oxidants the catalytic 
Cys residue gets irreversibly oxidized to either sulfinic acid (Cys-SO2H) or sulfonic 
acid (Cys-SO3H) which results in abrogation of enzymatic activity. Thus in order to 
assess the feasibility of employing our activity-based probes for monitoring the H2O2-
mediated PTP inactivation, PTP1B (1 μg) was treated with 1 mM H2O2 in 20 μL 
reaction at 25 oC for 5 min followed by treatment with the Probe 3 for 1 h. The 
reaction was quenched with 6X SDS loading dye followed by heating at 95 oC for 10 
min. A control experiment without H2O2 treatment was also performed 
simultaneously. As shown in Figure 2.6, H2O2-treated PTP1B didn’t not show any 
trace of labeling showing the effectiveness of the probe in distinguishing the active 
versus oxidatively inactivated forms of the enzyme. 









2. 5. 5 Kinetic characterizations and substrate specificities of the probes 
and the corresponding phosphopeptides 
     Kinetic characterizations of the labeling reactions were carried out, with PTP1B as 
the model, by time- and concentration-dependent measurements of the enzyme’s 
inactivation in the presence of the ten probes, as well as measurements of PTP1B-
mediated dephosphorylation with ten corresponding phosphopeptides. The kinetic 
experiments were performed at 25 oC in HEPES buffer (50 mM, pH = 7.5, 150 mM 
NaCl). Appropriate dilutions of the probes (0.2 mM to 2 mM) in the reaction buffer 
(45 μL) were treated with 5 μL aliquots of PTP1B stock solution. From this, 2 μL was 
withdrawn at appropriate time intervals (1 to 60 min) and added into 48 μL of a 20 
μM solution of DiFMUP in the same reaction buffer in a black 384 well flat-bottom 
plate. The fluorescence intensity in relative fluorescence units (RFU) were 
continuously measured for 15 min (e.g. until a consistent trend is observed) using a 
Tecan fluorescence plat reader at excitation wavelength of 360 nm and emission 
wavelength of 460 nm at a gain of 65. Background corrections for non-enzymatic 
hydrolysis of the DiFMUP were made. The experiments were performed in triplicate 
and the data for each probe were averaged and used to derive the kinetic parameters. 
The inactivation reactions follow Kitts and Wilson kinetics63 and the pseudo-first 
order inactivation constants (kobs) at various concentrations of the probes were 
obtained from the initial slope of the semilogarithmic curves of ln(vt/v0) versus 
preincubation time, where vt and v0 are the enzyme activities at time t and zero, 
respectively. A non-linear regression fit of the double-reciprocal plot of kobs versus 
probe concentration gave the maximal inactivation rate constant (ki) and dissociation 
constant Ki according to the following equation. 
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kobs = ki × [I] / Ki + [I]                                                                             Eq. 1 
  
     Ten phosphopeptides with the same amino acid sequence as those in the probes 
were also synthesized (with the only difference being that in the 10 phosphopeptides, 
phosphotyrosine was used in place of the unnatural amino acid, and biotin in place of 
the rhodamine dye) and the dephosphorylation preference of these peptides by PTP1B 
was measured in a microplate-based enzymatic assay using the malachite green 
phosphatase assay.64 First, a standard phosphate assay was performed in order to 
quantify the absorbance values (Figure 2.8a). For the phosphate standard curve, 20 μL 
aliquots of different concentrations of phosphate (0.02 to 120 μM) prepared in TETBS 
buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 5 mM EDTA, 0.05% Tween20) were 
treated with 5 μL of malachite green reagent in a 384-well plate (transparent flat-
bottom) at 25 oC for 15 min and the absorbance at 620 nm was measured using the 
Tecan plate reader. The absorbance was found to be linear in the range of 30 to 800 
picomoles of phosphate (inset in Figure 2.8a). Next, the phosphatase assay was 
performed with 3 μg/mL of PTP1B and a 100 μM solution of each of the 10 
phosphopeptides in TETBS buffer. The reaction was incubated for 10 min at 25 oC in 
a final reaction volume of 20 μL. The phosphatase reaction was quenched by adding 5 
μL of malachite green reagent containing hydrochloric acid and the absorbance at 620 
nm was measured after 15 min. The experiments were carried out in duplicate and 
averaged values were used to derive the number of nanomoles of inorganic phosphate 
released per min per mg of the enzyme (Table 2.2). Corrections were made for the 
non enzymatic hydrolysis of the peptides. In order to further verify the substrate 
specificity, the kobs values for the dephosphorylation reaction were obtained via 
following the time course of dephosphorylation (Figure 2.8b & Table 2.2). Briefly, 
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the Absorbance values were measured at 620 nm over 60 min. and fitted into the 
following equation, 
A = A∞ [1 – exp (- kobs . t) ]                                                                 Eq. 2 
where kobs = (kcat/KM). E, represents the observed kcat/KM at a given enzyme 
concentration (E). The assay was run under conditions where the enzyme and peptide 
substrate concentrations were well below the KM, such that the relative rates of 
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Figure 2. 7 Determination of the kinetics of inactivation for the 10 probes on PTP1B 























Figure 2. 8  (a) Standard curve of phosphate detection using the Malachite green assay, with 
inset showing the linear portion (30 to 800 pmoles of phosphate). (b) Time-dependant 
variation in the absorbance value for the 10 phosphopeptides with PTP1B. The kobs values 
were derived from the curves using eq.2.  
 
 
Probe  Ki (mM)    Phosphopeptide  Phosphate released 
(nmol/min/mg) 
      kobs  
   1     2.81               1               6741       0.072 
   2     1.00               2             10524       0.121 
   3     0.97               3             13549       0.127 
   4     2.19               4               9083       0.109 
   5     3.89               5               7528       0.086 
   6     1.93               6               8707       0.111 
   7     0.94               7             14419       0.137 
   8     2.48               8             11180       0.107 
   9     1.48               9             12397       0.123 
  10     1.00              10             15749       0.143 
 





























Table 2. 2 Comparison of the substrate specificity of PTP1B obtained from the probe 
mediated inactivation of the enzyme (Ki values) and that from the standard Malachite green 
phosphatase assay of the corresponding phosphopeptides. Red indicates preferred substrate, 















Figure 2. 9 Comparison of relative activity of the 10 probes against PTP1B as determined 
from () quantitative analysis of the fluorescent gel shown in Figure 2.3a, (⊞) 1/Ki values 
obtained from inactivation kinetic experiments and ( ) data obtained from the 
dephosphorylation of ten corresponding phosphopeptides catalyzed by PTP1B. All three sets 
of data were internally normalized. % Activity: relative extent of 
labeling/inactivation/dephosphorylation for each probe/peptide (100%: most active 
probe/peptide within each set). 
     Analysis of pseudo-first-order inactivation rate constants, kobs, as a function of 
probe concentration showed time- and concentration-dependant inactivation with 
saturation kinetics typical of irreversible inhibition. The dissociation constants of the 
probes reflect their substrate preferences, with highest 1/Ki values correlated well 
with the most active probes (in their fluorescent labeling), as well as the most 
preferred phosphopeptide substrates (in the amount of PO32- release). All these lines 
of evidence suggest our peptide-based activity-based probes can be used to report not 
only PTP enzymatic activities, but also the substrate specificities of individual PTPs.  
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2. 5. 6 Labeling experiments in the presence of complex proteomes 
2. 5. 6. 1 Labeling experiments in the presence of bacterial cell lysate 
     To evaluate the performance of the probes in a complex proteome, we set up the 
labeling reaction with spiked PTP1B in a bacterial lysate. Cell lysates from E. coli 
strain BL21 (DE3) were used as there is no known PTP present in this bacterial 
genome. The procedures for bacterial culturing and cell-lysate preparation are 
explained in section 2.6.1. Selectively labeling of spiked PTP1B was observed even in 
the presence of large excess of other proteins in the bacterial proteome, demonstrating 
the highly selective nature of the probe’s PTP trapping reaction. Also labeling 
reactions with the panel of the 10 probes (10 μM in reaction) in the presence of the 
bacterial proteome (10 μg total protein) with 0.1 μg of spiked PTP1B generated 
labeling fingerprint (Figure 2.10) identical with the fingerprint obtained using pure 
PTP1B, demonstrating the usefulness of the probes in a complex proteome. 
 








Figure 2. 10  Labeling fingerprint of PTP1B spiked in the bacterial proteome using the panel 





2. 5. 6. 2 Labeling experiments with mammalian cell proteome 
     Total cell lysates from two different mammalian cells (HEK293T and NIH3T3) 
were prepared and treated with P3 (25 µM in reaction) in Tris buffer (50 mM Tris, 
pH=7.5) at 25 oC for 1h (Figure 2. 11b). The proteins were separated on SDS-PAGE 
and the labeled bands were visualized by in-gel fluorescence scanning (left panel) and 
Western blotting using anti-PTP1B antibody (right panel); Western blotting indicated 
the presence of endogenously expressed PTP1B in HEK293T (~52 kDa) but not in 
NIH3T3 cells. A corresponding fluorescent band was observed in the fluorescence gel 
from HEK293T cell lysate (lane 1, highlighted in red box). Neither the probe nor the 
antibody detected PTP1B in the NIH3T3 cells (lanes 2 in Figure 2. 11b). This is in 
agreement with the previously reported extremely low or undetectable expression 
levels of endogenous PTP1B in NIH3T3 cell lines.65 In addition to the endogenous 
PTP1B, the probe also labeled a number of other proteins in the HEK293T cell lysates. 
This might have originated from other endogenous PTPs which were present in the 
cell lysate and accepted P3 as a substrate. To further validate the labeling of 
endogenous PTP1B, we performed pull-down experiments using P11 - the 
biotinylated version of P3. As shown in Figure 2.11c, upon labelling with P11, the 
HEK293T cell lysate was subjected to affinity enrichment and subsequently analyzed 
by Western blotting; endogenous PTP1B was successfully detected (lane 2). This 
experiment thus demonstrates the feasibility of our peptide-based activity-based 




Figure 2. 11 (a) Labeling of spiked PTP1B in the presence of bacterial proteome. Different 
amounts (left to right: 1000 ng, 400 ng, 200 ng, 100 ng, 20 ng, 5 ng & 0.5 ng) of recombinant 
PTP1B was spiked to 10 µg BL21 bacterial proteome and the labeling was performed with 10 
µM probe P3 for 1 h. (b) Labeling of PTPs in mammalian cell lysates. Left panel, in-gel 
fluorescence analysis of global PTP activity profiles obtained from total cell lysates of 
HEK293T cells and NIH3T3 cells (20 µg total proteins in each lane) with probe P3. Right 
panel, Anti PTP1B blot of the two labeled lysates detecting endogenous PTP1B at ~52 kDa 
from the HEK293T cell lysate (lane 1) while no PTP1B was detected from the NIH3T3 cells 
(lane 2). (c) Pull-down results using the biotinylated probe P11 with HEK293T cell lysate 
followed by enrichment with NeutrAvidine agarose beads. Anti PTP1B WB of the probe 
treated HEK293T cell lysate after pull-down experiments detected the endogenous PTP1B at 








2. 6 Conclusions 
In conclusion, a novel unnatural amino acid (2-FMPT) which is a close mimic of 
phosphotyrosine was synthesized and incorporated into peptide sequences to generate 
peptide-based probes for PTPs. With the peptide-based probe design, target-specific 
profiling of PTPs present in mammalian cell lysates was demonstrated using PTP1B 
as an example. Further improvement of the probes may be achieved by incorporation 
of longer peptide recognition sequences or by genetically or semi-synthetically 
incorporating the unnatural amino acid into suitable protein-based substrates of 
PTPs.66 Ultimately, it might be possible to extend the strategy to in vivo profiling of 












2. 7 General procedures for sample preparations and labeling experiments 
using proteomes 
2. 7. 1 Preparation of bacterial cell lysates and labeling experiments 
using the lysates 
     Bacterial lysates were prepared as follows. Briefly, an overnight culture of LB 
(100 ml) inoculated with a single colony of the bacteria, and grown at 37 oC with 
shaking (300 rpm), was harvested by centrifugation at 4000 rpm for 10 min at 4 °C. 
The resulting Pellets were suspended in the lysis buffer (50 mM Tris at pH 7.5, 
150 mM NaCl) and sonicated (to complete lysis, 20 rounds of 1s on and 5s off, at 
25 % amplitude), before centrifugation for 10 min (1000 rpm at 4 oC). The 
resulting supernatant was further centrifuged for 15 min (13000 rpm at 4 °C). The 
total protein concentration of this lysate was then quantified by Bradford’s Assay 
(Biorad), and adjusted to 6.0 mg/ml, aliquoted and stored in -20 °C, and used for 
all subsequent labeling experiments. 
     In a typical labeling reaction, different amounts of PTP1B (1 μg to 0.05 ng) 
was spiked into 10 µg of the bacterial proteins in Tris buffer (50 mM Tris, pH 7.5, 
150 mM NaCl) at a reaction volume of 19 μL at 25 oC. To this was added 1 μL of 
the probe 3 (10 μM in the reaction) and incubated for 1h at 25 oC before protein 
separation on SDS-PAGE and in-gel fluorescence scanning. 
 
2. 7. 2 Procedure for Western Blot Analysis  
     The proteins in the gel after in-gel fluorescence scanning were electrotransferred 
overnight at 4 oC to a PVDF membrane. The membrane was blocked with 5% non-fat 
dry milk in Tris-Buffered Saline with 0.1% Tween 20 (TBS-T) for 1 h at 25 oC. After 
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two quick washes with TBS-T, the membrane was treated with PTP1B antibody 
(abcam, product code: ab52650, EP1837Y) in 5% BSA in TBS-T (1:105 dilution) for 
2 h at 25 oC. The membrane was then washed three times (5 min for each wash) with 
TBS-T and subsequently incubated with goat anti-rabbit HRP antibody (1:2000 
dilution in TBS-T) for 1 h. The secondary antibody treated blot was then washed three 
times (10 min for each wash) with TBS-T, rinsed with TBS and subsequently treated 
with HRP substrate. Excess chemiluminescence reagent was removed and the image 
was acquired using dark room development facilities.   
2. 7. 3 Procedure for Pull-down of biotinylated probe labeled PTP          
     The pull-down followed by immunoblot experiments were carried out as described 
below. HEK293 cell lysates were prepared as previously described. Before PTP probe 
labeling, lysates was incubated with washed NeutrAvidin-Agarose beads (Pierce) to 
remove endogenously biotinylated proteins. This flow-through fraction was used for 
PTP probe labeling. After 1 h reaction at RT, proteins were precipitated from the 
lysate by acetone and re-dissolved in solubilizing buffer (PBS with 1% SDS). Before 
incubation with NeutrAvidin Agarose Beads, samples volumes were adjusted by 
adding PBS to dilute SDS to 0.1%. After incubation with washed beads for 1 h at RT, 
beads were washed with 10 bed volumes of PBS with 0.1%SDS for 3 times. Bounded 
protein was eluted by boiling in SDS sample buffer.  For immunoblot analysis, this 
pull down sample was then separated on 12% SDS-PAGE gel, transferred to PVDF 
membrane and probed with anti-PTP1B antibody. 52 kDa PTP1B band was observed 
in the pull-down elute fraction while not in the negative control (lysate without probe 




2. 8 Synthetic details and characterizations of compounds 
2-(tert-Butoxycarbonylamino)-3-(4-hydroxyphenyl) propanoic acid (2-2): 
To a solution of L-Tyrosine, 2-1 (Aldrich, 40 g, 220.8 mmol) in 1/1 dioxane/water 
(250 mL each) was added triethylamine (46 mL, 1.5 eq., and 331.2 mmol). The 
reaction flask was cooled to 0 oC with an ice bath and di-tert-butyl-dicarbonate (53 g, 
1.1 eq., 331.2 mmol) was added. After 1 h, the cold bath was removed and the 
reaction mixture was stirred at ambient temperature for 20 h. The reaction mixture 
was then concentrated on a rotary evaporator and the residue diluted with water and 
ethyl acetate. The aqueous layer was acidified to pH 1 with 1 N HCl and back 
extracted with ethyl acetate. The organic layer was washed with brine, dried over 
Na2SO4 and evaporated to give the protected amino acid, Compound 2-2, as a white 
solid (56 g, 90%) which was used without further purifications.1H- NMR (300 MHz, 
CDCl3) δ 6.95 (2H, d, J = 8.22 Hz), 6.70 (2H, d, J = 7.41 Hz), 5.92 (1H, bs, OH), 5.16 
(1H, bs, NH), 4.53 (1H, unresolved m, α H), 3.01 (2H, unresolved m, βH), 1.40 (9H, s, 
Boc); ESI-MS: m/z =  280.2 [M-H]-   
2-(tert-Butoxycarbonylamino)-3-(3-formyl-4-hydroxyphenyl) propanoic acid (2-
3): 
Compound 2-2 (40 g, 142.3 mmol) in 600 mL of CHCl3 was heated to 65 oC. To this 
was added a hot (65 oC) solution of NaOH (22.8 g, 4 eq., 569 mmol) in 80 mL of 
water and the mixture was refluxed for 1.5 h. After cooling, CHCl3 was evaporated 
off and the reaction mixture was diluted with water and EtOAc, and the aqueous layer 
was acidified to pH 1 with 1 N HCl and back extracted with EtOAc. The organic layer 
was washed with brine, dried over Na2SO4 and concentrated. Flash column 
chromatography (silica gel, 12/1 CHCl3/MeOH with 1% acetic acid eluent) afforded 
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2-3 as a pale yellow oil (17.1 g, 39%).Unreacted starting material 2-2 was also 
recovered. 1H-NMR (300 MHz, CDCl3) δ 10.9 (1H, s, OH), 9.8 (1H, s, CHO), 7.36 
(1H,s C2-H), 7.32 (1H,d, J = 8.37 Hz), 6.91 (1H, d, J = 8.37 Hz, C5-H), 5.27 (1H, bs, 
NH), 4.57 (1H, unresolved m, α H), 3.15 (1H, unresolved m, β H), 3.02 (1H, 
unresolved m, βH), 1.38 (9H, s, Boc); 13C-NMR (75.5 MHz, CDCl3) δ 196.52, 177.03, 
160.52, 155.29, 138.08, 134.23, 127.62, 120.37, 117.72, 80.43, 54.16, 36.83, 28.16; 
ESI-MS: m/z = 308.1 [M-H]-   
Benzyl 2-(tert-butoxycarbonylamino)-3-(3-formyl-4-hydroxyphenyl) propanoate 
(2-4): 
To a solution of 2-3 (10 g, 32.36 mmol) in CH2Cl2 was added benzyl alcohol (6.73 
mL, 64.72 mmol, 2 eq.) followed by DMAP (0.6 g, 0.15 eq.) and the solution was 
cooled to 0 oC with an ice-water bath while stirring. EDC (7.45 g, 38.83 mmol, 1.2 eq.) 
was added and after 30 min the ice bath was removed, and continued stirring at room 
temperature for 3 h. The reaction mixture was then extracted with water, brine, dried 
over Na2SO4 and concentrated. Flash column chromatography (silica gel, 
CHCl3/MeOH, 12/1) afforded 2-4 as a pale yellow oil (13.8 g, 80%) 1H-NMR (300 
MHz, CDCl3) δ 10.84 (1H, s, OH), 9.59 (1H, s, CHO), 7.33-7.24 ( 5H, unresolved m), 
7.12 (2H, m), 6.8 (1H, d, J = 8.4 Hz) 5.27 (1H, bs, NH), 5.10 (2H, m, CH2-benzyl), 
4.57 (1H, unresolved m, α H), 3.15 (1H, unresolved m, βH), 3.02 (1H, unresolved m, 
βH), 1.38 (9H, s, Boc) ; 13C-NMR (75.5 MHz, CDCl3) δ 196.37, 171.37, 160.40, 
154.99, 137.99, 135.04, 134.07, 128.57, 127.56, 120.26, 117.58, 79.95, 67.08, 54.34, 
37.03, 28.21 
Benzyl-2-(tert-butoxycarbonylamino)-3-(4-(diethoxyphosphoryloxy)-3-
formylphenyl) propanoate (2-5): 
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Compound 2-4 (8 g, 20 mmol) was dissolved in CH2Cl2 (90 mL). To this was added 
DBU (6 mL, 40 mmol, 2 eq.) and the reaction mixture was cooled to 0 oC with an ice-
water bath while stirring under N2 gas. After 15 min, diethylchlorophosphate (6.4 mL, 
44 mmol, 2.2 eq.) was added and the ice bath was continued for 45 min, and after that 
the ice bath was removed and stirring continued at room temperature for 8 h. The 
reaction was extracted with 5% citric acid solution, brine, dried over Na2SO4 and 
concentrated. Flash column chromatography (silica gel, Hexane/EtOAc, 10/2) 
afforded 2-5 as a pale yellow oil (7.5 g, 70%). 1H-NMR (300 MHz, CDCl3) δ 10.29 
(1H, s, CHO), 7.35-7.28 (5H,unresolved m), 7.27-7.23 (2H,m C2-H & C6-H), 7.21 
(1H, d, J = 8.37 Hz, C5-H), 5.10 (2H, m, CH2-benzyl), 4.55 (1H, unresolved m, α H), 
4.22 (4H, q, CH2 -phosphate) 3.14 (1H, unresolved m, βH), 2.98 (1H, unresolved m, 
βH), 1.33 (9H, s, Boc), 1.28 (6H, t, phosphate) ; 31P-NMR (121.5 MHz, CDCl3) δ = -
6.0902 (s);  ESI-MS: m/z = 558.2 [M+Na]+   
Benzyl-2-(tert-butoxycarbonylamino)-3-(4-(diethoxyphosphoryloxy)-3-
(hydroxymethyl) phenyl) propanoate (2-6): 
To a solution of the aldehyde 2-5 (6 g, 11.2 mmol) in absolute EtOH (90 mL), THF 
(20 mL) and water (900 μL) was added NaBH4 (0.43 g, 11.2 mmol) at 0 oC and stirred 
for 15 min. The reaction mixture was then diluted with acidic water (pH = 4; 80 mL) 
and stirring continued for 10 min. The mixture was extracted with EtOAc (2 × 90 mL) 
and concentrated under reduced pressure. The oily compound obtained was then 
coevaporated with MeOH three times, again dissolved in EtOAc, extracted with brine, 
dried over Na2SO4 and concentrated at reduced pressure. It was then purified by silica 
gel flash chromatography (DCM/ MeOH 10/1) to provide 2-6 as a pale yellow oil (4.2 
g, 69.7%) 1H-NMR (300 MHz, CDCl3) δ 7.35-7.27 (5H,unresolved m), 7.15 (1H,s) 
7.05 (1H, d, J = 8.22 Hz), 6.92 (1H, d, J = 8.04 Hz), 5.1 (2H, m, CH2-benzyl),  4.62 
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(2H, s, CH2-alcohol), 4.55 (1H, m, α H),  4.21 (4H, m, CH2-phosphate)  3.14 (1H, 
unresolved m, βH), 2.98 (1H, unresolved m, βH), 1.33 (9H, s, Boc), 1.28 (6H, t, CH3-
phosphate) ; 13C-NMR (75.5 MHz, CDCl3) δ 171.72, 155.31, 146.97, 135.35, 133.66, 
130.56, 129.26, 128.53, 120.11, 79.63, 66.98, 64.85, 59.33, 54.70, 37.27, 28.23, 16.07; 
31P-NMR (121.5 MHz, CDCl3) δ =  -5.1757(s)   
Benzyl-2-(tert-butoxycarbonylamino)-3-(4-(diethoxyphosphoryloxy)-3-
(fluoromethyl) phenyl) propanoate (2-7): 
A solution of the alcohol 2-6 (3.23 g, 6 mmol) in dry CH2Cl2 (40 mL) was cooled to 0 
oC and diethylaminosulfurtrifluoride (2.36 mL, 18 mmol, 3 eq.) was added and stirred 
for 30 min to complete the reaction. Saturated NaHCO3 solution (40 mL) was added 
to quench the DAST and stirring continued for another 10 min. The reaction was then 
extracted with water, brine, dried over Na2SO4 and concentrated on a rotary 
evaporator. The yellow oily compound obtained was purified by flash column 
chromatography on silica gel (Hexane/ EtOAc 70/30) to obtain 2-7 as pale yellow oil 
(2.4 g, 74.1%). 1H-NMR (300 MHz, CDCl3) δ 7.33-7.27 (5H,unresolved m), 7.25 
(1H,s ) 7.03 (1H, d, J = 8.22 Hz), 7.05 (1H, d, J = 8.22 Hz), 5.46-5.30 (2H, d, J = 
47.50 Hz, CH2F), 5.12 (2H, m, CH2-benzyl), 4.58 (1H, m, α H), 4.18 (4H, m, CH2-
phosphate), 3.1-2.97 (2H, unresolved m, βH), 1.39 (9H, s, Boc), 1.30 (6H, t, CH3-
phosphate); 13C-NMR (75.5 MHz, CDCl3) δ 171.35, 154.99, 147.21, 135.11, 133.24, 
130.76, 130.19, 128.23, 127.54, 119.70, 80.54, 78.32, 66.83, 64.62, 54.40, 36.96, 
28.02, 15.87; 31P-NMR (121.5 MHz, CDCl3) δ =  -5.8829 (s); 19F-NMR (288.2 MHz, 
CDCl3) δ = -138.41 (t, J = 47.45 Hz ); ESI-MS: m/z = 562.2 [M+Na]+ 
2-(tert-butoxycarbonylamino)-3-(4-(diethoxyphosphoryloxy)-3-(fluoromethyl) 
phenyl) propanoic acid (2-8): 
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To a degassed solution of 2-7 (2 g, 3.7 mmol) in dry MeOH (40 mL) was added 10% 
Pd/C (0.2 g) and the solution was stirred under hydrogen atmosphere for 20 min to 
complete the reaction. The Pd/C was removed by filtration through a celite and the 
filtrate was concentrated under reduced pressure to afford 2-8 as pale yellow oil (1.6 g, 
96%). It was used in the next reaction without further purification 1H-NMR (300 MHz, 
CDCl3) δ 7.32 (1H, m), 7.27 (1H, s) 7.19 (1H, d, J = 8.22 Hz), 5.51-5.35 (2H, d, J = 
47.50 Hz, CH2F), 4.52 (1H, m, α H), 4.22 (4H, m, CH2-phosphate), 3.22-3.01 (2H, 
unresolved m, βH), 1.41 (9H, s, Boc), 1.34 (6H, t, CH3-phosphate); 13C-NMR (75.5 
MHz, CDCl3) δ 173.55, 155.41, 147.31, 133.84, 131.20, 130.75, 130.66, 119.79, 
80.82, 78.61, 65.23, 54.19, 37.16, 28.28, 15.97; 31P-NMR (121.5 MHz, CDCl3) δ = -
6.1999 (s); 19F-NMR (288.2 MHz, CDCl3) δ = -138.25 (t, J = 47.41 Hz ); ESI-MS: 
m/z = 448 [M-H]-   
2-amino-3-(4-(diethoxyphosphoryloxy)-3-(fluoromethyl) phenyl) propanoic acid 
(2-9): 
The N-Boc unnatural amino acid 2-8 (1.6 g, 3.56 mmol) was dissolved in a mixture of 
TFA/DCM (1/1; 40 mL each) and the solution was stirred for 3 h in an open RBF. 
TFA and DCM are evaporated off under reduced pressure to obtain 2-9 as pale yellow 
oil which was used in the next reaction without further purification. 1H-NMR (300 
MHz, CDCl3) δ 12.90 (1H, COOH), 7.57 (2H, bs, NH2), 7.37 (2H, m), 7.15 (1H, m), 
5.47-5.31 (2H, d, J = 48 Hz, CH2F), 5.27 (1H, m, α H), 4.25 (4H, t, CH2-phosphate), 
3.32-3.04 (2H, unresolved m, βH), 1.37 (6H, t, CH3-phosphate); 31P-NMR (121.5 
MHz, CDCl3) δ = -7.2485 (s) 
2-(((9H-fluoren-9-yl) methoxy) carbonyl amino)-3-(4-(diethoxyphosphoryloxy)-3-
(fluoromethyl) phenyl) propanoic acid (2-10):  
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Compound 2-9 (1.6 g, 3.45 mmol) was dissolved in a mixture of THF/Water (1/1; 30 
mL each) and the solution was adjusted to pH = 9 by adding NaHCO3 (0.87 g, 10.35 
mmol, 3.3 eq). To this was added FmocOSu (1.28 g, 3.8 mmol, 1.1 eq) and stirring 
continued for 4 h. THF from the reaction mixture was evaporated off and the solution 
was diluted with EtOAc. The aqueous layer was then acidified to pH = 2 by 1 N HCl 
and back extracted with EtOAc. The organic layer was then extracted with brine, 
dried over Na2SO4 and concentrated. Flash column chromatography (silica gel, 90/10 
hexane/EtOAc to 97/3 EtOAc/MeOH with 0.1% acetic acid) afforded the N-Fmoc 
unnatural amino acid 2-10 as an off white foam (1.51 g, 76.5%). 1H-NMR (300 MHz, 
CDCl3) δ 10.38 (1H, s, COOH), 7.72 (2H, d, J = 7.38 Hz), 7.56 (2H, t, J = 7.08 Hz), 
7.36 (1H, s), 7.31 (1H, s), 7.28 (4H, m), 7.16 (1H, d, J = 7.89 Hz), 6.93 (1H, m), 5.48-
5.33 (2H, d, J = 47.00 Hz, CH2F), 4.69 (1H, unresolved m, α H), 4.20 (4H, m, CH2-
phosphate), 3.23-3.06 (2H, unresolved m, βH), 1.31 (6H, t, CH3-phosphate); 13C-
NMR (75.5 MHz, CDCl3) δ 173.11, 163.32, 155.77, 147.33, 143.69, 141.20, 133.39, 
131.18, 130.53, 127.31, 127.00, 125.04, 119.61, 80.73, 78.53, 66.97, 65.04, 47.03, 
36.77, 15.97; 31P-NMR (121.5 MHz, CDCl3) δ = -6.2853 (s); 19F-NMR (288.2 MHz, 








Chapter 3: Caged Activity-Based Probes for Protein 
Tyrosine Phosphatases (PTPs) 
Summary: 
This chapter summarizes the design and development of peptide-based light-
controllable activity-based probes for PTPs. A novel caged unnatural amino acid 
(caged-2-FMPT) bearing photolabile o-nitrobenzyl group on the phosphate moiety of 
2-fluoromethyl phosphotyrosine was synthesized and the unnatural amino acid was 
incorporated into peptides to generate peptide-based, caged, activity-based probes.  
With PTP1B as a model system, the concept of photo-uncaging followed by activity-
based labeling was validated. The caged ABPs, with further improvements in design, 
could potentially be used for the spatially and temporally resolved investigation of 
PTP activities in cells. 
3. 1 Introduction 
     The term, “caged compounds” in chemical biology contexts represents molecules 
in which a critical reactive functionality is masked with a chemical entity, which can 
be irreversibly unmasked using a suitable physical or chemical trigger such that it 
allows the spatially and temporally controlled release of a concentration burst of the 
reactive species, making possible a corresponding spatio-temporal resolution in the 
investigations of the downstream signalling events associated with the reactive 
functionality.67 Photolabile groups are used extensively for this purpose mainly 
because of the precise focussing and manipulations of photons possible with the 
developments in laser and microscope technologies. Historically, the term caging was 
coined by J. F. Hoffman et al. in 1978 when the γ-phosphate of ATP was protected 
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with a photolabile o-nitrobenzyl group.68 The caged ATP was found to be inert 
towards Na, K- ATPases while upon UV-irradiation the release of free ATP occurred 
and the photo-uncaging was characterized by the consumption of Na, K- ATPases and 
Na+ efflux from the cells through the Na:K pump. Indeed, a cyclic AMP derivative 
with a photolabile o-nitrobenzyl protecting group on the phosphate was reported by 
Engels et al. prior to Hoffman’s report of the caged-ATP, although the use of photo-
uncaging was not the focus of their paper.69  
 
Scheme 3. 1 Proposed mechanism for light-mediated uncaging of o-nitrobenzyl caged 
molecules.74 
     The selection of a suitable caging group for a particular biological application is 
based on a number of criteria such as 1) synthetic considerations of the caged 
molecule 2) physical and chemical properties of the cage (the cage should not alter the 
fundamental properties of the system to be investigated) 3) photo-physical properties 
of the uncaging process such as the quantum yield of uncaging, the wavelength and 
molar extinction coefficient of excitation and the kinetics of uncaging 4) toxicity and 
chemical reactivity properties of photo-uncaging byproducts. The most extensively 
used caging groups in biological studies is the o-nitrobenzyl and its derivatives, as 
these protecting groups possess several desirable properties such as synthetic ease, 
good quantum yield of uncaging, inertness to cellular environment and water soluble 
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photo-uncaging byproducts. Several other molecules such as coumarin derivatives,70 
cinammic acid derivatives,71 hydroxyphenacyl derivatives,72 ketoprofen derivatives73 
etc. have also been used for caging applications in different biological experiments.  
     Caged versions of several biologically relevant molecules such as co-factors, 
neurotransmitters, secondary messengers, hormones, nucleic acids, lipids, peptides 
and even full-length proteins have been developed and they find great values in 
unravelling the roles of these important molecules in cellular functions which are 
otherwise difficult to achieve. Given the paramount importance of the reversible 
protein phosphorylation in cellular signal transduction events, significant research 
efforts have been dedicated to develop caged compounds useful in the study of 
protein kinases. In 1998, Lawrence and co-workers and Bayley and co-workers 
independently reported the first caged versions of c-AMP-dependent protein kinase 
(PKA).75 While Bayley and co-workers employed a thiol reactive small molecule, 2-
nitrobenzyl bromide (NBB), to covalently attach the photolabile group to a cysteine 
residue near the catalytic site of PKA, Lawrence and co-workers employed a peptide-
based affinity label equipped with the thiol reactive 2-nitrobenzyl bromide at the C-
terminal side to covalently label the cysteine residue (Cys-199) near the active site of 
the kinase. These caged versions of PKA remain catalytically inactive until exposure 
to UV light, while the photo-irradiation causes photo-uncaging and recovery of at 
least 50% of the kinase activity. In the same year Lawrence and co-workers reported a 
peptide-based caged inhibitor of PKA which was shown to inhibit the kinase activity 
only when uncaged with UV light.76 In 2003, Lawrence and co-workers reported the 
first caged probe for intracellular PKC activity.77 The probe design was based on a 
substrate peptide sequence of PKC which was equipped with an environmentally 
sensitive fluorophore at the N-terminal side and an adjacent serine residue (which acts 
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as the phosphorylation site for the kinase) was caged with 2-nitro-4, 5-dimethoxy 
benzyl group. Upon photo-uncaging, the serine residue gets receptive for 
phosphorylation and the phosphoryl transfer to which causes changes in the 
fluorescence of the environmentally sensitive fluorophore. Thus a simple 
measurement of fluorescence change following the photo-uncaging provides readout 
of the kinase activity. In 2003, Imperiali and co-workers designed a caged 
phosphopeptide derived from the autophosphorylation region of focal adhesion kinase 
(FAK).78 Photo-uncaging of the phosphopeptide was used to cause temporally 
controlled lamellar arrest in a rat bladder tumour cell line. Nagamune and co-workers 
recently reported light-controlled activation of the lipid kinase, phosphatidylinositol- 
3-kinase (PIK), using a caged phosphopeptide.79 Lawrence and co-workers recently 
reported a photodeactiavable bisubstrate-based inhibitor of Src tyrosine kinase.80 The 
inhibitor was equipped with a photolabile site positioned at the β-Ala tether separating 
the catalytic (SH1) and SH2 domains targeting peptide sequences and upon photo-
irradiation, the inhibitor gets split to its component peptides which no longer serves as 
an effective bisubstrate inhibitor of the kinases, thus providing a photodeactiavable 
version of a bisubstrate inhibitor of the kinase.   
     Although caging has been applied as a useful method for regulating the activity of 
various kinases, the strategy is relatively less explored in the study of protein 
phosphatases. A significant study involves the development of an imaging approach 
based on Förster Resonant Energy Transfer (FRET) between a GFP-tagged PTP1B 
and a fluorophore incorporated synthetic phosphopeptide to spatially resolve the 
enzyme-substrate interactions in live cells.81 By using a caged phosphopeptide 
substrate, Bastiaens and co-workers performed temporally controlled live-cell 
imaging of PTP1B-substrate interactions which revealed the establishment of a 
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Figure 3. 1 Chemical structures of reagents used in the synthesis of caged phosphates 
     In line with the development of the peptide-based ABPs for PTPs, discussed in the 
previous chapter, we sought to develop caged versions of the probes which could be 
used for temporally controlled ABPP. Similar to the 2-FMPT based peptide probes, 
we decided to make a caged 2-FMPT, which could be incorporated into peptide 
synthesis to generate the caged ABPs. Imperiali and co-workers have previously 
reported the use of phosphoramidites such as 1 and 2 (Figure 3.1) to synthesize caged 
versions of phospho-serine, phospho-threonine and phospho-tyrosine amino acids and 
such phospho-caged amino acids have been shown to be compatible with standard 
solid-phase peptide synthesis protocols.82 However, attempts to make caged version 
of 2-FMPT using the phosphoramidite strategy were unsuccessful presumably 
because of the steric bulk near the reaction site of the unnatural tyrosine substrate. So 
we decided to make the chlorophosphate reagent 3 for generating the caged 2-FMPT, 
which was indeed proven to be a convenient reagent to accomplish the target 
molecule (Scheme 3.2). The caged 2-FMPT thus synthesized was subsequently 

















The key idea of photo-uncaging followed by PTP-trapping is schematically shown in 
Figure 3.2. The presence of o-nitrobenzyl group on the phosphate protects the caged 
probe from reacting with PTPs while upon UV-irradiation, uncaging occurs 
generating the PTP-reactive 2-FMPT-based peptide probe. A nucleophilic attack of 
the catalytic cysteine residue from the active site of the PTP on the phosphate leads to 
dephosphorylation of the probe. Subsequent charge delocalization followed by 
elimination of F- generates the reactive quinone methide intermediate which, upon 
attack by a nearby nucleophilic residue in the enzyme, would give rise to the covalent 










Figure 3. 2 Proposed mechanism of photo-uncaging of the peptide-based probe followed by 
labeling of PTP. The presence of o-nitrobenzyl group on the phosphate protects the caged 
probe from reacting with PTPs while upon UV-irradiation, uncaging of the phosphate occurs 



































Scheme 3. 2 Synthesis of caged 2-FMPT 
 
     The synthesis of caged 2-FMPT was started with compound 2-3 which was an 
intermediate in the synthesis of 2-FMPT (the synthesis of 2-FMPT is discussed in 
chapter 2). The carboxylic acid group in 2-3 was protected with p-methoxybenzyl 
ester (PMB) to get 3-3 at 55% yield.  In the next step the hydroxyl group of the 
unnatural tyrosine 3-3 was phosphorylated with the chlorophosphate reagent 3-2 to 













































1. TFA-CH2Cl2 (2:1), 0 oC - RT




















































prepared from bis (2-nitrobenzyl) hydrogen phosphate 3-1 via treatment with oxalyl 
chloride and compound 3-1 was indeed prepared from commercially available 2-
nitrobenzyl alcohol and methyl dichlorophosphate in pyridine at 39% yield according 
to published procedure.83 The formyl group in 3-4 was subsequently reduced with 
NaBH4 (63% yield) to get compound 3-5 which was then fluorinated with DAST 
(82% yield) afforded compound 3-6. The PMB and Boc protective groups in 
compound 3-6 were simultaneously removed via treatment with TFA and the free 
amino group was then protected with Fmoc using FmocOSu afforded the final caged 






























Scheme 3. 3 Synthesis of caged peptide-based ABPs 
 
     Solid-phase synthesis of peptide-based probes with caged 2-FMPT were carried 












FmocHN Rink amide resin
1. Piperidine-DMF (1:4)


















































































peptide-based probes were synthesized. The sequences of the probes (Table 3.1) were 
derived from putative PTP1B substrates reported in the Human Protein Reference 
Databank. The resin (in microreactors) was swelled in DMF for 30 min after which 
the Fmoc group was deprotected by treatment with 20% piperidine in DMF for 1 h 
followed by washing with DMF (3  10 min), DCM (3  10 min) and DMF again (3  
10 min). The microreactors were then introduced into a reaction vessel containing 
Fmoc amino acid (4.0 eq., 2.0 eq. when 3-7 was used), pre-activated with HOBt (4 
eq.), HBTU (4 eq.) and diisopropylethylamine (DIEA, 8 eq.) in DMF (2 mL). 
Coupling reactions were carried out overnight following which the microreactors 
were collected and washed with DMF (3  10 min), dichloromethane (3  10 min) 
and DMF again (3  10 min) followed by the next cycle of Fmoc deprotection and 
coupling. The N-terminus of each peptide was coupled to a Lys-(biotin) (4.0 eq.) 
unnatural amino acid followed by a rhodamine dye derivative (4.0 eq.) using the same 
pre-activation method as described before. Following the coupling of the rhodamine 
dye, the resin was washed extensively and dried thoroughly in vacuo. The peptides 
were cleaved from the resin for 3 h with a cocktail of TFA (95%), TIS (2.5%) and 
H2O (2.5%). After cleavage, the solution was concentrated in vacuo until >80% of the 
cleavage cocktail was removed. To this was added cold ether (-20 C) to precipitate 
the peptides and the mixture was left at -80 C overnight to complete the precipitation. 
The peptides were then washed with cold ether (3 ) and dried under reduced pressure. 
The probes were further purified by preparative HPLC and stock solutions were 
prepared in DMSO. Notably, it was found that one of the o-nitrobenzyl protecting 
groups on caged 2-FMPT was removed during the course of peptide synthesis, 









c-P1 Stat5b Rho-Lys(Biotin)KAVDGXVKPQI 
c-P2 Tyk2 Rho-Lys(Biotin)PEGHEXYRVRE 
      1 = Obtained from www.hprd.org             X = caged 2-FMPT 
Table 3. 1 Amino acid sequences in the two peptide-based caged PTP probes 
3. 4 Results and Discussions 
     In order to evaluate the strategy of photo-uncaging followed by activity-based 
labeling, we performed time- and UV-irradiation dependant labeling reactions with 
pure PTP1B using the two caged probes c-P1 and c-P2. As shown in Figure 3.3, no 
labeling of PTP1B was detected during incubation of the probes with the enzyme in 
the absence of UV-irradiation whereas irradiation-time-dependant increase in labeling 
intensity was observed after exposure of the sample to UV-light.  
                          
     Time of UV-irradiation (min)     0   10   20   30       0   10   20   30 
     Fluorescence                                    
     Coomassie                                        
                                                                 c-P1                      c-P2 
Figure 3. 3 UV-irradiation-dependant labeling of PTP1B (1 µg, Tris buffer, pH = 7.5) with 
the probes c-P1and c-P2 (4 µM each in reaction).  A handheld UV-light source (4W, ~ 360 
nm light) was used for the irradiating the samples.  
The photo-uncaging of the peptide probes (600 µM solutions in DMSO) were 
monitored by HPLC, which showed complete uncaging of the probes in 
approximately 120 minutes of UV-irradiation (Figure 3.4). 
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Figure 3. 4 (a) Scheme showing the photo-uncaging of the caged-peptide-based probe (b) 
HPLC profiles of the caged probe, c-P1, after increasing time (0 min, 30 min, 60 min and 120 
min) of UV-irradiation. The peak highlighted in the blue box corresponds to the caged probe 
whereas the peak highlighted in the red box corresponds to the uncaged probe. 
 
3. 5 Conclusions 
In conclusion, a novel caged unnatural amino acid (caged 2-FMPT) was synthesized, 
which was successfully incorporated into solid-phase peptide synthesis to generate 
peptide-based caged activity-based probes. With PTP1B as a model system, the 
concept of photo-uncaging followed by activity-based labeling was validated in vitro 
and confirmed that light-mediated deprotection of the o-nitrobenzyl protecting group 
of the phosphate in the unnatural amino acid is essential for the activity-based 
labeling of the enzyme. Spatially and temporally resolved investigations of individual 
PTP activities in intact cells remains a formidable task within the current molecular 
and cellular biology research premises. Even a partial accomplishment of this 
extremely challenging task could be the key to unravel the critical roles that various 
PTPs play in the cellular signal transduction networks. It is hoped that the design of 
the caged-ABPs for PTPs discussed in this chapter could provide the guideline for the 







3. 6 Synthetic details and chemical characterizations  
Bis (2-nitrobenzyl) hydrogen phosphate (3-1): 
Compound 3-1 was synthesized according to published procedures with some 
modifications.83 To a solution of anhydrous pyridine (10 mL) at 0 C was added 
dropwise methyl dicholorophosphate (1.0 g, 7.0 mmol). The mixture was kept at 0 C 
for a further 15 min after which 2-nitrobenzyl alcohol (2.6 g, 17.5 mmol) was added. 
The ice bath was removed and the sealed reaction mixture was stirred overnight at 
room temperature. After 20 h, the mixture was poured into 10% aqueous NaHCO3 (50 
mL) and extracted with diethyl ether. The aqueous layer was acidified with 4N HCl to 
pH 1, the filtered, washed with cold H2O and dried in vacuo to give 3-1 as a white 
solid (1.01 g, 39%). 1H-NMR (300 MHz, DMSO)  8.1 (d, 2H, J = 9.0 Hz), 7.8 (m, 
4H), 7.6 (t, 2H, J = 7.4 Hz), 5.3 (d, 4H, J = 7.2 Hz). 13C-NMR (75 MHz, DMSO)  
146.7, 134.2, 132.7, 132.6, 129.0, 128.5, 124.8, 64.5, 64.4. 31P-NMR (121 MHz, 




To a solution of 2-(tert-butoxycarbonylamino)-3-(3-formyl-4-
hydroxyphenyl)propanoic acid, 2-3 (5.7 g, 18.4 mmol) in dichloromethane (50 mL) 
was added p-methoxybenzyl alcohol (3.4 mL, 27.7 mmol) and DMAP (0.3 g, 2.8 
mmol). The solution was cooled to 0 C followed by the addition of 1-ethyl-3-(3-
dimethylaminopropyl)carbo-diimide hydrochloride (EDC-HCl, 4.2 g, 22.1 mmol). 
The reaction was stirred at 0 C for 1 h after which the ice bath was removed and the 
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reaction was stirred for 3 h. After 3 h, the reaction was extracted with water, washed 
with brine and dried over anhyd. Na2SO4. Following the removal of the solvent, the 
crude product was purified by flash column chromatography (3:1 hexane:ethyl acetate) 
to give 3-3 as a white solid (4.33 g, 55%). 1H-NMR (300 MHz, CDCl3) . 10.9 (s, 1H), 
9.6 (s, 1H), 7.2 (d, 2H, J = 8.7 Hz), 7.1 (m, 2H), 6.9 (d, 2H, J = 8.7 Hz), 6.8 (d, 1H, J 
= 8.4 Hz), 5.1 (m, 2H), 4.6 (m, 1H), 3.8 (s, 3H), 3.0 (m, 2H), 1.4 (s, 9H). 13C-NMR 
(75 MHz, CDCl3)  196.4, 171.4, 160.6, 160.0, 155.0, 138.1, 134.2, 130.6, 127.5, 
127.2, 120.4, 117.7, 114.0, 80.1, 67.1, 55.3, 54.4, 37.3, 28.3. ESI-MS: m/z 
[(M+Na+)/1] calculated for C23H27NNaO7: 452.2, found: 452.1. 
 4-Methoxybenzyl-3-(4-(bis (benzyloxy) phosphoryloxy)-3-formylphenyl)-2-(tert-
butoxy-carbonylamino) propanoate (3-4): 
To a suspension of 3-1 (100 mg, 0.3 mmol) in distilled dichloromethane (3 mL) was 
added a catalytic amount of DMF (2 L). Oxalyl chloride (172.5 mg, 1.4 mmol) was 
then added dropwise at room temperature to the reaction mixture. The reaction 
mixture was allowed to stir for 1 h after which the solvents were completely removed 
in vacuo to give 3-2 as a light yellow oil. The product was used immediately in the 
next step without further purification. Compound 3-2 was dissolved in distilled 
dichloromethane (2 mL) followed by the addition of DMAP (1.6 mg, 0.01 mmol) and 
3-3 (58 mg, 0.14 mmol). The solution was cooled to 0 C and triethylamine (30.2 mg, 
0.3 mmol) was added dropwise. The ice bath was removed and the reaction mixture 
was stirred overnight. After 20 h, the reaction mixture was diluted and extracted with 
0.25 N HCl. The organic layer was dried over anhyd. Na2SO4 and concentrated. The 
crude product was purified by flash column chromatography (1:1 hexane:ethyl acetate) 
to give 3-4 as an oil (76 mg, 72%). 1H-NMR (300 MHz, CDCl3)  10.2 (s, 1H), 8.1 (d, 
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2H, J = 8.0 Hz), 7.7 (m, 4H), 7.5 (m, 3H), 7.34 (d, 1H, J = 8.4 Hz), 7.26 (m, 3H), 6.9 
(d, 2H, J = 8.7 Hz), 5.7 (d, 4H, J = 7.9 Hz), 5.1 (m, 2H), 4.6 (m, 1H), 3.8 (s, 3H), 3.1 
(m, 2H), 1.4 (s, 9H). 13C-NMR (75 MHz, CDCl3)  187.8, 171.2, 159.9, 155.0, 150.8, 
150.7, 146.8, 136.6, 134.3 134.2, 131.5, 131.3, 130.6, 130.5, 129.4, 128.6, 127.1, 
127.0, 126.9, 125.2, 121.0, 114.0, 80.1, 67.24, 67.18, 55.3, 54.3, 37.3, 28.2. 31P-NMR 
(121 MHz, CDCl3)  -6.5. ESI-MS: m/z [(M+Na+)/1] calculated for C37H38N3NaO14P: 
802.2, found: 802.2. 
(S)-4-Methoxybenzyl-3-(4-(bis(2-nitrobenzyloxy)phosphoryloxy)-3-
(hydroxymethyl) phenyl)-2-(tert-butoxycarbonylamino) propanoate (3-5): 
Compound 3-4 (0.8 g, 1.0 mmol) was dissolved in a mixture of ethanol (18 mL), THF 
(4 mL) and water (180 L) and cooled to 0 C. NaBH4 (38 mg, 1.0 mmol) was then 
added and the reaction mixture was stirred at 0 C for 5 min. The reaction was 
quenched with 0.25 N HCl and stirred for another 15 min after which the organic 
solvents were removed in vacuo. The residue obtained was diluted with water and 
extracted ethyl acetate. The combined organic extracts were washed with brine and 
dried over anhyd. Na2SO4 and concentrated. The crude product was purified by flash 
column chromatography (1:1 hexane:ethyl acetate) to give 3-5 as a white solid (0.50 g, 
63%). 1H-NMR (300 MHz, CDCl3)  8.1 (d, 2H, J = 8.2 Hz), 7.7 (m, 4H), 7.5 (m, 2H), 
7.2 (m, 3H), 7.1 (d, 1H, J = 8.4 Hz), 6.9 (d, 1H, J = 8.1 Hz), 6.8 (d, 2H, J = 8.6 Hz), 
5.6 (d, 4H, J = 7.7 Hz), 5.1 (m, 2H), 4.6 (m, 3H), 3.8 (s, 3H), 3.0 (m, 2H), 1.4 (s, 9H). 
13C-NMR (75 MHz, CDCl3)  171.6, 159.8, 155.1, 146.7, 134.2, 134.1, 132.7, 132.6, 
131.6, 131.5, 131.2, 130.4, 129.8, 129.2, 128.6, 127.3, 125.1, 120.2, 113.9, 79.9, 67.1, 
67.0, 59.7, 55.2, 54.5, 37.4, 28.2. 31P-NMR (121 MHz, CDCl3)  -5.3. ESI-MS: m/z 





To a solution of 3-5 (0.45 g, 0.6 mmol) in distilled dichloromethane (5 mL) at 0 C 
was added diethylaminosulfurtrifluoride (DAST, 0.25 g, 1.5 mmol). The reaction 
mixture was stirred for 1 h at 0 C and a further 20 min at room temperature. 
Following which the reaction was quenched with saturated NaHCO3 and stirred at 
room temperature for an additional 15 min. The reaction mixture was partitioned 
between dichloromethane and water, the organic extracts were washed with brine and 
dried over anhyd. Na2SO4. Following concentration, the crude product was purified 
by flash column chromatography (3:2 hexane:ethyl acetate) to give 3-6 as an oil 
(0.37g, 82%). 1H-NMR (300 MHz, CDCl3)  8.1 (d, 2H, J = 8.6 Hz), 7.7 (m, 4H), 7.5 
(m, 2H), 7.3 (m, 1H), 7.2 (d, 2H, J = 8.7 Hz), 7.1 (m, 1H), 7.0 (d, 1H, J = 8.2 Hz), 6.9 
(d, 2H, J = 8.7 Hz), 5.6 (d, 4H, J = 7.7 Hz), 5.4 (d, 2H, J = 46.3 Hz), 5.0 (m, 2H), 4.6 
(m, 1H), 3.8 (s, 3H), 3.0 (m, 2H), 1.4 (s, 9H). 13C-NMR (75 MHz, CDCl3)  171.3, 
159.9, 157.5, 155.0, 154.9, 147.3, 147.2, 146.7, 135.0, 134.2, 133.8, 132.2, 131.9, 
131.8, 131.7, 131.6, 131.3, 130.9, 130.8, 130.5, 129.2, 129.1, 128.7, 128.5, 128.2, 
127.2, 126.2, 125.1, 119.8, 114.0, 109.5, 80.7, 80.0, 78.5, 67.9, 67.1, 67.0, 66.9, 66.8, 
55.5, 55.2, 54.8, 54.4, 37.8, 37.3, 28.4, 28.3. 19F-NMR (282 MHz, CDCl3)  -137.0 (t, 
J = 47.4 Hz). 31P-NMR (121 MHz, CDCl3)  -5.8, -6.4. ESI-MS: m/z [(M+Na+)/1] 
calculated for C37H39FN3NaO13P: 806.2, found: 806.1. 
(S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(4-(bis(2-nitrobenzyloxy) 
phosphoryloxy)-3-(fluoromethyl)phenyl)propanoic acid (3-7): 
To a solution of 3-6 (30 mg, 0.04 mmol) in dichloromethane (1 mL) at 0 C was 
added water (2 L) and TFA (2 mL). The reaction was stirred for another 5 min at 0 
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C following which the ice bath was removed and stirring was continued at room 
temperature. After 4 h, dichloromethane and TFA were removed completely in vacuo. 
The residue obtained was dissolved in THF (1 mL) and water (1 mL) following which 
solid NaHCO3 was added to adjust the pH to 8. To this mixture was added N-(9-
fluorenylmethoxycarbonyloxy) succinimide (FmocOSu, 14.2 mg, 0.04 mmol) and 
stirred overnight. After 21 h, THF was removed in vacuo and the residue was diluted 
with water and extracted with ethyl acetate. The aqueous layer was then acidified to 
pH 1 with 1 N HCl and extracted with ethyl acetate. The combined organic extracts 
were washed with brine, dried over anhyd. Na2SO4 and concentrated. The crude 
product was purified by flash column chromatography (2:3 hexane:ethyl acetate with 
1 % acetic acid) to give 3-7 as an off-white solid (21 mg, 70%). 1H-NMR (300 MHz, 
CDCl3)  8.1 (d, 2H, J = 8.2 Hz), 7.7 (d, 2H, J = 7.4 Hz), 7.6 (m, 4H), 7.5 (m, 2H), 
7.4 (m, 2H), 7.3 (t, 2H, J = 7.3 Hz), 7.2 (m, 4H), 7.1 (d, 1H, J = 7.9 Hz), 5.6 (d, 4H, J 
= 7.4 Hz), 5.3 (d, 2H, J = 47.4 Hz), 4.6 (m, 1H), 4.3 (m, 2H), 4.1 (t, 1H, J = 6.9 Hz), 
3.1 (m, 2H). 13C-NMR (75 MHz, CDCl3)  173.7, 156.0, 147.2, 147.2, 146.7, 143.7, 
141.3, 134.2, 131.5, 131.4, 131.2, 131.1, 129.2, 128.6, 127.7, 127.1, 125.1, 120.0, 
80.8, 78.6, 67.9, 67.2, 67.1, 55.4, 54.8, 54.7, 47.1, 37.1. 19F-NMR (282 MHz, CDCl3) 
 -136.2 (t, J = 46.3 Hz). 31P-NMR (121 MHz, CDCl3)  -6.6. HRMS (ESI): m/z 







Chapter 4: High-Throughput Synthesis of Abelson Tyrosine 
Kinase (Abl) Inhibitors using Click Chemistry 
Summary: 
This chapter summarizes the development of a synthetic strategy using the modular 
and efficient nature of the Cu (I) catalyzed Huisgen 1, 3-dipolar cycloaddition 
reaction between azides and terminal alkynes (or click chemistry) to rapidly assemble  
inhibitors of Abelson (Abl) tyrosine kinase. A generic kinase inhibitor library using 
the click assembly of an ADP-alkyne and a 344-member library of azides was first 
synthesized. Kinase inhibition assays with this generic inhibitor library revealed a 
preference for short chain linkers by the Abl kinase. Subsequently, a second 
generation of Abl inhibitor library was assembled using click chemistry with azides of 
short chain linkers and alkyne warheads derived from the Abl-selective drug Imatinib. 
Biochemical assays revealed a set of moderately potent and selective inhibitors, some 
of which have comparable potency as Imatinib against Abl. This work highlights the 
power of click chemistry to quickly generate inhibitor libraries of clinically relevant 
proteins.  
4. 1 Introduction 
     Protein kinases catalyze the phosphorylation of serine, threonine and tyrosine 
residues in proteins. The reversible phosphorylation is one of the major modes of 
cellular signal transduction and it plays regulatory roles in most metabolic pathways. 
Hence, virtually every aspect of cellular physiology is inherently linked to the proper 
functioning of these enzymes.  Aberrant regulation of kinase activity has been 
implicated in many diseases including several cancers.  Thus new strategies in kinase 
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inhibitor design remain an active area of research with direct relevance to drug 
development. The majority of kinase inhibitors targets the ATP-binding site of the 
enzymes and, due to the highly conserved nature of the ATP-binding pocket amongst 
the various kinases, such inhibitors usually lack selectivity. An inhibitor that exploits 
binding pockets other than the ATP-binding site could potentially override this 
problem as such secondary binding pockets (e.g. substrate-binding or allosteric 
pockets) are less likely to be conserved. But there exist relatively few strategies for 
the rational design of such inhibitors. The most commonly used approach makes use 
of large libraries of synthetic compounds and natural products coupled with cell-based 
assays but so far, these methods, yielded only a limited number of hits. (Examples of 
this class of compounds include a substrate competitive inhibitor, ON012380,84 of 
Bcr-Abl kinase and an allosteric inhibitor, GNF-2,85 targeting the myristoyl binding 
pocket of the same kinase).  
     The recent development of certain kinase inhibitors with bidentate mode of 
inhibition86 exploiting both the ATP-binding site and an allosteric site or a substrate-
binding site opens up exciting opportunities for the rational design of bidentate kinase 
inhibitors. The strategy works by simply appending an inhibitor scaffold that targets 
the ATP-binding site of a kinase with another inhibitor scaffold that targets the 
allosteric/substrate-binding site, resulting in a bidentate inhibitor with improved 
selectivity and potency. Successful implementation of this method, however, largely 
depends on the available knowledge of secondary site-binding scaffolds on the target 
kinase, which is so far quite limited. Thus combinatorial approaches are necessary to 
identify such scaffolds and to generate new bidentate inhibitors.  
     We were particularly interested in Abl kinase as the aberrant activity of this kinase 
in a fusion protein form (Bcr-Abl) has been directly implicated in the 
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myeloproliferative disorder called Chronic Myelogenous Leukaemia (CML).87 The 
cellular form of Abl is a close relative of the Src family of tyrosine kinases. It consists 
of approximately 1150 residues with two regulatory domains (SH3 and SH2) and a 
catalytic domain (SH1) with ~ 47% sequence homology with Src.88  But unlike Src, 
the c-Abl kinase adopts a unique autoinhibitory mechanism involving the interaction 
of an N-terminal myristoyl group with a C-terminal myristoyl binding cleft.88,89 This 
autoinhibition is of paramount importance as in the absence of such a regulatory 
mechanism the kinase remains turned on always and the aberrant kinase activity leads 
to most of the pathological causes in the CML. The remarkable clinical success of the 
drug Imatinib (or ST1571, Gleevec™) and the recent cases of drug resistance due to 
mutations in the BCR-Abl gene have accelerated the search for new Abl inhibitors.90 
New development of Imatinib analogues and molecules possessing unique inhibitory 
mechanisms against Abl may offer promising approaches to tackle the drug resistance 
problem.90,91 We decided to develop a click chemistry-based strategy to generate 
potential bidentate inhibitors against Abl as the strategy had previously been shown to 
be highly modular and efficient for rapid assembly of bidentate inhibitors against 
many other enzymes.92 
4. 2 Results and Discussions 
4. 2. 1 The First-Generation of Kinase Click Inhibitors 
     At first, the possibility of assembling kinase inhibitors using click chemistry with 
ADP-alkyne (as a promiscuous ATP-surrogate) and a 344-member library of azides 
(Fig. 4.1) was investigated. The ADP-alkyne was synthesized (Scheme 4.1) using 
procedures similar to the synthesis of GDP-alkyne employed by Wong et al..93 Briefly, 
propargyl alcohol was phosphorylated with crystalline phosphorous acid in presence 
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of iodine as oxidizing agent and the resultant propargyl phosphate 4-1 was isolated as 
a cyclohexylammine salt via precipitation form acetone containing cyclohexyl amine. 
The propargylphosphate-cylohexylamine salt was exchanged for pyridinium ion form 
4-2 using Dowex 50W-X2 resin in pyridinium form and subsequently coupled with 
AMP-morpholidate 4-3 using 1-H tetrazole as coupling reagent in anhydrous pyridine, 
affording the ADP-alkyne 4-4 in 21.5% yield over 4 steps. The 344-member library of 
azides was synthesized via a highly efficient solid-phase traceless protocol recently 
developed in the Yao’s laboratory.41c The click assembly of the two fragments was 
then carried out in a 384-well plate in a mixed solvent system containing t-BuOH, 
Water and DMSO (1:1:0.1) with CuI (0.1 eq.) as catalyst and tributylamine (0.2 eq.) 
as Cu (I) stabilizing base. The triazole formation was found to complete in 24 h. The 
crude reactions were evaporated to dryness and redissolved in DMSO to prepare 
standard solutions for kinase inhibition assays and LC-MS characterizations.  
     Upon “click” assembly, the 344-member library was screened for inhibition 
against Abl and Src kinases using a non-radioactive luminescence-based kinase assay; 
unique and distinctive inhibitor fingerprints were obtained for the library against the 
two kinases (Fig. 4.2). Detailed analysis of the inhibition profiles revealed a clear 
preference for short-chain linkers by Abl inhibitors whereas no such linker length 
preference was observed for Src inhibitors. The preference for short-chain azides by 
Abl kinase may point to the presence of secondary binding sites not too far from its 
ATP-binding site. This generic 344-member inhibitor library may be used as a 
platform for high-throughput identifications of preliminary bidentate inhibitors 







































Figure 4. 1 Schematic representation of the click-assembly of the 344-member inhibitor 
























Figure 4. 2 The heat-map of the inhibition assay obtained with the 344-member inhibitor 
library against Src and Abl kinases. The preference for short-chain linkers by the Abl kinase 
is highlighted 
 
4. 2. 2 The Second-Generation of Kinase Click Inhibitors 
     Having successfully established the platform for click-assembly of bidentate 
kinase inhibitors, the focus turned to Abl kinase. As shown in Scheme 4.2, the 
promiscuous, weak binding, ADP-alkyne warhead was replaced with the head 
portion of Imatinib, as this was reasoned to improve the selectivity as well as 
potency of the resulting inhibitors. Compared to the ADP-alkyne click library, the 
new click products should also be more ‘drug-like’. Short-chain (2C) azides were 
chosen based on the results obtained in Figure 4.2. Two clickable warheads (W1 
and W2) containing the Imatinib core structure were designed by replacing the 
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alkyne group. Previously, results found that the piperazine moiety of Imatinib does 
not contribute significantly to the inhibition of Abl.90 Thus it was conceived that, 
upon click chemistry, the warhead will guide the binding of the assembled 
inhibitor to the ATP-binding site and, at the same time, project the diversity 
element (from the azide) to the adjacent secondary binding site in the kinase (i.e. 
substrate-binding or allosteric site). The triazole ring formed should closely mimic 
the benzene ring in Imatinib, minimizing potential structural disruption of the 
inhibitor. W1 was synthesized in 5 steps starting from acetylpyridine. The 
enamination reaction of acetylpyridine with N,N-dimethylformamide 
dimethylacetal in refluxing ethanol provided the enaminone 4-5, which was 
converted to the pyrimidinyl amine 4-6 by reacting with guanidine hydrochloride 
in refluxing isopropanol in basic medium. Compound 4-6 was converted to 4-7 via 
a Cu(I)-catalyzed “Ullmann-Type” reaction as previously reported.94  Subsequent 
reduction of 4-7 via catalytic hydrogenation gave 4-8. Standard coupling of 4-8 
with propiolic acid using DCC in DMF yielded 4-9 (W1) in 25.6% overall yield 
(in 5 steps). W2 was synthesized similarly from the key intermediate 4-11. Methyl 
ester deprotection of 4-11 gave 4-12 which was then coupled with propargyl amine 
using HATU in DMF to afford 4-13 (W2)  in 13.6% yield over 6 steps. 
 Next, a 90-member inhibitor library based on Imatinib was assembled, by 
click chemistry, using the two warheads and 45 azides (2C) (Scheme 4.2). Briefly, in 
each reaction a warhead was mixed with an azide in a MeOH/H2O/DMSO mixed 
solvent with catalytic amounts of CuSO4 and sodium ascorbate. The click chemistry 
proceeded in quantitative yields in ~ 12 h at room temperature. The solvents were 











Scheme 4. 2 Synthesis of the two warheads (W1 & W2) for Imatinib-based click library 
 
4. 2. 3 Kinase Inhibition Assays 
4. 2. 3. 1 Screening of the inhibitor library and generation of heat-map 
     A non-radioactive, luminescence based kinase inhibition assay (Kinase-Glo® Plus 
from Promega)95 was employed to identify the inhibition potency of each compound 
in the library. The assay was based on the amount of ATP left after the kinase 
catalyzed phosphorylation of a substrate peptide (Figure 4.3). The ATP left after the 
kinase reaction is utilized for the monooxigenation of Luciferin catalyzed by the 
enzyme Luciferase and this reaction is accompanied with liberation of light. The 
Luciferase reaction produces one photon per turnover and the kinase activity is 

























































Sealed tube (120 0C)






























































Figure 4. 3 Luminescence-based kinase assay 
     The click-inhibitors were directly used for enzymatic screening against Src and 
Abl kinases. The results are shown in Figure 4.4. Detailed analysis of the inhibition 
profiles revealed that many inhibitors showed better inhibition against Abl over Src 
kinase. Eleven of these inhibitors were further identified (Figure 4.4; structures shown 
on right). They were scaled up, purified to homogeneity (by preparative HPLC), 
characterized (by LC-MS) before quantitative inhibition assays were carried out to 

























Figure. 4. 4  Heat-map showing the relative inhibition of the 90-member Imatinib-based 
bisubstrate inhibitor library against Src and Abl kinases. Structures of representative 




4. 2. 3. 2 IC50 evaluation of the click-inhibitors against Abl/Src kinases 
     Concentration-dependent experiments were performed to confirm the potency of 
the identified initial hits (structures shown above in Figure 4.4). All the 11 hits were 
purified by Semi-Prep reverse-phase HPLC using water with 0.1% TFA and 
acetonitrile with 0.1% TFA as eluents on a Luna 5 µ C-18 (2) 100A column (50 × 30 
mm, 5 micron) at a flow rate of 10 ml/min before subjecting to the detailed inhibition 
measurements. The dose-dependent inhibition assays were performed by varying the 
concentration of the inhibitors under fixed enzyme concentration of 50 nM. The IC50 
values for each inhibitor were calculated from the percentage activity vs. log 
[concentration of inhibitor] curves generated using the GraphPad Prism software. 
     The IC50 results showed that most of the inhibitors exhibited 10-20 folds in 
selectivity for Abl over Src kinase (Figure 4.5). None of the azide components were 
found to exhibit any significant inhibition against either kinase. The warhead W1 
alone was more potent (IC50 = 1.36 µM) than W2 (IC50 = 27.3 µM) against Abl kinase; 
this was presumably contributed by the proper positioning of the amide bond in W1 
which resulted in more favourable Hydrogen bonding interactions with residues 
located in the ATP-binding pocket of the kinase. The same phenomenon had 
previously been observed in the Imatinib-Abl complex as well.89 W1 was nearly as 
potent as Imatinib (IC50 = 0.8 µM) under identical assay conditions, indicating indeed 
the piperazine moiety in Imatinib was not essential for binding to Abl. Although the 
five inhibitors derived from W1 showed only marginal improvement in potency over 
W1 against Abl, with the best inhibitor, W1-SA20, having an IC50 of 0.70 µM (2-fold 
improvement over W1), the six W2-derived bisubstrate inhibitors were > 10-fold 










IC50 = 2550 nM (Abl)













IC50 = 1674 nM (Abl)













IC50 = 2834 nM (Abl)













IC50 = 704 nM (Abl)














IC50 = 2860 nM (Abl)













IC50 = 2492 nM (Abl)
















IC50 = 2161 nM (Abl)













IC50 = 3060 nM (Abl)













IC50 = 1123 nM (Abl)













IC50 = 1608 nM (Abl)














IC50 = 1621 nM (Abl)











150 W1 & W2
IC50 = 1360 nM (W1) Abl









Figure 4. 5 IC50 evaluation of the selected click-inhibitors and the warheads against Abl/Src 
kinases 
4. 2. 4 Cell culturing and anti-proliferation assay 
     Human leukemic cell lines K-562 (p-210 Bcr-Abl expressing chronic myelogenous 
leukemia) were treated with the 11 inhibitor hits identified against recombinant Abl 
from the in-vitro assay and the effect of the compounds on cell viability was tested 
with an anti-proliferation assay (XTT-assay).96 The compounds, unfortunately, did not 
 90 
 
show significant effect on the cell viability. Even the best inhibitor identified in the 
cell-based assay (W2-SA17, IC50 = 1608 nM in in-vitro assay) shows only 60% 
inhibition of the cell proliferation at 50 µM concentration (All other compounds 
including the best inhibitor W1-SA20 from the in-vitro assay were found to be less 
potent with less than 50% inhibition of cell proliferation at 50 µM concentration. The 
exact reason for the lack of cellular potency of the compounds is not clear, although 
we speculate that it could most likely be due either to the poor solubility of the 
compounds in the assay medium or the cell-impermeability of the compounds.  
 
Figure 4. 6 Antiproliferation assay of K-562 cells in the presence of the 11 click-inhibitors at 
two different concentrations (50 µM and 10 µM). The Y axis represents the cell proliferation 
normalized with respect to the no inhibitor control (DMSO alone). Shorter column heights 









IC50 (in µM) Cell-based 
assay  
(% inhibition)a Abl Src 
Imatinib 0.8b   
W1 1.36         >100 - 
W1-SA9 2.55 13.5 - 
W1-SA10 1.67 42.9 - 
W1-SA17 2.83 9.37 - 
W1-SA20 0.70 26.6 35 
W1-SA22 1.00 55.7 19 
W2 27.3         >100 - 
W2-SA3 2.49 38.8 - 
W2-SA4 2.16 43.1 - 
W2-SA7 3.06 55.2 - 
W2-SA13 1.12 17.9 32 
W2-SA17 1.61 10.4 60 
W2-SA18 1.62 24.8 - 
 
aThe cell-based assay was done at 50 µM concentration of inhibitors.  bData obtained from reference 97. “-“ = Not determined. 
 








Table 4. 2 Azide library used for the synthesis of the Imatinib analogue click-
library 
The azides were synthesized via a highly efficient traceless solid-phase method we 
recently developed.41c  



















































































































































































































































































































































































4. 3 Conclusions 
In conclusion, the first click-chemistry approach for rapid assembly of potential 
bidentate  inhibitors of Abelson tyrosine kinase have been developed. Selected 
compounds identified from this “click-based” library, though showed only 
comparable potency as that of Imatinib in their inhibition of Abl kinase, they 
nevertheless offer the first glimpse of the generality and utility of the click strategy in 
future development of bidentate inhibitors against a variety of other protein kinases. 
The click-products are more ‘drug-like’ compared to the existing peptide based 
bisubstrate kinase inhibitors and have lot more scope to further optimize their 
pharmacological properties. Therefore, the strategy should provide a useful tool in the 













4. 4 General experimental procedures 
4. 4. 1 The click-assembly of inhibitors 
4. 4. 1. 1 General procedure for the click-assembly of 344-member 
library formed from ADP-alkyne and azides 
     The click-assembly of the two fragments (ADP-alkyne and azides) was carried out 
in a 384-well plate in a mixed solvent system containing t-BuOH, Water and DMSO 
(1:1:0.1) with CuI (0.1 eq.) as catalyst and tributylamine (0.2 eq.) as Cu(I) stabilizing 
base. Other commonly employed click-catalytic systems such as CuSO4-Sodium 
ascorbate and Cu-CuSO4 were not successful. The triazole formation was found to 
complete in 24 h. The crude reactions were evaporated to dryness and redissolved in 
DMSO to prepare standard solutions for kinase inhibition assays and LC-MS 
characterizations. 
4. 4. 1.2 General procedure for the click-assembly of 90-member 
Imatinib analogue library formed from the two warheads (W1 & W2) 
and azides 
     The following optimized condition was used for the click-assembly of the 
inhibitors: 
The alkyne warhead (W1 or W2) = 5 mM in DMSO, 20 µL,  
The Azide = 5 to 7.5 mM in DMSO, 20 µL, 
CuSO4 = 0.1 mM, Sodium ascorbate = 1 mM,  
Reaction volume = 200 µL (100 µL water + 40 µL DMSO + 60 µL Methanol)  
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Briefly, the alkyne warhead and the azide were mixed in the above mentioned 
solvent system in the presence of indicated amounts of CuSO4 and sodium 
ascorbate. The reactions were shaken for 12 h at room temperature upon which the 
entire warhead was converted to the triazole (monitored by LC-MS). The reactions 
were concentrated and redissolved in DMSO to prepare standard solutions for 
enzyme inhibition assays. 
 
4. 4. 2 General procedure for Kinase inhibition assays 
     The kinase inhibition assay was performed with Kinase-Glo® Plus Luminescent 
Kinase assay kit from Promega following the manufactures instructions. Briefly, 
the kinase, the peptide substrate, ATP and the inhibitor were mixed in the kinase 
reaction buffer (100 mM Tris, pH=7.5, 10 mM MgCl2) at a volume of 25 µL in a 
flat-bottom solid white 384-well plate (or 55 µL in a flat-bottom solid white 96-
well plate). The incubation was allowed to continue for 30 min at 37 oC and the 
kinase reaction was then quenched by the addition of an equal volume of the 
Kinase-Glo reagent. After 5 min of incubation the luminescence readouts from the 
wells were measured using Tecan microplate reader with i-control software. The 
ATP and substrate peptide concentrations used in the assay were 5 µM and 50 µM, 
respectively. The following control reactions were also performed simultaneously. 
 
1. Enzyme control (No kinase, Buffer + Substrate + ATP),  
2. Inhibitor control (No inhibitor + Buffer + Kinase + Substrate + ATP) 
3. Substrate control (No substrate, Buffer + Kinase + ATP)   
4. Buffer alone.  
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The inhibition assays with Abl and Src kinases were performed at nearly equal 
activities of the two kinases at a concentration of ~ 50 nM for Abl and ~ 90 nM for 
Src kinases respectively. The substrate peptides used are shown below. 
Abl substrate peptide: KKGEAIYAAPFA-NH2 
Src substrate peptide: KVEKIGEGTYGVVYK-NH2 
The inhibitors were screened against the closely related kinases Abl and Src in a 
384-well plate or 96-well plate as described above. The luminescence intensity 
from each well was measured and the inhibition potency was calculated using the 
following relation. 
 
Potency = 1 - Remaining activity 
 
The average value of potency across the entire library was calculated and the heat-
maps were generated by assigning the standard deviation values to each compound. 
 
4. 4. 3 General procedure for cell-culturing and anti-proliferation assay 
     Human leukemic cell lines K-562 (p-210 Bcr-Abl expressing chronic 
myelogenous leukemia) were maintained in RPMI-1640 medium supplemented with 
L-glutamine and 10% FBS. The cells (0.2-0.4 × 106 per mL) were plated in duplicate 
in 96-well plates containing two different concentrations (50 and 10 µM) of the 11 
inhibitor hits identified against recombinant Abl from the in-vitro assay. After 
incubation at 37 oC in 5% CO2 for 48 h, the effect of the compounds on the cell 
proliferation was determined by the XTT (sodium 3’ – [1-(phenylaminocarbonyl)-3, 
4-tetrazolium]-bis (4-methoxy-6-nitro) benzene sulfonic acid hydrate) colorimetric 
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dye reduction method. Briefly, the procedure for the assay was as follows. The XTT 
was dissolved in hot RPMI media (37 oC) at a concentration of 1 mg/mL. 
Immediately before use, the electron coupling reagent PMS (N-methyl 
dibenzopyrazine methyl sulfate) was added to the XTT solution giving a PMS 
concentration of 125 µM (The PMS was stored as 100 mM stock solution in saline at 
4 oC). 25 µL of this XTT/PMS solution was added to each well in the 96-well plate 
containing ~ 100 µL per well culture giving a final concentration of 0.2 mg/mL XTT 
and 25 µM PMS. After incubation at 37 oC in 5% CO2 for 2-6 h the absorbance of 
each well was measured at a wavelength of 450 nm using Tecan microplate reader 
and effect of the compounds on the cell proliferation was determined by comparing 
with the DMSO (no inhibitor) controls. 
4. 5 Synthetic details and characterizations of compounds 
Prop-2-ynyl phosphate cyclohexylamine salt (4-1):  
Compound 4-1 was synthesized as previously reported.93 Briefly, to a solution of 
propargyl alcohol (30 mL, 516 mmol) and triethylamine (7.5 mL, 54 mmol) was 
added phosphorous acid (1.23 g, 15 mmol). To this was added 5.7 g of iodine 
(22.47 mmol) in small portions over 5 min with stirring. The stirring was 
continued for 10 more minutes and then the reaction mixture was pored into 400 
mL of acetone containing 15 mL cyclohexylamine. A white precipitate was 
formed immediately and the solution was kept for 2 h, then the precipitate was 
filtered, recrystallized from 95% ethanol containing few drops of cyclohexylamine. 
The precipitate obtained was dried to give 3.11 g (yield = 68%) of the propargyl 
cyclohexylamine salt 4-1 as a white solid. 1H-NMR (300 MHz, D2O) δ ppm = 1.1 
(2H, m), 1.25 (8H, m), 1.61 (2H, m), 1.75 (4H, m), 1.93 (4H, m), 2.75 (1H, t, J = 
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2.46 Hz), 3.09 (2H, m), 4.34 (2H, dd, J = 7.07 Hz, 2.46 Hz). 31P-NMR (121.5 
MHz, D2O) δ ppm = 4.17. 
Prop-2-ynyl phosphate pyridinium salt (4-2):  
The propargyl cyclohexylamine salt (0.83 g, 2.71 mmol) was dissolved in water 
(1.5 mL) and converted to the pyridinium ion form via ion exchange on a 
pyridinium form of Dowex 50W-X2 resin. The pyridinium form of Dowex resin 
was prepared from the commercially available H+ form of the resin by repeated 
elution of a pre-washed (with water) column of the resin with 10% pyridine. The 
product 4-2 was eluted with 30 mL of water in nearly quantitative yield and 
concentrated on a rotary evaporator. 1H-NMR (300 MHz, D2O) δ ppm = 2.78 (1H, 
t, J = 2.46 Hz), 4.41 (2H, dd, J = 7.07 Hz, 2.46 Hz), 7.95 (t, J = 7.23 Hz), 8.50 (m), 
8.65 (d, J = 5.28 Hz). 13C-NMR (75 MHz, D2O) δ ppm = 53.50, 75.72, 78.96, 
127.29, 140.90, 147.07. 31P-NMR (121.5 MHz, D2O) δ ppm = 0.48. 
 
AMP-morpholidate (4-3):  
The AMP-morpholidate was synthesized as previously reported with minor 
modifications.98 Briefly, adenosine monophosphate monohydrate (0.84 g, 2.3 
mmol) was dissolved in a mixture of water (23 mL), t-butanol (23 mL) and 
distilled morpholine (0.78 mL, 11.4 mmol, 5 eq.). The mixture was heated under 
reflux and DCC (1.9 g, 9.2 mmol, 4 eq.) in t-butanol (35 mL) was added dropwise 
over 60 min and the reaction mixture was maintained under reflux for 2 h. The 
progress of the reaction was monitored by TLC using a 6:3:2 
isopropanol/ammonia/water solvent system. Upon completion of reaction after 2 h, 
the reaction mixture was cooled to room temperature; dicyclohexyl urea was 
filtered off and washed with water. The filtrate was concentrated and extracted 
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with diethyl ether to remove excess of DCC. The aqueous solution was 
concentrated and purified by column chromatography on silica gel using 
isopropanol/ammonia/water (6:3:2) solvent system. The product was concentrated 
to give 0.86 g (yield = 90%) of 4-3 as an off-white solid. 1H-NMR (300 MHz, D2O) 
δ ppm = 2.84 (4H, m), 3.46 (4H, t, J = 4.35 Hz), 3.96 (2H, m), 4.24 (1H, m), 4.41 
(1H, t, J = 4.92 Hz), 4.63 (1H, t, J = 4.92 Hz), 5.90 (1H, d, J = 4.77 Hz), 7.89 (1H, 
s), 8.21 (1H,s). 13C-NMR (75 MHz, D2O) δ ppm = 44.51, 63.65, 66.67, 70.01, 
74.06, 83.44, 87.21, 117.93, 139.22, 148.21, 152.33, 154.81. ESI-MS (m/z) 
calculated = 417.128 [M+H+], (m/z) observed = 417.120 [M+H+]. 
 
The warhead, ADP-alkyne (4-4):  
To the pyridinium salt form of the propargyl phosphate 4-2 (~ 2.5 mmol) was 
added trioctylamine (1.1 mL, 2.5 mmol) and anhydrous pyridine (30 mL) and the 
mixture was concentrated to an oil. It was subsequently subjected to repeated co-
evaporations with anhydrous pyridine (3×4 mL) followed by the addition of AMP-
morpholidate (1.04 g, 2.5 mmol). The mixture was again subjected to co-
evaporations with anhydrous pyridine (3×4 mL) and finally concentrated to a 
minimum volume. The coupling reagent 1H-tetrazole (0.56 g, 7.96 mmol) and 4 
mL of anhydrous pyridine were added and the reaction was stirred under Argon 
for 48 h. The solvent was then removed under reduced pressure and the reaction 
was quenched with saturated NaHCO3 until no CO2 was liberated. The mixture 
was washed with ethyl ether (3×20 mL), concentrated and purified by column 
chromatography on silica gel using isopropanol:ammonia:water (6:3:2) solvent 
system. The sample was further purified by Semi-Prep HPLC on C-8 column using 
acetonitrile and water as eluents with tributylamine (0.01%) as ion-pairing agent 
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afforded 0.41 g (yield = 35%) of the ADP-alkyne as off-white solid. 1H-NMR (300 
MHz, D2O) δ ppm = 2.76 (1H, t, J = 2.46 Hz), 4.17 (3H, unresolved m), 4.29 (1H, 
m), 4.42 (1H, m), 4.47 (2H, unresolved m), 6.03 (1H, d, J = 5.43 Hz), 8.31 (1H, s), 
8.49 (1H, s). 13C-NMR (75 MHz, D2O) δ ppm = 54.03, 65.15, 70.07, 74.49, 75.69, 
78.88, 83.94, 87.90, 118.25, 142.31, 144.60, 148.09, 149.63. ESI-MS (m/z) 
calculated = 466.052 [M+H+], (m/z) observed = 466.052 [M+H+] 
 
3-(Dimethylamino)-1-(pyridin-3-yl) prop-2-en-1-one (4-5):99  
A 250 mL round-bottomed flask was charged with 6.4 mL (58.3 mmol) of 3-
acetylpyridine, 9.4 mL (70 mmol, 1.2 eq.) of N,N-dimethylformamide 
dimethylacetal and 50 mL of ethanol. The reaction mixture was refluxed overnight, 
cooled to room temperature and the solvent was removed under reduced pressure. 
To the crude residue approximately 50 mL of diethyl ether was added and cooled 
to 0 oC. The product 3-(dimethylamino)-1-(pyridin-3-yl) prop-2-en-1-one was 
subsequently filtered off as yellow crystals (7.18 g, yield = 70%) and used in the 
subsequent steps without further purification. 1H-NMR (300 MHz, CDCl3) δ 2.92 
(3H, s), 3.14 (3H, s), 5.65 (1H, d, J = 12.33 Hz), 7.32 (1H, m), 7.81 (1H, d, J = 
12.33 Hz), 8.15 (1H, d, J = 9.18 Hz), 8.62 (1H, d, J = 7.38 Hz), 9.04 (1H,s); 13C-
NMR (75 MHz, CDCl3) δ 38.01, 45.85, 92.50, 123.93, 135.73, 136.30, 149.51, 
152.05, 155.36, 187.02. ESI-MS (m/z) calculated = 177.102 [M+H+], (m/z) 
observed = 177.099 [M+H+] 
 
4-(Pyridin-3-yl) pyrimidin-2-amine (4-6):100  
3-(dimethylamino)-1-(pyridin-3-yl) prop-2-en-1-one (2.64 g, 15 mmol) and 
guanidinium hydrochloride (1.5 g, 15.75 mmol, 1.05 eq.) were mixed in 25 mL of 
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2-propanol. To the suspension was added 0.7 g of NaOH (17.5 mmol, 1.17 eq.) 
and the mixture was refluxed for 18 h. The reaction was then cooled to 0 oC and 
the precipitate was filtered off, suspended in water, filtered off once more and 
washed with 2-propanol and diethyl ether. The residue was dried in oven at 60 to 
70 0C and the desired product was obtained as a white powder (1.68 g, yield = 
65%). 1H-NMR (300 MHz, DMSO-d6) δ 6.77 (2H, s), 7.19 (1H, d, J = 5.1 Hz), 
7.52 (1H, m), 8.34 (1H, d, J = 5.1 Hz), 8.39 (1H, d, J = 7.89 Hz), 8.68 (1H, d, J = 
6.57 Hz), 9.22 (1H, s); 13C-NMR (75 MHz, CDCl3) δ 106.01, 123.71, 132.46, 
134.11, 147.95, 151.10, 159.35, 161.56, 163.79. ESI-MS (m/z) calculated = 
173.082 [M+H+], (m/z) observed = 173.079 [M+H+] 
 
N-(2-Methyl-5-nitrophenyl)-4-(pyridin-3-yl) pyrimidin-2-amine (4-7):94  
3-(dimethylamino)-1-(pyridin-3-yl) prop-2-en-1-one 4-6 (0.456 g, 2.65 mmol, 1.1 
eq.), CuI (0.12 g, 0.6 mmol, 0.25 eq.) and anhydrous K2CO3 (0.67 g, 4.82 mmol, 2 
eq.) were added to a sealed tube (50 mL) equipped with a rubber septum and a 
magnetic stirring bar. The tube was filled with N2 gas and subsequently was added 
a mixture of 2-bromo-1-methyl-4-nitrobenzene (0.518 g, 2.41 mmol, 1 eq.) and 
DMEDA (0.064 mL, 0.6 mmol, 0.25 eq.) in anhydrous dioxane (20 mL) by 
syringe at room temperature. The rubber septum was quickly replaced with a 
Teflon screw cap and the reaction mixture was stirred at 120 oC for 20 h. The 
reaction was cooled to room temperature and concentrated ammonia (10 mL) and 
saturated solution of NaCl (40 mL) were added then extracted with ethyl acetate (5 
× 40 mL). The organic layers were dried over Na2SO4, concentrated under reduced 
pressure and the residue was purified by column chromatography on silica gel to 
give 0.62 g (yield = 83.7%) of 4-7 as a yellow powder. ESI-MS (m/z) calculated = 
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308.114 [M+H+], (m/z) observed = 308.120 [M+H+] 
 
6-Methyl-N1-(4-(pyridin-3-yl) pyrimidin-2-yl) benzene-1,3-diamine (4-8):  
To a degassed solution of 0.4 g  (1.302 mmol) of N-(2-methyl-5-nitrophenyl)-4-
(pyridin-3-yl) pyrimidin-2-amine 4-7 in 50 mL ethyl acetate was added 10% Pd/C 
(0.04 g) and stirred under a hydrogen atmosphere (balloon) for 3 h to complete 
disappearance of the starting material. The reaction was then filtered through 
celite, concentrated and the product was obtained as a yellow solid (0.36 g, 
quantitative yield) and used in the subsequent steps without further purification. 
1H-NMR (300 MHz, CDCl3) δ 2.25 (3H, s), 6.40 (1H, m), 6.98 (1H, s), 7.01 (1H, 
m), 7.15 (1H, d, J = 5.1 Hz), 7.41 (1H, m), 7.60 (1H, s), 8.33 (1H, m), 8.49 (1H, d, 
J = 5.1 Hz), 8.71 (1H, m), 9.27 (1H,s). ESI-MS (m/z) calculated = 278.140 
[M+H+], (m/z) observed = 278.101 [M+H+] 
 
N-(4-Methyl-3-(4-(pyridin-3-yl) pyrimidin-2-ylamino) phenyl) propiolamide 
(4-9):  
To a solution of propiolic acid (0.0665 mL, 1.08 mmol, 1.2 eq.) in 8 mL DMF was 
added 0.223 g (1.08 mmol, 1.2 eq.) of DCC followed by 0.25 g (0.902 mmol) of 6-
methyl-N1-(4-(pyridin-3-yl) pyrimidin-2-yl) benzene-1,3-diamine and the reaction 
mixture was stirred at room temperature for 4h until the starting material was 
completely used up. The reaction was concentrated on a rotary evaporator and the 
crude product was purified by column chromatography on silica gel to give 0.2 g 
(yield = 67.3%) of 4-9 as a pale yellow solid. 13C-NMR (75 MHz, DMSO-d6) δ 
17.62, 76.90, 78.52, 107.75, 116.06, 116.45, 128.19, 130.28, 135.97, 136.18, 
137.83, 146.87, 149.46, 149.94, 159.56, 160.96, 161.03. ESI-MS (m/z) calculated 
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= 330.135 [M+H+], (m/z) observed = 330.135 [M+H+] 
 
Methyl 3-iodo-4-methylbenzoate (4-10):101  
A solution of 3-iodo-4-methyl benzoic acid (0.75 g, 2.86 mmol) and catalytic 
amount of H2SO4 (~ 0.05 mL) in 20 mL methanol was refluxed for 20 h. The 
reaction mixture was cooled and the solvent was removed under reduced pressure. 
The residue obtained was dissolved in diethyl ether, washed with saturated 
NaHCO3 (3×), water, brine, dried over Na2SO4 and the solvent was removed to 
give 4-10 as an orange viscous liquid (0.73 g, yield = 92.3%). ESI-MS (m/z) 
calculated = 276.972 [M+H+], (m/z) observed = 276.964 [M+H+] 
 
Methyl 4-methyl-3-(4-(pyridin-3-yl) pyrimidin-2-ylamino) benzoate (4-11):  
3-(dimethylamino)-1-(pyridin-3-yl) prop-2-en-1-one 4-6 (0.415 g, 2.41 mmol), 
CuI (0.12 g, 0.6 mmol, 0.25 eq.) and anhydrous K2CO3 (0.67 g, 4.82 mmol, 2 eq.) 
were added to a sealed tube (50 mL) equipped with a rubber septum and a 
magnetic stirring bar. The tube was filled with N2 gas and subsequently was added 
a mixture of methyl 3-iodo-4-methylbenzoate 7 (0.67 g, 2.41 mmol, 1 eq.) and 
DMEDA (0.064 mL, 0.6 mmol, 0.25 eq.) in anhydrous dioxane (20 mL) by 
syringe at room temperature. The rubber septum was quickly replaced with a 
Teflon screw cap and the reaction mixture was stirred at 120 oC for 20 h. The 
reaction was cooled to room temperature and concentrated ammonia (10 mL) and 
saturated solution of NaCl (40 mL) were added and then extracted with ethyl 
acetate (5 × 40 mL). The organic layers were dried over Na2SO4, concentrated 
under reduced pressure and the residue was purified by column chromatography 
on silica gel to give 0.63 g (yield = 81%) of 4-11 as a pale yellow powder. 1H-
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NMR (300 MHz, CDCl3) δ 2.39 (3H, s), 3.95 (3H, s), 7.19 (1H, d, J = 5.25 Hz), 
7.29 (1H, m), 7.42 (1H, m), 7.72 (1H, m), 8.41 (1H, m), 8.49 (1H, d, J = 5.1 Hz), 
8.71 (1H, m), 8.98 (1H, s), 9.29 (1H, s); 13C-NMR (75 MHz, CDCl3) δ  18.86, 
52.67, 108.90, 122.90, 124.20, 125.04, 129.20, 131.06, 133.01, 133.88, 135.10, 
138.12, 149.15, 152.12, 159.75, 161.01, 163.00, 167.66. ESI-MS (m/z) calculated 
= 321.135 [M+H+], (m/z) observed = 321.130 [M+H+] 
 
4-Methyl-3-(4-(pyridin-3-yl) pyrimidin-2-ylamino) benzoic acid (4-12):  
LiOH (0.24 g, 10 mmol, 8 eq.) was dissolved in a 3:1 mixture of methanol and 
water (12 mL).To this was added the methyl ester 4-11 (0.4 g, 1.25 mmol) and the 
reaction mixture was stirred for 8 h at room temperature. The reaction was 
acidified to pH = 1 with 1 N HCl. The solvent was removed under reduced 
pressure and the residue obtained was purified by column chromatography on 
silica gel to obtain 0.23 g (yield = 60%) of 4-12 as an off-white solid. 1H-NMR 
(300 MHz, DMSO-d6) δ 2.30 (3H, s), 7.29 (1H, d, J = 8.07 Hz), 7.45 (1H, d, J = 
5.28 Hz), 7.53 (1H, m), 7.64 (1H, m), 8.22 (1H, s), 8.45 (1H, m), 8.52 (1H, d, J = 
5.25 Hz), 8.68 (1H, m), 9.01 (1H, s), 9.26 (1H, s). ESI-MS (m/z) calculated = 
307.118 [M+H+], (m/z) observed = 307.075 [M+H+]  
 
4-Methyl-N-(prop-2-ynyl)-3-(4-(pyridin-3-yl) pyrimidin-2-ylamino) 
benzamide (4-13):  
The acid 4-12 (0.2 g, 0.653 mmol) was added to 10 mL of DMF followed by 
HATU (0.3 g, 0.784 mmol, 1.2 eq.) and DIEA (0.133 mL, 0.784 mmol, 1.2 eq.). 
After stirring for 5 min. was added propargylamine (0.054 mL, 0.784 mmol, 1.2 
eq.) and the reaction was stirred for 2 h. The solvent was removed under reduced 
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pressure and the crude product obtained was purified by column chromatography 
on silica gel to give 0.15 g (yield = 67%) of the Warhead-2 as an off-white solid. 
1H-NMR (300 MHz, DMSO-d6) δ 2.30 (3H, s), 3.10 (1H,s), 4.05 (2H, m), 7.35 
(1H, d, J = 8.07 Hz), 7.54 (1H, d, J = 5.07 Hz), 7.61 (1H, m), 7.87 (1H, m), 8.13 
(1H, s), 8.60 (1H, d, J = 5.25 Hz), 8.78 (1H, d, J = 8.07 Hz), 8.86 (2H, m), 9.21 
(1H, s), 9.35 (1H, s); 13C-NMR (75 MHz, DMSO-d6) δ 18.03, 28.45, 72.67, 81.41, 
107.99, 123.26, 124.29, 125.50, 130.23, 131.76, 136.11, 137.68, 138.44, 144.64, 
147.66, 158.57, 159.76, 160.10, 160.95, 165.60. ESI-MS (m/z) calculated = 
344.151 [M+H+], (m/z) observed = 344.140 [M+H+] 
 
N-(4-Methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-1-(2-(2-
methylphenylsulfonamido)ethyl)-1H-1,2,3-triazole-4-carboxamide [W1-SA20]:  
100 µl of a stock solution of W1 (100 mM) in DMSO  was mixed with a 50 mM 
stock solution of the azide SA20 (200 µl in DMSO). To this was addes 200 µl 
water , 100 µl methanol, 50 µL copper sulphate solution (10 mM stock solution in 
water) and 50 µl sodium ascorbate solution (50 mM stock solution in water). The 
reaction was left overnight on a shaking incubator at room temperature. Upon 
completion of the reaction (< 12 h), the crude reaction mixture was purified by 
reverse phase Semi-Prep HPLC on a C-18 column. 1H-NMR (300 MHz, DMSO-d6) 
δ 2.23 (3H, s), 2.51 (3H, s), 3.34 (2H, m), 4.48 (2H, t, J = 5.59 Hz), 7.20 (1H, d, J 
= 8.37 Hz), 7.35 (2H, m), 7.47 (2H, d, J = 5.25 Hz), 7.53 (1H, m), 7.67 (1H, m), 
7.76 (1H, d, J = 7.71 Hz), 7.97 (1H, t, J = 5.91 Hz), 8.15 (1H, s), 8.55 (1H, d, J = 
5.07 Hz), 8.56 (1H,s), 8.63 (1H, d, J = 7.86 Hz), 8.76 (1H, bs), 9.03 (1H, s), 9.32 





methylphenylsulfonamido)ethyl)-1H-1,2,3-triazole-4-carboxamide [W2-SA13]:  
100 µl of a stock solution of W2 (100 mM) in DMSO was mixed with a 50 mM stock 
solution of the azide SA13 (200 µl in DMSO). To this was added 200 µl water , 100 
µl methanol, 50 µL copper sulphate solution (10 mM stock solution in water) and 50 
µl sodium ascorbate solution (50 mM stock solution in water). The reaction was left 
overnight on a shaking incubator at room temperature. Upon completion of the 
reaction (< 12 h), the crude reaction mixture was purified by reverse phase Semi-Prep 
HPLC on a C-18 column. 1H-NMR (300 MHz, DMSO-d6) δ 2.29 (6H, s), 3.20 (2H, 
m), 4.37 (2H, t, J = 6.00 Hz), 4.49 (2H, d, J = 5.43 Hz), 7.33 (1H, d, J = 7.89 Hz), 
7.49 (4H, m), 7.63 (1H, d, J = 7.89 Hz), 7.79 (1H, m), 7.95 (2H, m), 8.14 (1H, s), 8.57 
(1H, d, J = 5.28 Hz), 8.72 (1H, d, J = 8.04 Hz), 8.83 (1H, bs), 8.94 (1H, t, J = 5.76 
Hz), 9.17 (1H, s), 9.32 (1H, bs). 
 
High Resolution Mass Spectrometry (HRMS) results of the selected click-
inhibitors: 
W1-SA9 [C27H24FN9O3S], (m/z)calculated = 596.1599 [C27H24FN9O3SNa] (m/z)observed = 
596.1586 (ESI-HRMS) 
W1-SA10 [C27H24FN9O3S], (m/z)calculated = 596.1599 [C27H24FN9O3SNa] (m/z)observed 
= 596.1590 (ESI-HRMS) 
W1-SA17 [C31H27N9O3S], (m/z)calculated =  606.2036 [C31H28N9O3S] (m/z) observed =  
606.2023 (ESI-HRMS) 
W1-SA20 [C28H27N9O3S], (m/z)calculated = 570.2036  [C28H28N9O3S] (m/z) observed =  
570.2031 (ESI-HRMS) 
W1-SA22 [C25H23N9O3S2], (m/z) calculated = 584.1258 [C25H23N9O3S2Na] (m/z) observed 
= 584.1251 (ESI-HRMS) 
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W2-SA3 [C28H26ClN9O3S], (m/z)calculated = 626.1460 [C28H26ClN9O3SNa] (m/z)observed 
= 626.1441 (ESI-HRMS) 
W2-SA4 [C26H24ClN9O3S2], (m/z)calculated = 632.1024 [C26H24ClN9O3S2Na] 
(m/z)observed = 632.0999 (ESI-HRMS) 
W2-SA7 [C28H25F2N9O3S], (m/z)calculated = 628.1661 [C28H25F2N9O3SNa] (m/z)observed 
= 628.1692 (ESI-HRMS) 
W2-SA13 [C29H28FN9O3S], (m/z)calculated = 624.1912 [C29H28FN9O3SNa] (m/z)observed 
= 624.1939 (ESI-HRMS) 
W2-SA17 [C32H29N9O3S], (m/z)calculated = 642.2006 [C32H29N9O3SNa] (m/z)observed = 
642.2013 (ESI-HRMS) 















This chapter summarizes the synthesis and biochemical evaluation of an improved 
mechanism-based chemical cross-linker, naphthalene 2,3-dicarboxaldehyde-adenosine 
(NDA-AD), for the identification of kinase-substrate interactions from crude 
proteome. The design of the cross-linker was based on a previously reported 
mechanism-based cross-linker, orthophthalaldehyde-adenosine (OPA-AD), developed 
by Shokat et al. that potentially allows researchers to use known 
phosphopeptides/proteins to identify their upstream protein kinases.  Although OPA-
AD could detect kinase-substrate interactions with purified kinases, the compound 
was found to produce several non-specific labelling in a complex proteome which 
severely limit its potential applications. This prompted us to develop the improved 
version of the cross-linker.  In addition to improved labeling performances, the 
compound NDA-AD was found to be suitable for the detection of kinase-substrate 
interactions of both tyrosine-specific and serine/threonine-specific protein kinases.  
5. 1 Introduction 
     The human genome encodes 518 protein kinases, and hundreds of thousands of 
potential phosphorylation sites are present in the human proteome.102 It is estimated 
that at any given time in the life cycle of a cell, approximately 30% of cellular 
proteins are phosphorylated on at least one residue.4b Existing biochemical and 
proteomic methods have offered invaluable tools for the identification of 
phosphoproteins as well as phosphorylation sites in proteins.103 Powerful methods for 
the identification of kinase substrates have also been developed.104 However, the 
opposite problem of identification of the upstream kinase for a specific 
phosphorylation event/phosphoprotein remains a much more challenging one, mainly 
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due to the very transient and weak-binding nature of kinase-substrate interactions. 
Towards this, Shokat and co-workers developed a mechanism-based cross-linker, o-
phthalaldehyde-adenosine (OPA-AD), which potentially allows researchers to use 
known phosphoproteins/phosphopeptides to identify their upstream kinases.105 OPA 
and its derivatives have conventionally been used in amino acid/peptide analysis 
where a three-component reaction between primary amino group from amino acids, 
formyl functionality of OPA and a proximal thiol functional group or a nucleophilic 
cyanide ion leads to the formation of a stable isoindole product which facilitates 
sensitive detection of the primary amino functionality.106 The compound OPA-AD 
enabled the researches to carryout this three-component reaction at the active site of 
kinases as the adenosine unit in the reagent drives the molecule to the ATP-binding 
pocket of the enzyme. Once the molecule occupies the ATP-binding pocket, the 
catalytic lysine residue (this lysine is conserved in most of the kinases) forms a 
reversible imine adduct with one of the formyl functionalities in OPA, which 
subsequently reacts with a thiol functionality (from a cysteine residue) from a pseudo-
peptide substrate leading to the formation of an isoindole product, cross-linking the 











































Figure 5. 1 Chemical structure of ATP, OPA-AD and NDA-AD. 
 
 
Scheme 5. 1 Scheme showing the three-component cross-linking reaction of the kinase with 
its pseudosubstrate and NDA-AD. 
 
 
5. 2 Synthesis of the cross-linkers 
5. 2. 1 Synthesis of OPA-AD 
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     The cross-linker OPA-AD was synthesized as previously reported.105 It was 
resynthesized for a direct comparison of its labeling performance with our cross-
linker NDA-AD. Briefly, the commercially available compound 3,4-dimethylbenzoic 
acid was converted to the tetrabromo product 5-1 via treatment with N-
bromosuccinimide in the presence of benzoyl peroxide under reflux condition. 
Compound 5-1 was then converted to 3,4-diformylbenzoic acid (5-2) via treatment 
with a hot aqueous solution of sodium carbonate followed by acidic hydrolysis. The 
formyl groups in 5-2 were subsequently protected with a cyclic bis-acetal group via 
treatment with “super-dry” methyl alcohol in the presence of catalytic amount of 
methanesulfonic acid under reflux condition. The methyl ester in compound 5-3 was 
subsequently deprotected to free acid by treatment with LiOH yielded the compound 
5-4, which was used to couple to the 5’-hydroxyl group of the commercially available 
compound 2’,3’-isopropylidineadenosine using the coupling reagent MSNT to give 
the compound 5-5. Finally, the cyclic bis-acetal protecting group in 5-5 was 
deprotected by treatment with 1:1 TFA:H2O afforded the target compound, OPA-AD 
(5-6), which was purified by Prep-HPLC using reverse-phase C-18 column with a 
suitable gradient of water with 0.1% TFA and acetonitrile with 0.1% TFA as the 





















































Scheme 5. 2 Synthesis of the cross-linker, OPA-AD 
 








Scheme 5. 3 Synthesis of the cross-linker, NDA-AD 
     The synthesis of the cross-linker, NDA-AD, was started with the intermediate 5-2 
from the OPA-AD synthetic scheme. A double aldol condensation reaction of 5-2 














































































catalytic amount of piperidine afforded the key intermediate 6,7-diformyl-2-naphthoic 
acid (5-7). Treatment of 5-7 with “super-dry” methyl alcohol in the presence of 
catalytic amount of methanesulfonic acid under reflux condition yielded the cyclic 
bis-acetal compound 5-8, which was subsequently treated with LiOH to get 5-9. The 
free carboxylic acid group in compound 5-9 was subsequently coupled to the 5’-
hydroxyl group of the commercially available compound 2’,3’-
isopropylidineadenosine using the coupling reagent MSNT yielded the compound 5-
10. Finally, the cyclic bis-acetal protecting group in 5-10 was deprotected by 
treatment with 1:1 TFA:H2O afforded the target compound, NDA-AD (5-11), which 
was purified by Prep-HPLC using reverse-phase C-18 column with a suitable gradient 
of water with 0.1% TFA and acetonitrile with 0.1% TFA as the mobile phases. 
5. 3 Synthesis of Peptide Pseudosubstrates 
    Solid phase peptide synthesis (SPPS) was performed on an automated peptide 
synthesizer (Chemspeed Technologies ASW2000) utilizing standard Fmoc chemistry 
on rink amide resin (ChemPep Inc.). Fmoc amino acids (Advanced ChemTech) were 
activated by DIC/HOBt (Advanced ChemTech) and the coupling reaction was 
performed for 2 hours with amino acids (4 eq) during each cycle. After washing with 
DMF (6X), the Fmoc-protecting group was removed using 20% piperidine in DMF, 
followed by another washing with DMF (6X). The N-terminus was capped by 
agitating the resin for 20 hours in the presence of a fluorescein tag (4eq), HATU (4eq) 
and DIEA (8eq), or a biotin tag (4eq), HATU (4eq) and DIEA (8eq). Prior to cleavage, 
the resin was washed with MeOH (6X), DCM (6X), and MeOH (6X). The 
synthesized peptides were cleaved from the resin and deprotected from its side chain 
protecting groups in a 1mL cleavage mixture containing 94% TFA, 2.5% H2O, 2.5% 
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EDT and 1% TIS for 2.5 hours. After filtration and precipitation with ether, the 
precipitated peptides were washed once with TFA and twice with ether and dried 
using Genevac (Biomedia). Each peptide was then dissolved in 1mL DMF and 
characterized by LC-MS (Shimadzu). 
Csk-pseudosubstrate (Csktide): Fluorescein-GG-KKKKEEICFFF. Molecular 
weight calculated = 1960, LC-MS: m/z [M+2H]/2 = 980.9. 
Erk 1 and Erk 2 -pseudosubstrates: Fluorescein-GG-ELVEPLCPSGEAPNQ. 
Molecular weight calculated = 2096, LC-MS: m/z [M+2H]/2 = 1048.9. 
Src-pseudosubstrate: Fluorescein-GG-KVEKIGEGTCGVVYK. Molecular weight 
calculated = 2122, LC-MS: m/z [M+2H]/2 = 1062.0. 
Abl-pseudosubstrate: Fluorescein-GG-EAICAAPFAKKK. Molecular weight 
calculated = 1790, LC-MS: m/z [M+2H]/2 = 895.9. 
PKA-pseudosubstrate: Fluorescein-GG-LRRACLG. Molecular weight calculated = 
1300, LC-MS: m/z [M+2H]/2 = 651.3. 
5. 4 Results and Discussions 
     Although OPA-AD was found to be useful in cross-linking kinase-pseudosubstrate 
pairs with purified kinases, we observed that in the presence of complex proteome, 
the compound produces a large number of non-specific cross-linking bands in 
addition to the one corresponding to the desired kinase-pseudosubstrate pair.  This 
non-selective cross-linking severely limits its potential applications. So we aimed to 
improve the selectivity of the cross-linker via modulating the reactivity of the 
dialdehyde unit. We hypothesized that replacing the highly reactive OPA moiety with 
a less reactive naphthalene-2,3-dicarboxaldehyde (NDA) group may improve the 
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labeling selectivity, which was indeed found to be true as evident from the much more 
cleaner cross-linking of Pka/Pkatide complex with the new cross-linker naphthalene-
2,3-dicarboxaldehyde-adenosine (NDA-AD) in the presence of competing cellular 
proteins from E. coli DE3 cell lysate (Figure 5.2). The NDA moiety in the improved 
cross-linker is also a better structural fit in the kinase active site compared to OPA in 










Figure 5. 2 Comparative labeling profiles of OPA-AD and NDA-AD for the kinase PKA 
(with PKA-pseudosubstrate) in the presence of bacterial cell lysate.    
 
     Next we assessed whether the NDA-AD could serve as a general mechanism-based 
cross-linker for both Tyrosine and Serine/Threonine kinases. The cross-linking 
reactions were tested with a set of 6 purified kinases, of which three are Tyr kinases 
(Csk, Src & Abl) and the other three Ser/Thr kinases (Erk1, Erk2 & Pka). All kinases 
were recombinantly expressed and tested to ensure their purity as well as enzymatic 
activities. Fluoresceine-labelled, cysteine-containing kinase pseudosubstrates were 
chemically synthesized based on their known peptide substrate sequences. As shown 
in Figure 5.3, incubation of each of the six kinases, regardless of whether they are Tyr 
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or Ser/Thr kinases, with their cognate pseudosubstrates in the presence of NDA-AD 
led to the successful cross-linking of kinase-substrate complex, as indicated by a 
fluorescence band on the SDS-PAGE. All three components (i.e. kinase, 
pseudosubstrate and NDA-AD) were necessary, as labelling was not observed in the 
absence of any of the components. No cross-linking was observed with heat-
denatured kinases, indicating the cross-linking was indeed activity-dependent.  
Tyr Kinase+ + + +
+ + + +
+ 95 0C, 10 min
2 (20 M) 
Peptide (1 M) + + ++
Ser/Thr Kinase
95 0C, 10 min








+ + + +




Figure 5. 3 Fluorescence-scanned gels showing cross-linking profiles of NDA-AD against 







5. 5 Conclusions 
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An improved mechanism based kinase-pseudosubstrate cross-linker, NDA-AD, was 
synthesized with which we demonstrated a general and useful approach for 
identifying kinase activities from a crude proteome.108 The cross-linker NDA-AD, not 
only showed improved labeling performances from crude cellular proteome but was 
found to be compatible with detecting the kinase-substrate pairs of both 
serine/threonine-specific and tyrosine-specific protein kinases. Thus given the fact 
that peptide pseudosubstrates of any sequence could be synthesized easily, this 
approach would be compatible for detecting activities of any diverse sets of kinases. 
The establishment of the NDA-adenosine guided kinase/peptide cross-linking reaction 
and the initial applications represents a significant step towards tackling the problem 
of identifying the upstream kinase for a given phosphoprotein of interest, although 
much more progress remains to be made to accomplish this goal. Further 
improvements in the strategy that allows cross-linking of protein substrates rather 
than peptide pseudosubstrates with full-length endogenous protein kinases in cellular 
lysates, and more desirably in intact live cells, would provide an invaluable tool in the 
detailed investigations of cellular signal transduction networks in which protein 





5. 6 Synthetic details and characterizations of compounds 
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3,4-Bis(dibromomethyl)benzoic acid (5-1):  
3,4-dimethylbenzoic acid (15.33 g, 0.1 mol) was dissolved in hot carbon tetrachloride 
(250 mL). N-bromosuccinimide (73.70 g, 0.41 mol, 4.1 eq.) and benzoylperoxide (3 g, 
cat.amt.) were added and the reaction mixture was refluxed for 12 hours while stirring. 
The reaction was then cooled down to room temperature and filtered. The solid 
filtered out was washed with benzene (50 mL) three times and the residue obtained 
was dissolved in diethyl ether (250 mL) and stirred for 2 hours. The mixture was then 
filtered and the residue was again dissolved in diethyl ether (250 mL) and stirred for 2 
hours. The mixture was filtered for the last time and the ether extracts were combined 
and concentrated under reduced pressure to dryness. The orange solid obtained was 
recrystallized from acetonitrile to yield 26.0 g (yield = 54.7%) of compound of 5-1 in 
white powdered form. 1H- NMR (DMSO-d6):  δ 7.77 (s, 1H), 7.79 (s, 1H), 7.93-8.03 
(m, 2H), 8.35 (s, 1H), 13.54 (bs, 1H, exchangeable with D2O addition, COOH). ESI-
MS: m/z [M-H]- = 464.9. 
3,4-Diformylbenzoic acid (5-2):  
3,4-bis(dibromomethyl)benzoic acid 5-1 (20 g, 0.04 mol) was dissolved in 10% 
aqueous sodium carbonate solution (200 mL). The mixture was heated at 70°C for 3 
hours and the precipitation evolved was filtered out. The filtrate obtained was 
acidified with concentrated HCl until pH 1 while cooling on ice. The acidic solution 
was then extracted with ethyl acetate three times. The organic layers were combined, 
washed with deionized water and dried with anhydrous sodium sulphate. Solvent was 
removed on a rotary evaporator to give 6.7 g (yield = 85.9%) of compound 5-2 as a 
pale yellow powder which was used for subsequent steps without further purification. 
1H-NMR (DMSO-d6):  δ 8.06 (d, 1H, J = 7.89 Hz), 8.34 (dd, 1H, J1 = 7.98 Hz, J2 = 
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1.74 Hz), 8.49 (d, 1H, J = 1.65 Hz), 10.50 (s, 1H), 10.54 (s, 1H), 13.53 (bs, 1H, 
exchangeable with D2O addition, COOH). ESI-MS: m/z [M-H]- = 177.0. 
Methyl 1,3-dimethoxy-1,3-dihydroisobenzofuran-5-carboxylate (5-3): 
3,4-diformylbenzoic acid 5-2 (0.45 g, 2.5 mmol) was dissolved in ‘super-dry’ 
methanol (62.5 mL) in a flame-dried rbf under nitrogen gas  atmosphere. Catalytic 
amount of methanesulfonic acid was added and the reaction was refluxed overnight 
with stirring. The resulting reaction mixture was cooled and concentrated on a rotary 
evaporator to afford an amber coloured oil. The oil was dissolved in ethyl acetate and 
washed with water. The water layer was washed with ethyl acetate two times. The 
organic layers were combined and washed with water and brine, dried over anhydrous 
sodium sulphate and concentrated on a rotary evaporator to afford an amber coloured 
oily compound which was then purified by silica gel flash column chromatography to 
yield compound 5-3 as a  yellowish oil 0.4 g (yield = 71.0%). 1H-NMR (DMSO-d6):  
δ 3.31 (s, 6H), 3.88 (s, 3H), 6.10 (s, 1H), 6.36 (s, 1H), 7.57 (d, 1H, J = 7.89 Hz), 7.95 
(s, 1H), 8.05 (d, 1H, J = 7.89 Hz). ESI-MS: m/z [M+H]+ = 239.1. 
1,3-Dimethoxy-1,3-dihydroisobenzofuran-5-carboxylic acid (5-4):  
Methyl 1,3-dimethoxy-1,3-dihydroisobenzofuran-5-carboxylate 5-3 (0.5 g, 2.1 mmol) 
was dissolved in a 1:1 mixture of tetrahydrofuran and water (15 mL:15 mL). Lithium 
hydroxide (0.06 g, 2.5 mmol, 1.2 eq.) was added and the yellow coloured solution was 
stirred at room temperature for 1.5 hours. Solvent was then removed on a rotary 
evaporator and the remaining water was washed with ether. The pH of the aqueous 
layer was adjusted very cautiously and quickly to pH = 2 with 1N HCl, and then 
quickly extracted with ethyl acetate. The organic layer was washed with brine, dried 
over anhydrous sodium sulphate and concentrated to yield 0.46 g (yield 98.8%) of 
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compound 5-4 as a yellow powder. 1H-NMR (DMSO-d6):  δ 3.31 (s, 3H), 3.35 (s, 
3H), 6.10 (s, 1H), 6.35 (s, 1H), 7.53 (d, 1H, J = 7.89 Hz), 7.92 (s, 1H), 8.03 (d, 1H, J 
= 7.89 Hz). ESI-MS: m/z [M-H]- = 223.2. 
(6-(6-Amino-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-
yl)methyl 1,3-dimethoxy-1,3-dihydroisobenzofuran-5-carboxylate (5-5): 
1,3-dimethoxy-1,3-dihydroisobenzofuran-5-carboxylic acid 5-4 (140 mg, 0.6 mmol), 
2',3’-isopropylideneadenosine (375 mg, 1.2 mmol, 2 eq.), DIEA (0.21 mL, 1.25 mmol. 
2.08 eq.), and DMF (4 mL) were added into a flame-dried rbf under nitrogen gas  
atmosphere. The reaction mixture was cooled to 0°C and the coupling reagent MSNT 
(180 mg, 0.6 mmol, 1 eq.) was added portion-wise. The reaction mixture was stirred 
at room temperature for 12 hours and then concentrated. The resultant red oil was 
dissolved in ethyl acetate (100 mL), and extracted with 10% citric acid (50 mL), and 
10% sodium bicarbonate (50 mL).  The organic layer was then dried over anhydrous 
sodium sulphate, concentrated and purified over silica gel flash column 
chromatography (5% methanol in chloroform) to yield 0.17 g (yield 54.0%) of 5-5 as 
a crystalline solid. 1H-NMR (CDCl3):  δ 1.42 (s, 3H), 1.63 (s, 3H), 3.44-3.47 (m, 6H), 
4.49-4.66 (m, 3H), 5.17-5.20 (m, 1H), 5.55-5.62 (m, 1H), 6.02-6.10 (m, 2H), 6.27-
6.31 (m, 1H), 7.37-7.43 (m, 1H), 7.86-8.01 (m, 3H), 8.32 (d, 1H, J = 5.76Hz). ESI-
MS: m/z [M+H]+ = 514.7. 
(5-(6-Amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl 3,4-
diformylbenzoate (5-6): 
Compound 5-5 (15 mg, 29 µmol) was dissolved in 1:1 TFA/H2O (0.5 mL:0.5 mL) and 
stirred for 1 hour at room temperature. TFA was removed on a rotary evaporator and 
the resultant aqueous solution was purified using Prep-HPLC on a C-18 reverse-phase 
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column. (CH3CN with 0.1% TFA and H2O with 0.1% TFA as the mobile phases). The 
purified product was concentrated by lyophilisation to afford 5 mg (yield = 40%) of 
compound 5-6 as a white powder. 1H-NMR (1:1 DMSO-d6/D2O-d2):  δ 4.30-4.45 (m, 
4H), 4.65-4.78 (m, 3H), 5.90-5.92 (m, 1H), 6.15-6.18 (m, 1H), 6.43-6.44 (m, 1H), 
7.41- 7.45 (m, 1H), 7.75-7.87 (m, 2H), 8.01-8.03 (m, 1H), 8.21-8.22 (m, 1H). ESI-MS: 
m/z [M+H]+ = 428.1. 
6,7-Diformyl-2-naphthoic acid (5-7):107 
3,4-diformylbenzoic acid 5-2 (0.6 g, 3.37 mmol) was placed in a 25 mL rbf. 
Deionized water (3 mL), glacial acetic acid (2 mL), 2,5-dimethoxytetrahydrofuran 
(0.436 mL, 3.37 mmol, 1 eq.) and 3 drops of piperidine catalyst were added and the 
reaction mixture was refluxed for 23 hours with stirring. The orange precipitate 
formed was collected by filtration, washed twice with water, twice with 1N HCl, and 
once with ether. The solids were dried further under vacuum to yield 0.38 g (yield = 
49.7%) of compound 5-7. 1H-NMR (DMSO-d6):  δ 8.23 (dd, 1H, J1 = 8.55 Hz, J2 = 
1.65 Hz), 8.36 (d, 1H, J = 8.70 Hz), 8.67 (s, 1H), 8.81 (s, 1H), 8.88 (s, 1H), 10.52 (s, 
1H), 10.56 (s, 1H).  
Methyl 1,3-dimethoxy-1,3-dihydronaphtho[2,3-c]furan-6-carboxylate (5-8): 
6,7-diformyl-2-naphthoic acid 5-7 (0.38 g, 1.66 mmol) was dissolved in ‘super-dry’ 
methanol (60 mL) in a flame-dried rbf under nitrogen gas  atmosphere. Catalytic 
amount of methanesulfonic acid was added and the reaction mixture was refluxed 
overnight with stirring. The reaction mixture was then cooled and concentrated to 
afford an amber coloured oil. The oily compound was dissolved in ethyl acetate and 
washed with water. The aqueous layer was washed with ethyl acetate two times. The 
organic layers were combined and washed with water and brine. The organic layer 
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was then dried over anhydrous sodium sulphate, concentrated and purified over silica 
gel flash column chromatography to yield 0.31 g (yield = 65.7%) of compound 5-8 as 
a yellowish oil. 1H-NMR (CDCl3):  δ 3.50 (s, 3H), 3.52 (s, 3H), 3.99 (s, 3H), 6.21 (d, 
1H, J = 3.78 Hz), 6.45 (s, 1H), 7.91 (s, 1H), 7.95 (s, 1H), 7.98 (s, 1H), 8.09 (dd, 1H, 
J1 = 8.55 Hz, J2 = 1.65 Hz), 8.65 (s, 1H).  
1,3-Dimethoxy-1,3-dihydronaphtho[2,3-c]furan-6-carboxylic acid (5-9): 
Methyl 1,3-dimethoxy-1,3-dihydronaphtho[2,3-c]furan-6-carboxylate 5-8 (0.2 g, 0.7 
mmol) was dissolved in a 1:1 mixture of tetrahydrofuran and water (10 mL:10 mL). 
Lithium hydroxide (0.04 g, 1.4 mmol, 2 eq.) was added and the yellow solution was 
stirred at room temperature for 2 hours. Solvent was then removed on a rotary 
evaporator and the remaining water was washed with ether. The pH of the aqueous 
layer was adjusted very cautiously and quickly to pH = 2 with 1N HCl, and then 
quickly extracted with ethyl acetate. The organic layer was washed with brine, dried 
over sodium sulphate and concentrated to yield 0.19 g (yield = 99.5%) of compound 
5-9 as a yellow powder. 1H-NMR (CDCl3):  δ 3.52 (s, 3H), 3.54 (s, 3H), 6.23 (s, 1H), 
6.47 (s, 1H), 7.94-8.02 (m, 3H), 8.14 (d, 1H, J = 1.47 Hz), 8.76 (s, 1H). ESI-MS: m/z 
[M-H]- = 273.2. 
(6-(6-Amino-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-
yl)methyl 1,3-dimethoxy-1,3-dihydronaphtho[2,3-c]furan-6-carboxylate (5-10): 
1,3-dimethoxy-1,3-dihydronaphtho[2,3-c]furan-6-carboxylic acid 5-9 (100 mg, 0.36 
mmol), 2’,3’-isopropylideneadenosine (224 mg, 0.72 mmol, 2eq.), DIEA (0.13 mL, 
0.76 mmol. 2.08 eq.), and DMF (4 mL) were added into a flame-dried rbf under 
nitrogen gas  atmosphere. The reaction mixture was cooled to 0°C and MSNT (107 
mg, 0.36 mmol, 1 eq.) was added portion-wise. The reaction mixture was stirred at 
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room temperature for 12 hours and then concentrated on a rotary evaporator. The 
resultant red oil was dissolved in ethyl acetate (100 mL), and extracted with 10% 
citric acid (50 mL) followed by 10% sodium bicarbonate (50 mL).  The organic layer 
was then dried over anhydrous sodium sulphate, concentrated and purified over silica 
gel flash column chromatography to yield  0.11 g (yield = 54.3%) of 5-10 as a 
crystalline solid. 1H-NMR (CDCl3):  δ 1.44 (s, 3H), 1.65 (s, 3H), 3.50-3.56 (m, 6H), 
4.57-4.59 (m, 1H), 4.68-4.72 (m, 2H), 5.21-5.24 (m, 1H), 5.61-5.63 (m, 1H), 6.09-
6.19 (m, 2H), 6.44 (m, 1H), 7.84-7.96 (m, 5H), 8.28 (s, 1H), 8.44-8.50 (m, 1H). ESI-




yl)methyl 1,3-dimethoxy-1,3-dihydronaphtho[2,3-c]furan-6-carboxylate 5-10 (100 mg, 
0.18 mmol) was dissolved in 1:1 TFA/H2O (7 mL:7 mL) and stirred for 2 hours at 
room temperature. TFA was removed under vacuum and the resultant aqueous 
solution was purified using Prep-HPLC on a reverse-phase C-18 column. The purified 
product was concentrated by lyophilisation to afford  30 mg (yield = 34.9%) of 
compound 5-11 as an off-white powder. 1H-NMR (1:1 DMSO-d6):  δ 4.32 (m, 2H), 
4.51-4.56 (m, 2H), 4.69-4.77 (m, 2H), 5.01 (s, 1H), 5.97 (s, 2H), 6.23 (s, 1H), 8.10-








This chapter summarizes the development of selective small molecule-based activity-
based probes (ABPs) for the Abelson (Abl) tyrosine kinase using two different 
strategies namely a dialdehyde-based cross-linking and photo-affinity labeling. The 
probes were designed from the core structure of the Abl-selective inhibitor ImatinibTM. 
The dialdehyde-based probe, although found to be useful in detecting pure Abl kinase 
was found to have poor labeling performances in the presence of competing cellular 
proteins. A photo-affinity based probe (AfBP) with a fluorescent reporter tag was 
found to have more severe limitations in labeling performances even with pure 
proteins. This was attributed to the presence of the bulky reporter tag in the probe 
which might have disrupted the proper binding interactions of the probe with the 
active site of the kinase. On the other hand, a clickable “tag-free” version of the AfBP 
was found to have superior labeling performances both with pure protein and in the 
presence of competing cellular proteins. The probe also showed promising use for 
potential in situ screening of Abl inhibitors.  
6. 1 Introduction 
     Active site-directed probes capable of detecting functionally active form of a target 
protein/protein class have been developed for many proteins. The ABPP approach 
allows one to directly interrogate active enzymes present in complex proteomes using 
the ABPs. Protein kinases present significant challenge to the development of kinase-
selective ABPs partly because these classes of enzymes carry out catalysis with only 
transient and non-covalent interactions with the substrates and partly because of the 
absence of highly reactive residues near the active site of most of the kinases. In spite 
of these limitations, probes for the kinase RSK and EGFR, both based on irreversible 
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inhibitor scaffolds targeting a nucleophilic cysteine residue near the active sites of 
these kinase, have been reported.109 This approach, however, is not general as many 
protein kinases, including clinically highly relevant kinases such as Abl, do not 
possess such a nucleophilic cysteine residue near the active site. Targeting the 
generally conserved catalytic lysine residue of kinases is another option. There are a 
handful of both selective and broad-spectrum kinase probes based on this approach. 
For example, the fungal metabolite Wortmannin has been identified as covalent 
inhibitor targeting the catalytic lysine residue of phosphoinositol-3-kinase (PI3K) 
family and based on its irreversible mode of inhibition, biotin or fluorophore 
conjugated Wortmannin analogues have been developed as probes for PI3Ks and 
mammalian polo-like kinase-1.110 Fluorosulfonylbenzoyl adenosine (FSBA) is a small 
molecule known to target the catalytic lysine of kinases and biotin conjugates of 
FSBA have been developed as general probes for protein kinases.111 Acyl phosphate-
based promiscuous protein kinase probes targeting the catalytic lysine residue have 
been recently reported by Kozarich et al.112  Shokat and co-workers utilized the same 
lysine residue in a kinase to cross-link kinase/pseudopeptide substrate complex using 
an orthophthaldehyde (OPA)-derivatized ATP analogue.105 We further improved this 
method by replacing the OPA portion with naphthalene-2,3-dicarboxaldehyde (NDA), 
resulting in a cross-linker with improved kinase specificity (discussed in chapter-5).108 
Although the original motivation with these dialdehyde-based cross-linkers was to 
identify unknown kinases from putative phosphopeptides/phosphoproteins, we 
reasoned the same strategy could be used to develop activity-based probes for a 
specific kinase, for instance Abl kinase, if the dialdehyde cross-linker could be made 




Figure 6. 1 Two strategies to develop Abl-selective probes. (a) A three-component (kinase, 
pseudosubstrate and dialdehyde) reaction mediated labeling of Abl by the dialdehyde 7. (b) 
Clickable photo-affinity probe (Compound 6-13) mediated labeling of Abl.   
 
     Affinity-based probes (AfBPs) offer another potential strategy for targeting kinases 
that lacks nucleophilic residues near the catalytic site. Such probes have been 
developed for various classes of enzymes including kinases.14 An affinity-based probe 
essentially has three structural components: 1) a protein recognition unit; usually 
derived from a potent reversible inhibitor scaffold 2) a photoreactive group; which 
could be benzophenone, alkyl or aryl diazirine or aryl azides and 3) a reporter unit; 
which is typically a fluorescent dye or biotin. We hypothesized that the remarkable 
selectivity of Imatinib for Abl could be taken as a guiding principle for developing 
Abl-selective small-molecule probes. This chapter reports the synthesis of such Abl-
selective, active-site directed probes that utilize both design principles (i. e. 
dialdehyde-based cross-linking and photo-cross-linking) (see Figure 6.1). At the heart 
of the probe designs we used the Imatinib-core structure, essentially to ensure 
sufficient binding interaction of the probes with the active-site of the Abl kinase. At 
 133 
 
first, the dialdehyde-based cross-linker (compound 6-7 in Scheme 6.1) was 
synthesized. It has two key structural elements; the Imatinib-core structure (for kinase 
recognition) and the NDA reactive unit (for mechanism-based cross-linking of the 
kinase with pseudo-substrates). The choice of NDA as the reactive unit was based on 
our previous results (chapter-5), where we observed improved kinase labeling with 
the NDA-reactive unit compared to OPA-reactive unit. The proposed mechanism of 
labeling of Abl kinase using this dialdehyde-based cross-linker is shown in Figure 
6.2a. Briefly, the compound 6-7 first occupies the ATP-binding pocket (shaded) of the 
kinase by exploiting the high binding affinity and selectivity of the imatinib core 
structure (blue). The catalytic lysine residue from the kinase active site forms a 
reversible imine adduct by reacting with the formyl group in 6-7. The cysteine residue 
from the pseudosubstrate attacks the imino carbon with the subsequent removal of a 
water molecule, leading to the formation of a stable isoindole product. The cross-
linked Abl-pseudosubstrate pair is subsequently visualized by in-gel fluorescent 
scanning. For the development of photo-affinity-based probes we first synthesized 
compound 6-12, with three distinctive structural units; once again the Imatinib core-
structure for selectivity, a benzophenone-based photo-reactive group for light-
mediated covalent cross-linking of the probe with the kinase and a TER-based 
fluorescent dye for visualization of the labeled protein with in-gel fluorescence 
scanning after protein-separation using SDS-PAGE. Compound 6-12, however, 
exhibited very poor labeling performance which is presumably due to the presence of 
the bulky rhodamine dye unit in the probe which might have caused severe disruption 
in the probe’s active-site recognition of the kinase. So we designed a “label-free”, 
clickable version of the photo-affinity probe (Compound 6-13) which was equipped 
with a flexible alkyne handle for click-conjugation with an azide-functionalized 
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rhodamine fluorophore following the actual covalent labeling of the kinase with the 
probe. This compound exhibited superior labeling performances, both with purified 
protein and in the presence of large excess of competing cellular proteins. The 
proposed mechanism of labeling of Abl kinase using the clickable cross-linker is 
shown in Figure 6.2b. Briefly, upon incubation with the kinase, compound 6-13 
occupies the active site by virtue of the imatinib core structure. Subsequent UV 
irradiation generates a highly reactive diradical intermediate from the benzophenone 
unit of 6-13, which quickly reacts with C-H bonds in the vicinity, leading to covalent 
binding of 6-13 with the kinase. The probe/kinase complex upon treatment with a 
rhodamine azide reporter (i.e. TER-N3) under click chemistry conditions enables the 
fluorescence visualization of the labeled kinase with in-gel fluorescence scanning. 
6. 2 Synthesis of the Probes 
     The structures of the probes are shown in Scheme 6.1 below. The dialdehyde 6-7 
was synthesized first. Briefly, the key intermediate 6-4 was synthesized as previously 
reported with minor modifications.94 Compound 6-4 was subsequently coupled with 
1,3-dimethoxy-1,3-dihydronaphtho[2,3-c]furan-6-carboxylic acid, 6-5, to give 6-6. 
The cyclic acetal protecting group in 6-6 was subsequently removed by treatment with 
TFA in water to afford the target compound 6-7 in 28.9% yield over six steps. For the 
synthesis of the affinity-based probes 6-12 and 6-13 (a clickable version of 6-12; vide 
infra), Boc-protected benzophenone, 6-8, was first coupled to 6-4, yielding compound 
6-9. Subsequent deprotection with TFA, followed by coupling with either the 
rhodamine dye 6-11 or pent-4-ynoic acid, gave the two probes, 6-12 and 6-13 in 
11.6% and 26.9% overall yield, respectively. 
























































6. 3 Results and Discussions 
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The proposed mechanism of labeling of Abl kinase using the two different probes is 








Figure 6. 2 Two different methods to label Abl kinase. (a) A three-component reaction 
(kinase + pseudosubstrate + dialdehyde 6-7) mediated labeling of Abl kinase. (b) Clickable 
photo-affinity probe (compound 6-13) mediated labeling of Abl.  
 
 6. 3. 1 Labeling Experiments with the Dialdehyde 7 
6. 3. 1. 1 Labeling Experiments using pure kinases and kinase spiked in 
cellular lysates  
 
    To evaluate the dialdehyde 7 (compound 6-7) as an activity-based probe for Abl 
kinase, a three-component reaction was initiated by incubating the kinase and the 
dialdehyde 7 with an Abl-selective peptide pseudosubstrate Fluoresceine-
K(biotin)-EAICAAPFAKKK. The peptide pseudosubstrate was equipped with a 
cysteine residue (underlined in the sequences), making the peptide suitable for the 








carried out in the following optimized conditions: kinase (400 to 600 nM), 
pseudosubstrate (2 µM) and dialdehyde 7 (10 µM) in the reaction buffer (25 mM 
HEPES at pH = 7.5, 150 mM NaCl, 2 mM MgCl2) were incubated for 20 min at 
RT before adding 6X loading dye (reducing). The sample was heated at 95oC for 
10 min before SDS-PAGE and in-gel fluorescence scanning (excitation at 480 nm, 
emission collected at 520 nm filter). As shown in Figure 6.3a, intense fluorescent 
labeling of the Abl kinase was observed. Unlike Abl kinase, only a weak labeling 
was observed from the three-component reaction of Csk kinase  with the 
dialdehyde 7 and the Csk pseudosubstrate, Fluoresceine-K(biotin)-
KKKKEEICFFF (i.e. Csktide), thus demonstrating the Abl selective nature of the 
dialdehyde probe. It was also observed that, unlike the previous generations of 
kinase-directed dialdehyde cross-linkers, labeling of the Abl kinase with 6-7 
showed little preference for the amino acid sequence in the peptide 
pseudosubstrates (see lanes 1 & 2). This lack of substrate selectivity could be due 
to the high binding affinity of the dialdehyde 7 towards Abl kinase (IC50 = 194 nM) 
as a result of its imatinib core. Thus, unlike the previous dialdehyde-based 
kinase/substrate crosslinking strategy, which targets a kinase with the selectivity 
of the pseudopeptide substrate, the new dialdehyde probe (compound 6-7) labels 
Abl kinase by taking advantage of the strong binding interaction of its kinase-
binding scaffold. Next, we asked if the probe could selectively label Abl in the 
presence of competing cellular proteins. But unfortunately in a spike experiment 
with varying amounts of CHO-K1 cell lysate, the labeling was severely affected 





Figure 6. 3 Fluorescence scanned gels showing the labeling of Abl and Csk kinases (500 
nM each) with the 6-7 (10 µM) in the presence of the pseudosubstrates (2 µM). (b) 
Labeling of Abl (500 nM) with 6-7 in the presence of increasing amounts of the CHO-K1 
proteome. 
 
6. 3. 1. 2 pH-dependence of the cross-linking reaction 
     HEPES buffer in the pH range of 6 to 9 were used to determine the pH dependence 
of the labeling reaction of Abl kinase with the dialdehyde 7. As shown below, 
efficient labeling was observed at pH > 7 while a low pH was found to be 




Figure 6. 4  pH-dependence of the  labeling profiles of the 6-7 mediated cross-linking of Abl 
kinase with the pseudosubstrate 
 
 





6. 3. 1. 3 Effect of exogenous thiols on the efficiency of the labeling 
     In order to determine the exogenous thiol tolerance of the dialdehyde-guided cross-
linking reaction of the kinase with the thiol peptide pseudosubstrate, reactions were 
done at varying concentrations of an exogenous competing thiol, β-mercaptoethanol. 
Briefly, 500 nM of Abl kinase was incubated in the buffer (25 mM HEPES at pH = 
7.5, 150 mM NaCl, 2 mM MgCl2) with varying amounts of β-mercaptoethanol (BME). 
To this mixture was added the dialdehyde 7 (10 µM) and the Abl-pseudosubstrate (2 
µM). The reactions were incubated for 20 min at RT and subsequently denatured and 
subjected to SDS-PAGE and in-gel fluorescence scanning.  As shown in Figure 6.5, 5 
to 10 fold excess of the exogenous thiol was found to have no significant effect in the 
cross-linking efficiency while higher concentrations (> 50 fold excess) of the thiol 







Figure 6. 5 Effect of β-mercaptoethanol (BME) on the three-component reaction of Abl 










6. 3. 1. 4 Effect of exogenous amines on the efficiency of the labeling 
Since the labeling reaction was based on the selectivity of the dialdehyde 7 towards 
Abl kinase, we tested if the reaction is tolerated in the presence of exogenous amines 
(e.g. lysine). Thus cross-linking reactions were set up in the presence of varying 
amounts of lysine. As shown in Figure 6.6, even 800 fold excess of lysine was found 
to have no significant effect in the labeling efficiency. This indicates that the labeling 






Figure 6. 6  Effect of exogenous lysine on the labeling reaction. 
 
6. 3. 1. 5 IC50 evaluation of the probe 
     Concentration-dependent experiments were performed to determine the inhibition 
potency and hence the binding affinity of the probes towards the Abl kinase. The 
inhibition assay was performed with Kinase-Glo® Plus Luminescent Kinase assay kit 
from Promega following the manufactures instructions. Briefly, recombinant Abl 
kinase, a consensus Abl peptide substrate with sequence KKGEAIYAAPFA-NH2, 
ATP and the probe were mixed in the kinase reaction buffer (100 mM Tris, pH = 7.5, 
10 mM MgCl2) at a volume of 55 µL in a flat-bottom solid white 96-well plate. The 







subsequently quenched by the addition of an equal volume of the Kinase-Glo reagent. 
After 5 min of incubation, the luminescence readouts from the wells were measured 
using Tecan microplate reader with i-control software. The ATP and substrate peptide 
concentrations used in the assay were 10 µM and 50 µM, respectively. The following 
control reactions were also performed simultaneously.  
            1. Enzyme control (No kinase, Buffer+Substrate+ATP),  
            2. Inhibitor control (No inhibitor, Buffer+Kinase+Substrate+ATP),  
            3. Substrate control (No substrate, Buffer+Kinase+ATP)   
            4. Buffer alone.  
The luminescence intensity from each well was measured and the inhibition potency 
was calculated using the following relation, 
            Potency = 1 - Remaining activity 
Dose-dependent inhibition assays were performed by varying the concentration of the 
probes under fixed enzyme concentration of 50 nM. The IC50 values of the probes 
were calculated from the percentage activity vs. log [concentration of probe] curves 
generated using GraphPad Prism software. The dialdehyde 7 was found to be a potent 
inhibitor of the Abl kinase as evident from its IC50 value of 194 nM for Abl kinase 
inhibition (Figure 6.7).                                     
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Figure 6. 7 IC50 evaluation of compound 6-7 for Abl kinase inhibition 
 
6. 3. 2 Labeling experiments with the photo-cross-linkers 
6. 3. 2. 1 Comparitive labeling experiments  
   The photo-cross-linkers 6-12 and 6-13 were tested for their ability to selectively 
label both recombinantly purified Abl kinase and Abl spiked in mammalian 
proteome (Figure 6.8). The general procedure for the labeling studies with the 
photo-affinity probe-1 (compound 6-12) is as follows; 2 µL of the enzyme stock 
solutions (0.4 µg/µL) were diluted with 17.6 µL of Tris.HCl buffer (50 mM, pH = 
7.5). Different concentrations of 6-12 (stock solutions in DMSO) were added (0.4 
µL) and the reactions were incubated at room temperature in the dark for 30 min. 
Subsequently the reaction mixtures were irradiated with a handheld UV lamp 
under the long UV channel for 20 min. The reactions were quenched by the 
addition of 4 µL of 6X SDS loading buffer followed by boiling at 95 oC for 10 min. 
Samples were resolved on a 10% denaturing SDS-PAGE gel and fluorescence was 
detected with a fluorescence gel scanner (Typhoon 9200, Amersham). The general 
procedure for the photo cross-linking with subsequent click-chemistry (for probe 
6-13) is as follows; 2 µL of the enzyme stock solutions (0.1 to 0.5 µg/µL) were 
diluted with 17.6 µL of Tris.HCl buffer (50 mM, pH = 7.5). The clickable probe, 
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6-13, (stock solution in DMSO) was added (0.4 µL) and the reactions were 
incubated at room temperature in the dark for 30 min. Subsequently the reaction 
mixtures were irradiated with a handheld UV lamp under the long UV channel (~ 
350 nm) for 20 min in the absence of other light sources. The reaction mixtures 
were then subjected to click-chemistry with a TER-azide dye in the following 
conditions. To each reaction was added 1 µL each of TER-N3 fluorescent dye 
(concentration in reaction = 50 µM, stock solution in DMSO), CuSO4 
(concentration in reaction = 1 mM, stock solution in water), TBTA (concentration 
in reaction = 100 µM, stock solution in DMSO) and sodium ascorbate 
(concentration in reaction = 1 mM, stock solution in water) and incubated for 2 h 
at room temperature. The reactions were quenched by the addition of 5 µL of 6X 
SDS loading buffer followed by boiling at 95 oC for 10 min. Samples were 
analyzed on a 10% denaturing SDS-PAGE gel and fluorescence was detected with 
the fluorescence gel scanner. 
     Compound 6-12 had rather poor labeling performance and a very high 
concentration of the probe (up to 100 µM) was required in order for sufficient Abl 
labeling to be observed (see lanes 1 & 2, Figure 6.8a). Furthermore, the probe was 
found to nonspecifically label other proteins as well (see a labeled band of YOP, 
i.e. a phosphatase). We speculated that the poor performance of this probe was 
mostly due to the presence of the bulky rhodamine dye which might have 
disrupted the binding of 6-12 to the active site of Abl. On the other hand we were 
delighted to find that the “clickable” probe, 6-13, performed much better at 
selective labeling of Abl kinase. 6-13 was equipped with an alkyne handle in place 
of the rhodamine. Upon labeling with Abl kinase by UV irradiation, the 
probe/kinase complex was subsequently reacted, via the well known click 
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chemistry, with a rhodamine azide reporter (i.e. TER-N3 in Scheme 6.1), before 
visualization with in-gel fluorescence scanning. This two-step, sequential labeling 
approach had previously been shown to minimize the adverse effects caused by 
introduction of bulky reporter dyes in other ABPs. As shown in Figure 6.8a, a low 
concentration of 6-13 (0.5 µM; lane 3) was sufficient to selectively label Abl 
kinase. The contaminant YOP in the same reaction was not labeled. Other proteins 
including kinases c-Src and ERK-2 were also tested for labeling with probe 6-13 
(Figure 6.8b); only Abl kinase was positively labeled, again indicating the 
selectivity of the probe  towards Abl. We next tested the labeling of Abl spiked in 
a complex mammalian proteome with 6-13. As shown in Figure 6.8c, although the 
Abl labeling was diminished in the presence of CHO-K1 proteome, less than 1% 
of Abl present in the total proteome lysate could be detected (see lanes 5 & 6). 
Finally, we performed labeling experiments in the presence of active-site 
competing inhibitor Staurosporine. Dose-dependent reduction in Abl labeling in 
the presence of the inhibitor (Figure 6.8d) was observed, indicating the labeling is 
activity-based and pointing to the possible use of the probe for in situ screening of 








Figure 6. 8 (a) Fluorescence gels of recombinant Abl (600 nM) labeled with 6-12 (lanes 1 
& 2) or 6-13 (lane 3). The concentrations of 6-12 in lanes 1 & 2 were 100 µM & 20 µM, 
respectively. The concentration of 6-13 in lane 3 was 0.5 µM. The contaminant YOP was 
also labeled by 6-12 in lanes 1 & 2 as well. The two-step sequential click chemistry was 
initiated by adding (to the UV-irradiated protein sample) TER-N3, Cu2+, TBTA and 
sodium ascorbate for 2 h before SDS-PAGE and fluorescence scanning. (b) Different 
proteins (lanes 1 to 5 are Abl, PTPB, BSA, ERK-2 and c-Src, respectively) were labeled 
with 6-13 (0.5 M). Only Abl was selectively labeled by the probe (see left gel). (c) 30 　
µg of CHO-K1 proteome was spiked with different amounts of Abl kinase (giving the 
final % of Abl to be 100 (1000 nM), 3.3 (1000 nM), 2.6 (800 nM), 1.3 (400 nM), 0.65 
(200 nM), 0.325 (100 nM), 0.162 (50 nM) and 0 (0 nM) from lane 1 to 8 respectively), 
then labeled with 6-13 (1 µM). (d) Dose-dependant reduction of labeling of Abl (600 nM) 





6. 3. 2. 2 Detection limit of the pure Abl with the photo-cross-linker 6-13.  
In order to determine the fluorescent detection limit of the Abl kinase by the clickable 
photo-affinity probe-2, photo-cross-linking reactions were set up as mentioned before 
with decreasing amounts of Abl. As shown in Figure 6.9 below, 0.3 to 0.2 µg of pure 




                                                               (Abl + Compound 6-13 + Click) 
Figure 6. 9  Labeling of decreasing amounts of pure Abl kinase with 0.5 µM clickable probe 
(6-13) 
6. 3. 2. 3 Labeling experiments with the clickable probe (6-13) in the 
presence of K562 cell lysate 
     Human leukemic cell line K562 is a p-210 Bcr-Abl expressing (Chronic 
Myelogenous Leukemia) cell line. Total cell lysates were prepared and used for 
labeling reactions with the clickable probe, 6-13. Neither endogenous Bcr-Abl (MW = 
210 kDa) nor endogenous c-Abl (MW = 130 kDa) were detected from the lysate with 
our probe. This is presumably due to the insufficient detection limit of the probe as 
well as due to the insufficient expression levels of these proteins in the cell lines. So 
we carried out labeling experiments from this mammalian proteome with varying 
amounts of spiked Abl kinase as follows. Decreasing amounts of recombinant Abl 
kinase was spiked to 30 µg of K562 total cell lysate (50 mM Tris buffer, pH = 7.5, 
150 mM NaCl). The cell lysates were prepared from approximately 1.5 × 107 cells 
cultured in T75 cell culture flasks. To 30 µg of the lysate was added 0.5 µM clickable 
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probe (6-13) and the reaction was allowed to continue for 20 min. Subsequently the 
reactions were irradiated with UV light (~ 350 nm) for 20 min followed by click-
chemistry with rhodamine azide (TER-N3) as described above. After 2 h of click 
reaction, 6X SDS loading dye were added, heated to 95 oC for 10 min and the proteins 
were resolved by SDS-PAGE. In-gel fluorescent scanning was used to visualize the 
labeled protein bands. As shown below in Figure 6.10, up to ~ 1% of the Abl kinase 











Figure 6. 10 Labeling of decreasing amounts of spiked Abl kinase in the presence of K562 














6. 4 Conclusions 
In conclusion, two different strategies for active site-directed, selective labeling of 
Abl kinase have been developed. These probes are the first activity-based probes for 
Abl kinase. One of the probes, compound 6-13 (an AfBP), showed promising results 
for proteomic profiling of Abl and for potential in situ screening of Abl inhibitors, 
though further improvements need to be made in order for it to be more useful in a 
complex biological system. Ultimately, new chemical proteomic tools will help us 
unravel the complex signalling cascades of this extremely important kinase and will 















6. 5 Synthetic details and characterizations of compounds 
 
1,3-Dimethoxy-N-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-1,3-
dihydronaphtho[2,3-c]furan-6-carboxamide (6-6):  
To a solution of 1,3-dimethoxy-1,3-dihydronaphtho[2,3-c]furan-6-carboxylic acid (6-
5) (0.05 g, 0.180 mmol, 1 eq.) in 10 mL of DMF was added bromo-tris-pyrrolidino 
phosphonium hexafluorophosphate (PyBrOP) (0.126 g, 0.27 mmol, 1.5 eq.) and 
diisopropylethylamine (DIEA) (0.048 mL, 0.27 mmol, 1.5 eq.) and the mixture was 
stirred for 10 min. Compound 6-4 (0.05 g, 0.180 mmol, 1 equiv.) was subsequently 
added, and the mixture was stirred at room temperature overnight. The solvent was 
then removed in vacuo and the residue dissolved in ethyl acetate and washed with 
water and brine. The organic layer was dried with anhydrous Na2SO4 and 
concentrated. Purification by column chromatography afforded the pure product as a 
yellow powder (0.077 g, 80%). LC-MS: m/z found = 534.15 [M + H]+ calculated = 
534.21  
6,7-Diformyl-N-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-2-
naphthamide (6-7):  
Compound 6-6 (0.077 g, 0.144 mmol) was dissolved in a mixture of TFA and H2O 
(1:1; total of 10 mL) and stirred at room temperature for 3 h, after which the solvent 
was removed under reduced pressure. Traces of TFA was removed by the addition of 
methylene chloride and then removing the solvent under reduced pressure, which was 
repeated for several times to yield the product as an orange powder (0.066 g, yield = 
95%) which was further purified by reverse phase semi-prep HPLC using  water and 
acetonitrile as eluents. 1H-NMR (300 MHz, CDCl3) δ 10.55 (s, 2H), 9.40 (s, 1H), 9.08 
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(s, 1H), 8.87 (s, 1H), 8.87 – 8.82 (m, 2H), 8.75 – 8.72 (m, 2H), 8.68 (s, 1H), 8.57 (d, J 
= 5.1 Hz, 1H), 8.40 – 8.26 (m , 2H), 8.20 – 8.15 (m ,1H), 7.77 – 7.68 (m, 1H), 7.56 – 
7.50 (m, 2H), 7.26 (d, J = 8.4 Hz, 1H), 2.26 (s, 3H). ESI-MS: m/z found = 488.14 [M 
+ H]+ calculated = 488.16. 
3-(4-Benzoylphenyl)-2-(tert-butoxycarbonylamino) propanoic acid (6-8):  
To 0.269 g (1 mmol) of commercially available 2-amino-3-(4-benzoylphenyl) 
propanoic acid (1 mmol) in 1:1 dioxane/water (5 mL each) was added 0.24 g of di-
tert-butyl-dicarbonate  (1.1 mmol) and 0.197 mL of triethylamine. The reaction was 
stirred for 4 h. The reaction the mixture was then concentrated on a rotary evaporator 
and the residue was diluted with water and ethyl acetate.  The aqueous layer was 
acidified to pH 1 with 1 N HCl and back extracted with ethyl acetate. The organic 
layer was washed with brine, dried over Na2SO4 and evaporated to give 0.332 g (yield 
= 90%) of the protected amino acid (compound 6-8) as an off-white solid. The 
compound was used in the subsequent steps without further purification. 
Tert-butyl 3-(4-benzoylphenyl)-1-(4-methyl-3-(4-(pyridin-3-yl) pyrimidin-2-
ylamino) phenylamino)-1-oxopropan-2-ylcarbamate (6-9):   
A 50 mL round-bottomed flask was charged with 0.29 g of 6-8 (0.785 mmol), 0.328 g 
of HATU (0.863 mmol), 0.162 mL of DIEA and 15 mL of DMF. After stirring for 5 
min, 0.217 g of 6-4 (0.785 mmol) was added and the reaction was allowed to run 
overnight. The solvent was removed under reduced pressure and the crude reside was 
purified by column chromatography on silica gel using hexane and ethyl acetate as 
eluents to give 0.4 g of the product 6-9 (yield = 81%) as a yellow solid, and use 




ylamino) phenyl) propanamide (6-10):  
Compound 6-9 (0.33 g, 0.525 mmol) was dissolved in a 1:1 mixture of TFA and 
DCM with 1% water (5 mL total volume) and stirred at room temperature in an open 
round-bottomed flask. The reaction was completed in 30 min and the solvents were 
removed under reduced pressure to give 0.33 g of the product 6-10 (yield = 92%) 
which was used in the subsequent steps without further purification. ESI-MS: m/z 




(6-12), Photo-Affinity Probe 1:  
A 25 mL round-bottomed flask was charged with 0.115 g of rhodamine B 4-(3-
carboxypropionyl) piperazine amide (6-11) (0.189 mmol), 0.079 g of HATU (0.206 
mmol), 0.045 mL of DIEA (0.258 mmol) and 5 mL of DMF. After stirring for 5 min, 
0.11 g of 6-10 (0.172 mmol) was added and the stirring was continued for 3 h upon 
which all of the starting material 6-10 was used up. The solvent was removed on a 
rotary evaporator and the crude residue was purified by Semi-Prep HPLC on a C18 
column, giving 0.08 g (yield = 41%) of the product 6-12 as a dark fine powder. ESI-
MS: m/z found = 561.257 = (M+2H+)/2, [M]+ calculated = 1121.53 
N-(3-(4-Benzoylphenyl)-1-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino) 




A 25 mL round-bottomed flask was charged with 0.018 g of pent-4-ynoic acid (0.189 
mmol), 0.079 g of HATU (0.206 mmol), 0.045 mL of DIEA (0.258 mmol) and 5 mL 
of DMF. After stirring for 5 min, 0.11 g of 6-10 (0.172 mmol) was added and the 
stirring was continued for 1 h upon which all of the starting material 6-10 was used up. 
The solvent was removed on a rotary evaporator and the crude residue was purified by 
column chromatography on silica gel using hexane and ethyl acetate as eluents to give 
0.1 g of the product 6-13 (yield = 95%) as off-white solid. 1H NMR (300 MHz, 
DMSO-d6) δ = 2.19 (s, 3H), 2.29 (m, 4H), 2.70 (s, 1H), 2.94-3.18 (m, 2H), 4.77 (m, 
1H), 7.15 (d, 1H, J = 8.4 Hz), 7.26 (d, 1H, J = 8.22 Hz), 7.42 (d, 1H, J = 8.4), 7.46 (d, 
2H, J = 8.22 Hz), 7.53 (m, 3H), 7.66 (m, 5H), 7.92 (s, 1H), 8.40 (d, 1H, J = 8.22 Hz), 
8.45 (d, 1H, J = 8.04 Hz), 8.50 (d, 1H, J = 5.10 Hz), 8.67 (d, 1H, J = 5.10 Hz), 8.97 (s, 
1H), 9.3 (s, 1H), 10.1 (s, 1H).  13C NMR (75 MHz, DMSO-d6) δ = 14.10, 17.59, 33.98, 
37.91, 54.46, 71.22, 83.68, 107.73, 115.87, 116.16, 124.72, 127.27, 128.53, 129.43, 
129.49, 129.57, 130.22, 132.57, 133.04, 135.21, 136.67, 137.23, 137.73, 142.91, 
149.42, 158.21, 159.58, 160.85, 160.98, 169.63, 170.45, 195.57. ESI-MS: m/z found = 











Chapter 7: Future directions 
Summary 
This chapter provides a brief outlook to some of the future developments possible 
in line with the ABPP- and inhibitor-developments of PKs and PTPs discussed in 
the previous chapters of this dissertation. The PTP-reactive unnatural amino acids 
(2-FMPT and caged-2-FMPT) could be incorporated into full-length substrate 
proteins of PTPs using the well-known Expressed Protein Ligation (EPL) method 
and the resultant protein-based probes may provide useful in the identification of 
the upstream/downstream PTP/PTPs responsible for a specific dephosphorylation 
event of the substrate protein. The construction of such a probe involves the 
generation of a trunkated protein with a C-terminal thioester and the unnatural 
amino acid incorporated peptide-ligation partner with an N-terminal cysteine 
residue. The key concepts and the preliminary results for the synthesis of the 
peptides are discussed in this chapter. The second part of this chapter discuss the 
possibility of developing AfBPs and bidentate inhibitors for a subset of the protein 
kinase family with a compact threonine gatekeeper residue. The synthesis of a key 
inhibitory scaffold, equipped with a bulky p-tolyl substituent on a 
pyrrolopyrimidine unit and the potential possibilities of the strategy are discussed.  
 
7. 1 Protein-based PTP probes to validate/identify the PTP/PTPs 
responsible for dephosphorylating a given substrate protein 
     As the metabolism and homeostasis of cells heavily relies on protein-protein 
interactions, several techniques have been developed to identify and characterize 
such interactions.113 Many of these techniques such as the yeast two-hybrid assays, 
 154 
 
glutathione-s-transferase fusion proteins, co-immunoprecipitation, and phage-
display methods have become routine in todays proteomic research. These 
techniques find significant use in phosphoproteomic research as well. However, 
protein kinases and protein phosphatases present significant challenges to such 
general techniques of mapping-out and characterizations of protein-interaction 
networks. In particular, many protein kinases and protein phosphatases, although 
display relatively tolerated substrate selectivities in vitro with synthetic peptide 
substrates, typically show high levels of substrate specificities in the living cell 
with their physiological protein substrate partner/partners and this property, in the 
light of the highly intricate nature of the signaling networks associated with these 
two classes of proteins, makes it more meaningful to characterize their 
physiological substrates rather than identifying/characterizing peptide substrates in 
vitro. In addition to contributions from sub-cellular localization and associated 
accesibility/proximity-driven interactions (also protein co-localization and 
associated variations in effective concentrations of interacting partners), long-
range interactions or interactions that are distal from the site of 
phosphorylation/dephosphorylation are thought to play critical roles in 
determining the high degree of substrate specificities observed with protein 
partners in vivo for these classes of enzymes.113  
     As the catalysis via protein kinases lead to the incorporation of a phosphate 
unit on to the substrate protein, in vivo identification of a kinase substrate is, at 
least conceptually, relatively easy with standard techniques based on radioactivity 
or chemiluminescence. The same goal in the cases of phosphatases is much more 
challenging as there is no direct method for the detection of the removal of a 
phosphate group from an already phosphorylated protein substrate in vivo. 
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However, the recent development of an ingenious approach known as “substrate-
trapping mutants” makes this highly challenging task possible at least in the case 
of several protein tyrosine phosphatases (PTPs).114 But the inverse problem, that 
of identifying the PTP responsible for dephosphorylating a particular substrate 
protein remains unsolved. We hypothesized that a “protein-based PTP-probe” 
could potentially address this problem as such a probe, by virtue of the presence of 
the full protein sequence could exploit most of the binding interactions between 
the original native substrate protein and the corresponding PTP/PTPs.  
     As a proof-of-concept, we decided to choose the membrane-associated non-
receptor protein tyrosine kinase, c-Src, for making the protein-based PTP-probe. 
The structural domain of c-Src kinase consists of an N-terminal myristoyl group, 
one SH3 domain, one SH2 domain and a catalytic domain (Figure 7.1).115 In the 
cell the c-Src kinase is normally maintained in an inactive state via an 
intramolecular interaction between its SH2 domain and a phosphotyrosine residue 
527 near the C-terminal side.115 The intracellular phophorylation of this Tyr-527 is 
known to be catalyzed by another protein kinase called Csk.116 This negative 
regulation of c-Src kinase activity is of high importance as the aberrant activity of 
this kinase has been identified in a variety of cancer cells.117 Once activated the c-
Src kinase could trigger the phosphorylation of an array of intracellular substrates 
with significant implications in several downstream signaling pathways affecting 
cell-division, cell-differentiation and cell-mobility. Although aberrant activity of 
this kinase is implicated in several cancers, its transient activation has been 
observed during important cellular events such as mitosis and growth factor 
receptor activation.118 The tyrosine phosphatase PTP1B has been shown to 
prefrentially dephosphorylate the phospho-Tyr-527 in c-Src in vitro.119 
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Furthermore, elevated levels of PTP1B expression has been observed in several 
cancer cell lines with increased c-Src activity.119 These lines of evidences point to 
the potential roles of PTP1B in positively regulating the activity of endogenous c-
Src along with several other activity-regulating mechanisms. 
     One could use the Expressed Protein Ligation (EPL) strategy120 to construct the 
protein-based PTP-probe using a c-Src construct. The overall scheme for 
constructing such a protein-based PTP-probe is shown below (Scheme 7.1). 
Briefly, amino acid residues 83 to 524 of chicken c-Src (K295M) with an N-
terminal His6 tag and a C-terminal thioester moeity could be generated via intein-
mediated protein splicing.121 The protein with the C-terminal thioester could 
undergo a Native Chemical Ligation (NCL)122 with the peptide bearing an N-
terminal cysteine residue. In our probe design, this peptide would carry the PTP-
reactive unnatural amino acid (indicated X in Scheme 7.1) so that the ligated 














Scheme 7. 1 Scheme for constructing the protein-based PTP-probe using Expressed 
Protein Ligation 
 
     We decided to make two different versions of the probes namely a PTP-
trapping probe and a PTP-sensor. The PTP-trapping probe (designated as pTRAP) 
would be equipped with the unnatural amino acid 2-FMPT for covalently reacting 
with the PTP whereas the PTP-sensor probe123 (designated as ppCAP) would be 
equipped with an unnatural amino acid pCAP which could report the PTP activity 
via fluorescence emission. The peptide ligation partner of the probes (Figure 7.2) 
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carry four distinctive structural units. They are 1. N-terminal cysteine residue (for 
ligating to the c-Src protein with C-terminal thioester), 2. The unnatural amino 
acid (for PTP-recognition), 3. A fluorescent dye (for visualization of the trapped 





Figure 7. 2 The peptide ligation partners for the construction of the protein-based PTP-
probes.  (A) the peptide for pTRAP probe and (B) the peptide for the ppCAP probe. The 








Scheme 7. 2 Solid-phase synthesis of the peptide ligation-partners. 
 
     The peptides were synthesized following standard Solid-Phase Peptide 
Synthesis (SPPS) protocols using rink-amide resin and Fmoc-protected amino 
acids (Scheme 7.2a). The crude peptides were purified by Prep-HPLC and 
characterized by LC-MS (Figure 7.3). Further improvements in the synthesis may 
be possible using the caged versions of the unnatural amino acids (caged-2-FMPT 
discussed in chapter-3, and caged-pCAP) as the use of such caged amino acids 
eliminate the need of harsh deprotection condition of ethyl ester protection of 
phosphate moeity using TMSI (Scheme 7.2b).  
     The future goals include validation of the protein-based probe concept with the 
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ultimate aim of using the probes to perform live-cell imaging and related 
experiments to identify the PTP/PTPs responsible for dephosphorylating a given 
protein substrate of interest.   
 
 (A) pTRAP peptide  




















(B) pCAP pptide 




























Figure 7. 3 LC-MS profiles of the purified (A) pTRAP  and (B) pCAP peptides. LC-
running condition: C-18 reverse phase column with 20 to to 100% ACN (80 to 20% water) 
with 0.1% TFA for 15 min.  
 
7. 2 Synthesis of a scaffold for the development of affinity-based 
probes (AfBPs) and bidentate inhibitors of protein kinases with a 
compact gatekeeper residue 
      
     Structural studies of kinases have revealed a “gatekeeper” residue, near a 
conserved β5 strand, at the opening of the active-site and close to the hinge region 
connecting the N- and C-terminal domains of the protein.124 The size of this 
gatekeeper residue has been shown to be the major determinant for selective 
accessibility of several small-molecule inhibitors to the active site of different 
kinases.125 A compact gatekeeper residue such as threonine or glycine would allow 
inhibitors with large aromatic substituents whereas bulky gatekeepers such as 
phenyl alanine, leucine or isoleucine would restrict their access. It has been 
observed that approximately 20% of protein kinases possess threonine as the 
gatekeeper residue126 and many kinase inhibitors exploit this compact residue as 
selectivity filter.  




discussed in chapters 4 and 6 respectively, we sought to develop AfBPs and 
bidentate inhibitors for protein kinases with a compact gatekeeper residue. 
Towards this we first synthesized a key inhibitory scaffold (compound 7-9 in 
Scheme 7-3) which was equipped with a bulky p-tolyl substituent on the 
pyrrolopyrimidine unit for the potential exploitation of the compact threonine 
gatekeeper residues in certain kinases such as c-Src, Rsk, c-Abl, EGFR, HER, Fyn, 
Lck, c-Kit, p38 etc. The design of the scaffold was based on a highly selective and 
potent clickable irreversible inhibitor, fmk-pa, of the  C-terminal domain of the 
p90 ribosomal protein S6 kinase (Rsk).109a Compound 7-9 could be clicked with 
various azides to generate a library of potential bidentate kinase inhibitors 
targeting some of the members in the 20% of kinases possessing compact 
gatekeeper residue and potentially the structural variants from the azide 
components in the inhibitors may exploit differences in secondary-binding pockets 
adjacent to the ATP-binding pocket in those kinases, and this in tern may lead to 
more selective and potent inhibitors of such kinases. Structural variants of 
compound 7-9 with different linker length for the alkyne handle and different 
bulky aromatic substituents at the position of the p-tolyl substituent on the 
pyrrolopyrimidine unit could also be synthesized to explore more possibilities. 
Compound 7-9 could also be used for developing AfBPs for kinases via attaching 



























Scheme 7. 3 Synthesis of a clickable scaffold (compound 7-9) for the potential 
development of AfBPs and bidentate inhibitors of protein kinases with a compact 

















































































Synthetic procedures and characterizations of compounds in the 
Scheme 7. 3 
2-(2-Oxo-2-p-tolylethyl)isoindoline-1,3-dione (7-1): 
To a solution of 3.79 g (25.81 mmol, 1.1 eq.) of phthalimide in 35 mL DMF was 
added 3.88 g (28.16 mmol, 1.2 eq.) of K2CO3 at RT and the solution was stirred for 45 
min. To this was added 2-bromo-1-p-tolylethanone (5 g, 23.47 mmol, 1 eq.) and 
stirred at RT for 3h. The reaction was then poured into 750 mL water upon which a 
white precipitate was formed. The solution was filtered and the residue was purified 
by recrystallization from DCM:Ether to afford 5.3 g of compound 7-1 (yield = 80%) 
as a white solid. ESI-MS: m/z = 280.1 [M+H]+   
2-Amino-4-p-tolyl-1H-pyrrole-3-carbonitrile (7-2): 
Compound 7-2 was prepared as previously reported. Briefly, to a solution of 
malononitrile (0.461 g, 6.98 mmol, 1.3 eq.) in 6:1:1 MeOH:48% aq. NaOH:H2O was 
added 1.5 g (5.37 mmol, 1 eq.) of compound 7-1 and the mixture was stirred at RT for 
1h upon which the product was precipitated out of the solution. The reaction mixture 
was filtered and the residue was washed with H2O, DCM and hexane to afford 0.87 g 
(yield = 82%) of 7-2 as an off-white flaky solid. 1H-NMR (300 MHz, CD3OD) δ 7.49 
(d, 2H, J = 7.6 Hz), 7.08 (d, 2H, J = 7.6 Hz), 6.36 (s, 1H), 4.83 (br s, 2H), 2.27 (s, 3H). 
ESI-MS: m/z = 198.1 [M+H]+ 
Ethyl N-3-cyano-4-p-tolyl-1H-pyrrol-2-ylformimidate (7-3): 
To a solution of compound 7-2 (0.5 g, 2.53 mmol) in triethyl orthoformate (5 mL) 
was added 70 µL of acetic anhydride and the reaction mixture was refluxed for 1h. 
The reaction mixture was then cooled to RT and the solvent was removed under 
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reduced pressure. The crude pyrrole iminoether was azeotropically dried with toluene 
and used in the subsequent step without further purification. 
Ethyl N-1-(3-(tert-butyldimethylsilyloxy)propyl)-3-cyano-4-p-tolyl-1H-pyrrol-2-
ylformimidate (7-4): 
To a suspension of NaH (0.056 g, 2.34 mmol) in 5 mL dry DMF was added ~ 2.34 
mmol of the crude pyrrole iminoether (compound 7-3) in 3 mL dry DMF and the 
solution was stirred at RT for 30 min. To this was then added 0.7 g (2.34 mmol) of 3-
(t-butyldimethylsilyloxy)propyl iodide over 10 min and the reaction was stirred for 3h. 
The solvent was then removed under reduced pressure and the residue was purified by 
flash column chromatography on silica gel to afford 0.59 g (yield = 59%) of 
compound 7-4 as a brown oil. 1H-NMR (300 MHz, CDCl3) δ 8.50 (s, 1H), 7.55 (d, 2H, 
J = 8.04 Hz), 7.22 (d, 2H, J = 8.04 Hz), 6.69 (s, 1H), 4.40 (q, 2H, J = 7.23 Hz), 4.02 (t, 
2H, J = 7.0 Hz), 3.65 (t, 2H, J = 5.76 Hz), 2.4 (s, 3H), 1.97-1.87 (m, 2H), 1.42 (t, 3H), 
0.97 (s, 9H), 0.09 (s, 6H). ESI-MS: m/z = 426.7 [M+H]+  
7-(3-(tert-Butyldimethylsilyloxy)propyl)-5-p-tolyl-7H-pyrrolo[2,3-d]pyrimidin-4-
amine (7-5): 
Compound 7-4 (0.32 g, 0.75 mmol) was dissolved in 10 mL MeOH and transferred to 
a 50 mL sealed-tube reaction vessel with a magnetic stirring bar. Argon gas was 
bubbled through the solution for 10 min. The tube was immersed in a cold bath of dry 
ice-MeOH mixture and NH3 gas was bubbled through the solution for 15 min. The 
tube was quickly sealed with a Teflon screw cap and the reaction was allowed to 
warm to room temperature. The reaction was stirred at 50 oC for 4 days. The sealed 
tube was subsequently cooled on an ice bath and the NH3 gas was slowly released. 
The solvent was removed under reduced pressure and the crude product was purified 
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by flash column chromatography to yield 0.18 g (yield = 60%) of compound 7-5. 1H-
NMR (300 MHz, CDCl3) δ 8.30 (s, 1H), 7.38 (d, 2H, J = 7.9 Hz), 7.25 (d, 2H, J = 
8.04 Hz), 6.95 (s, 1H), 5.67 (br s, 2H), 4.33 (t, 2H, J = 6.8 Hz), 3. 66 (t, 2H, J = 5.8 
Hz), 2.40 (s, 3H), 2.14-2.04 (m, 2H), 0.92 (s, 9H), 0.06 (s, 6H). 13C-NMR (75 MHz, 
CDCl3) δ 157.9, 152.2, 150.9, 137.2, 132.5, 130.2, 129.2, 123.6, 116.4, 101.7, 60.3, 
42.0, 33.5, 26.4, 21.6, 18.8, -4.8. 
Compound 7-6:  
To a solution of compound 7-5 (90 mg, 0.227 mmol) in 4 mL THF was added 
(Boc)2O (0.149 g, 0.681 mmol, 3 eq.) and  DMAP (5.6 mg, 0.045 mmol, 0.2 eq.) and 
the reaction was stirred at room temperature for 2.5 h. The solvent was evaporated off 
and the residue was dissolved in ethyl acetate, extracted with 0.5 N HCl, brine and 
dried over anhydrous Na2SO4 and concentrated. The residue was purified by flash 
column chromatography using 1:1 hexane:ethyl acetate pre-equilibrated column with 
fast elution to afford 0.12 g of (yield = 88%) compound 7-6. 1H-NMR (300 MHz, 
CDCl3) δ 8.83 (s, 1H), 7.37 (d, 2H, J = 7.89 Hz), 7.30 (s, 1H), 7.20 (d, 2H, J = 7.89 
Hz), 4.45 (t, 2H, J = 6.9 Hz), 3.67 (t, 2H, J = 5.75 Hz), 2.40 (s, 3H), 2.13-2.07 (m, 
2H), 1.3 (s, 18H), 0.94 (s, 9H), 0.07 (s, 6H). 13C-NMR (75 MHz, CDCl3) δ 153.9, 
151.8, 151.4, 151.2, 137.1, 131.1, 129.7, 129.1, 128.3, 116.5, 113.8, 83.5, 60.2, 42.3, 
33.3, 28.2, 26.5, 21.7, 18.8, -4.8.  
Compound 7-7: 
Compound 7-6 (0.12 g, 0.201 mmol) was dissolved in a 3:1 (V/V) mixture of THF:1N 
HCl and stirred for 45 min at room temperature. The reaction mixture was then 
diluted with 40 mL ethyl acetate and washed with saturated NaHCO3 followed by 
brine. The organic layer was dried with anhydrous Na2SO4 and concentrated. The 
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residue obtained was purified by flash column chromatography on silica gel with fast 
elution to afford 0.087 g (yield = 89%) of compound 7-7. 1H-NMR (300 MHz, CDCl3) 
δ 8.80 (s, 1H), 7.36 (d, 2H, J = 7.89 Hz), 7.27 (s, 1H), 7.19 (d, 2H, J = 7.80 Hz), 4.45 
(t, 2H, J = 6.30 Hz), 3.51 (t, 2H, J = 5.55 Hz), 2.39 (s, 3H), 2.06-2.02 (m, 2H), 1.29 (s, 
18H). 13C-NMR (75 MHz, CDCl3) δ 154.1, 152.2, 151.4, 151.1, 137.3, 130.7, 129.8, 
129.1, 128.2, 117.1, 113.7, 83.7, 58.6, 41.7, 33.5, 28.2, 21.6.  
Compound 7-8: 
To a solution of 87 mg (0.18 mmol) of compound 7-7 in 3 mL DCM was added 
DIPEA (70 µL, 0.414 mmol, 2.3 eq.) and methanesulfonyl chloride (17 µL, 0.216 
mmol, 1.2 eq.) at 0 oC. After 30 min the reaction mixture was diluted with ethyl 
acetate and extracted with saturated NH4Cl solution followed by brine. The organic 
layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced 
pressure. The crude mesylate was used for the reaction with propargyl amine without 
further purification.  
To the crude mesylate was added 0.8 mL propargyl amine at room temperature and 
the reaction was stirred at 40 oC for 20h. The solvent was removed under reduced 
pressure and the crude product was attempted to purify by flash column 
chromatography on silica gel which could remove most of the impurities. The crude 
product 7-8 was used in the next step without further purification.  ESI-MS m/z = 
520.8 [M+H]+ 
Compound 7-9:  
Compound 7-8 was dissolved in a 1:1 DCM:TFA mixture (1 mL each) and stirred for 
2h at room temperature. Solvent was removed under reduced pressure and the crude 
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residue was purified by Prep-HPLC using reverse-phase C-18 column with a gradient 
of acetonitrile with 0.1% TFA and water with 0.1% TFA as mobile phases afforded 
approximately 5 mg of compound 7-9 as a pale brown oil. 1H-NMR (300 MHz, 
CDCl3) δ 10.66 (br s, 1H), 8.17 (s, 1H), 7.28 (m, 4H), 7.15 (s, 1H), 5.89 (br s, 2H), 
4.41 (t, 2H, J = 6.40 Hz), 3.83 (s, 2H), 3.14 (t, 2H, J = 6.73 Hz), 2.5 (s, 1H), 2.40 (s, 
3H), 2.39-2.33 (m, 2H). 13C-NMR (75 MHz, CDCl3) δ 153.4, 148.3, 142.9, 139.5, 
















Chapter 8: Concluding remarks 
     My doctoral dissertation has been focused on the development of certain 
chemical techniques that facilitate activity-based profiling and inhibitor 
developments of some important members in the protein tyrosine phosphatase 
(PTP) and protein kinase (PK) family. Reversible phosphorylation of proteins 
catalyzd by the opposing actions of these two classes of enzymes play key roles in 
the cellular signal transduction events and thus in turn in maintaining the normal 
cellular physiology. Conventional proteomic techniques, although provide 
informations regarding the expression levels and to some extent about the 
interaction networks of these proteins, are however, incapable of directly reporting 
the activities of these proteins and given the fact that the enzyme activity, and not 
the expression level, being the major determinant of the functional roles of these 
proteins, development of techniques that facilitate their activity-based profiling is 
of more significance in understanding their roles in the cellular functioning. 
Furthermore, being signaling enzymes, disregulation of activitites of many of 
these proteins have been identified as the root causes for several pathological 
conditions; hence development of selective and potent inhibitors of some of the 
members in these two classes of enzymes is another related area with direct 
relevance to the development of effective therapeutic agents.         
     As desribed in Chapter 2, we have designed a new “PTP-reactive unnatural 
amino acid”, 2-FMPT, which although exploits quinone methide chemistry similar 
to most of the existing PTP probes, has a very significant advantage that, being an 
amino acid, it could be easily incorporated into peptide sequences with essential 
substrate recognition elements at the proximal positions of pTyr in a naturally 
occurring PTP substrate so that the corresponding peptide-based probes could 
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achieve target-specific profiling of different PTPs. A panel of peptide-based 
probes were synthesized and labeling reactions with the probes using purified and 
isolated proteins showed activity-based labeling specificity consistent with the 
known substrate preferences of the different PTPs. The strategy has also been 
found to be useful for efficient labeling reactions of PTPs from highly complex 
biological samples. Subsequently, a caged version of the unnatural amino acid 
with a photolabile o-nitrobenzyl group on the phosphate moiety (caged-2-FMPT) 
was synthesized and incorporated into peptides to generate peptide-based, caged, 
ABPs (Chapter 3). Using these caged probes, with PTP1B as a model system, the 
concept of photo-uncaging followed by activity-based labeling was validated.  
     In Chapter 4, we have demonstrated the potential of the “click chemistry” to 
rapidly assemble inhibitor libraries of the clinically highly relevant protein, 
Abelson (Abl) tyrosine kinase. Biochemical assays with the inhibitor library 
revealed a set of moderately potent and selective inhibitors of the Abl kinase. The 
in vitro hits identified from the library, however, did not show significant 
antiproliferative activities in cell-based assays. This was attributed mainly to the 
poor membrane permeability of the compounds and it is hoped that future designs 
that could account for this shortcomings may provide a highly useful and efficient 
strategy that could tackle most of the drug resistance problems observed in the 
treatment of Chronic Myelogenous Leukemia (CML) with Imatinib.  
     Similar to selective inhibition of a kinase of interest, selective detection of 
kinase-substrate interactions, in particular, detection of the upstream kinase 
responsible for a given phosphorylation event, remains a highly challenging task. 
Towards this, an improved mechanism-based kinase-peptide pseudosubstrate 
cross-linker, termed naphthalene 2,3-dicarboxaldehyde-adenosine (NDA-AD) has 
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been synthesized. The cross-linker, in addition to its improved labeling 
performances from crude proteomes compared to a previously reported cross-
linker OPA-AD, was found to be suitable for the detection of kinase-
pseudosubstrate interactions of both tyrosine-specific and serine/threonine-specific 
protein kinases. Further developments that allow cross-linking of protein 
substrates rather than peptide pseudosubstrates with full-length endogenous 
protein kinases in intact cells, would provide an invaluable tool in the study of 
signal transductions involving protein kinases.  
     The design and development of selective small molecule-based ABPs for the 
Abl kinase has been described in Chapter 6. Two different strategies namely a 
dialdehyde-based cross-linking and photo-affinity labeling were developed to 
selectively probe the Abl kinase. The dialdehyde-based probe, although useful for 
selective detection of purified Abl kinase, was found to have poor labeling 
performances in the presence of cellular lysates. On the other hand, a clickable 
“tag-free” version of the photo-affinity-based probe was found to have superior 
labeling performances both with purified protein and in the presence of competing 
cellular proteins.  
     It is hoped that the kinase- and phosphatase-directed ABP and inhibitor-
development approaches described in this thesis, would provide useful chemical 
biology tools for the investigation of these extremely important signalling 
enzymes. They also provide a guideline for the future designs of more powerful 
methods such as the developments of protein-based probes, which could exploit 
not only the binding interactions near the active-site of these enzymes but also 
many distal binding interactions that facilitate more detailed investigations of 
these enzymes and their roles in critical cellular events. 
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*** Acquisition  Parameters ***
BF1 :    300.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        1853.43 Hz
PULPROG : zg30
SFO1 :    300.1318534 MHz
SOLVENT : CDCl3
SW :        17.9519 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        155.201 degree
PHC1 :          3.398 degree

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































*** Acquisition  Parameters ***
DATE_t : 01:35:43




NS :              8
NUCLEUS : off
O1 :        1853.43 Hz
SFO1 :    300.1318534 MHz
SOLVENT : DMSO
*** 1D NMR Plot Parameters ***
NUCLEUS : off








































































































































































































































































































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    300.1300000 MHz
BF2 :    300.1300000 MHz
BF3 :    300.1300000 MHz
DATE_t : 06:01:12
DATE_d : Aug 25 2009
NS :             80
SOLVENT : DMSO





















































































































































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :     75.4677490 MHz
BF2 :   300.1300000 MHz
BF3 :     75.4677490 MHz
DATE_t : 06:49:55
DATE_d : Aug 13 2009
NS :          15360
SOLVENT : DMSO

































































































































































































































































































13C Standard AC300, B3-57
 
N
N N
NH
NH2
7-9
